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Abstract 
Pro-inflammatory cytokines and glucolipotoxicity are known mediators of beta cell 
death and dysfunction in the pathogenesis of type 1 and type 2 diabetes mellitus (DM). In 
contrast to the pro-apoptotic effects of long-chain saturated fatty acids in beta cells, mono- 
and poly- unsaturated species, including arachidonic acid (AA), are well-tolerated and can 
attenuate the effects of cytoxocity. AA-drived eicosanoids are well-studied in context to beta 
cell biology, with established contributions of cyclooxygenase (COX) and lipoxygenase (LOX) 
products in cytotoxicity studies, though comparatively less is known about the role of 
cytochrome P450-derived epoxyeicostrienoic acids (EETs) in this context, despite reported 
anti-inflammatory activity in other models. Therefore the aim of this thesis was to investigate 
the cytoprotective actions of EETs and their corresponding diol products of soluble epoxide 
hydrolase metabolism; dihydroxyeicosatrienoic acids (DHETs) in the rat pancreatic beta cell 
line BRIN-BD11. Preliminary investigations confirmed the cytotoxicity exerted by pro-
inflammatory cytokines and palmtiate in reducing cell viability and increasing apoptosis. These 
effects were attenuated by co-incubation of 8(9)-EET, 11(12)-EET and 14(15)-EET isomers, a 
novel observation in a beta cell model. In contrast, DHETs failed to ameliorate palmitate 
toxicity however, 8(9)-DHET remarkably produced comparable effects to that of EETs against 
cytokine toxicity. These effects were associated with a reduction in cytokine-induced NF-κB 
activation and, in the case of EETs, decreased nitrite production. Futhermore, in these models 
EET effects were PPARγ-independent, with a wider range of PPAR and GPR antagonists failing 
to identify a single high affinity receptor site mediating EET actions against palmitate toxicity. 
Similarly, whilst alterations in gene expression of enzymes involved in palmitate oxidation and 
triglyceride synthesis were observed in repsonse to EET treatments, with a modest increase 
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in intracellular lipid droplets, pharmacological inhibition of these pathways suggests these are 
not required in mediating EET actions. This was further supported by the attentuation of 
toxicity exerted with the poorly metabolisable palmitate analogue, 2-Bromopalmitate, by 
EETs. Therefore, whilst mechanisms of actions remain poorly defined, this thesis provides the 
first direct evidence for the cytoprotective actions of EETs and DHETs in a beta cell model, 
establishing a foundation for future work to explore the manipulation of endogenous EETs in 
pancreatic beta cells and to further define their mode of action in models of type 1 and 2 DM. 
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1 Introduction 
 
With a concerning rise in the prevalence of diabetes mellitus (DM), the World Health 
Organisation has emphasised the forthcoming of a diabetes burden, with an estimated 552 
million confirmed cases by 2030 by the International Diabetes Federation (IDF) (Alam et al., 
2014). The increasing rate of diagnosis of DM currently stands at 400 people per day in the 
UK, with estimated figures by 2025 to raise above a total four million cases. The spectrum of 
DM can be broadly classified as type 1 DM or type 2 DM. Type 1 DM (insulin dependent) 
represents an extreme of autoimmune destruction of the pancreatic beta cells and type 2 DM 
(typically non-insulin dependent) an extreme of metabolic dysfunction (Groop et al., 2014; 
American Diabetes Association, 2007) leading to the loss in effective regulation of plasma 
glucose homeostasis.  
Healthy individuals maintain glucose levels between 4.5-5mM, utilising glucose and/or 
fatty acids and ketones as a primary source of metabolic fuel in the ‘starve-feed’ cycle (Bano 
et al., 2013;). The mechanisms leading to the development of type 1 or type 2 DM may be 
diverse; however, patients from both cohorts may display characteristics of a type 1 DM 
phenotype with impaired secretion or type 2 DM phenotype with metabolic syndrome and a 
degree of insulin resistance (Groop et al., 2014). Patients with type 1 DM progressively display 
a decrease in insulin production, consequential to declining functional beta cell mass, whilst 
type 2 DM patients display an increase in insulin resistance in peripheral tissues, typically with 
an eventual decline in insulin secretion and reduction in beta cell mass. Although most newly 
diagnosed DM cases fall into one of these two main classifications, other distinct sub-types of 
DM include: Latent Autoimmune Diabetes in Adults (LADA), Maturity-Onset-Diabetes of the 
Young (MODY), neonatal diabetes, maternally inherited diabetes and deafness (MIDD) and 
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secondary diabetes; as a complication of either pancreas/endocrine related diseases 
(American Diabetes Association, 2007; Groop et al., 2014). 
 
1.1 Type 1 Diabetes Mellitus  
Type 1 DM was first described in 1902 by the German pathologist Schmidt in a case of a 
boy presenting with characteristic signs of an inflammatory infiltration in the islets of 
Langerhans, which was later termed ‘insulitis’ by a Swiss pathologist; Von Meyenburg (In’t 
Veld, 2011). The first link between the foci of small-cell infiltration, insulitis and type 1 DM 
was reported in 1928 by Stansfield and Warren whilst studying two patients; a six year-old girl 
(deceased two months after onset of type 1 DM in a diabetic coma) and an eleven year-old 
girl (deceased four weeks after initial symptoms) (In’t Veld, 2011). Warren subsequently 
contradicted these initial findings of insulitis in both patients in a later study of ten children, 
with only 10% displaying characteristics of insulitis (type 1 DM). From the inconclusive data 
provided by Schmidt and Warren, LeCompte revisited the findings in 1958 with four cases of 
children involving acute onset and short duration of the disease (type 1 DM), proposing four 
possible explanations for the presence of cellular infiltration: 1) A direct invasion of the islets 
by an infectious agent, 2) A manifestation of functional overstimulation or strain, 3) A reaction 
to damage by some unknown non-bacterial agent and 4) an antigen-antibody reaction 
(LeCompte 1958). 
 The year 1965 witnessed a landmark study by pathologist Willy Gepts, who obtained 
tissue samples from young, recent onset type 1 DM cases. Out of the 22 diabetic patients 
under the age of 40, 68% showed the presence of a characteristic inflammatory lesion in the 
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islets, with a reduced beta cell mass by approximately 10% compared to non-diabetic controls. 
The use of anti-insulin sera further confirmed these observations showing the presence of 
lymphocytic infiltrates, thought to point to an autoimmune aetiology of the disease (Gepts, 
1965). A follow-up study in 1978 found additional arguments in favour of an autoimmune 
process, observing that inflammation seemed to specifically target beta cell-containing islets, 
whilst islets whose beta cells had been depleted were devoid of lymphocytic infiltration 
(Gepts, 1978). Foulis et al., (1986) later confirmed these observations, with detectable insulitis 
present in 47/60 (78%) cases of young patients with recent onset diabetes (<1 year). These 
two landmark studies account for almost half of all cases with insulitis that have been 
published over the last century, owing to the limited availability of pancreatic donor 
specimens of recent onset type 1 DM patients (In’t Veld, 2011) and continue to contribute to 
our understanding of the orchestration of the immune reponse in DM pathogenesis (Willcox 
et al., 2010). 
 In 1985, Bottazzo et al., observed the nature of a lymphocytic infiltrate in the islets of 
Langerhans from the pancreas of a 12 year old girl. This study reported that insulitis was 
present in 24% of the islets and immunophenotyping of the infiltrate revealed a large T-
lymphocyte population, with CD8+  cytotoxic/suppressor cells being most abundant (Bottazzo 
et al, 1985). This was later supported by a study showing that at all stages of insulitis, CD8+ T 
cells were predominant in the islet infiltrate, increasing in number with decreasing insulin-
positive area, but disappearing when insulin-positivity was completely lost (In’t Veld et al., 
2007). CD20+ B-lymphocytes are the second most prominent cell type, whilst macrophages 
were present at relatively lower levels but become the most prominent infiltrating cell type in 
insulin-deficient islets (Willcox et al., 2010). 
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1.1.1 Insulitis 
The limited availbility of human pancreatic tissue sections from cadaveric donors with 
recent onset type 1 DM has been supported with studies in BB rat and NOD mice models, 
which develop spontaneous type 1 DM, to better understand the pathogenesis of type 1 DM, 
establishing pancreatic beta cells as the target for mononuclear cells in an autoimmune attack. 
During insulitis, a loss of functional beta cell mass occurs over a period of time (a protracted 
‘pre-diabetic’ stage) resulting in a reduction of around 70-80% at the time of diagnosis (Cnop 
et al., 2005; Yoon and Jun, 2005). The direct contact of activated macrophages and T-cells, and 
the exposure to soluble mediators secreted by these cells; cytokines, nitric oxide (NO) and 
oxygen free radicals, is believed to be the main cause of beta cell death in vivo (Pirot et al., 
2008). 
Autoantibodies can be detected several months or years before the appearance of 
clinical symptoms of type 1 DM and are used as markers in identifying patients at risk of 
developing the condition (Jahromi et al., 2007). The most common auto-antibodies detected 
in pre-diabetic patients are directed against the beta cell antigens glutamic acid decarboxylase 
(GAD65), tyrosine phosphatase-like protein (islet auto-antigen 2) (IA-2) and insulin (Pirot et 
al., 2008). Around 90% of newly diagnosed type 1 DM patients have one or more auto-
antibodies present and in combination with auto-antibodies against the zinc transporter ZnT8, 
this figure rises to 98% (Wenzlau et al., 2007). Through linkage analysis, the human leukocyte 
antigen (HLA) region found on chromosome 6p21.3 is suggested to be the strongest genetic 
determinant for type 1 DM; with 50% of all known genetic risks being associated with this 
region (Groop et al., 2014) however, more than 85% of cases show an absence of an affected 
first-degree relative. Those with inherited links to a first-degree relative have a 5% lifetime 
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risk of developing type 1 DM compared to 0.3% for the remaining population (Gan et al., 
2012), suggesting the requirement of an environmental trigger in the initiation of type 1 DM.  
In the 1970’s an association between specific HLA-loci (HLA-B alleles) and type 1 DM 
onset was first recognised, with further alleles including DR, DQB1 and A1 shown to 
predispose individuals to type 1 DM development (Gan et al., 2012). A study involving >1000 
patients with type 1 DM showed that ~95% express either the HLA-DR3 and/or DR4 allele, of 
which 40% were heterozygous for HLA-DR3 and DR4 in comparison to 3% of the general 
population, with DR4 then DR3 homozygosity and DR4/DRX having the next highest genetic 
risk genotypes (Gan et al., 2012). Although specific HLA types indicate susceptibility to type 1 
DM development; HLA-DR2, HLA-DR5 and HLA-DQB1 may confer protective roles, with HLA-
DQB1 giving a 1 in 15,000 chance of developing the condition (Gan et al., 2012). Other 
documented loci that have been shown to cause a predisposition in individuals are the insulin 
locus, cytotoxic T-lymphocytes antigen 4 (CTLA4) and phosphatase non-receptor type 22 
(PTPN22); PTPN22 and CTLA4 are both negative regulators of lymphatic activity (Pirot et al., 
2008). Insulin may be present at low levels within the thymus and may lead to inefficient 
elimination of self-reactive T-cells with PTPN22 de-phosphorylating components of the T-cell 
receptor cascade, thus inhibiting antigen-specific T-cell activation (Todd et al., 2007) and 
CTLA4, a T-lymphocyte receptor, can cause inhibition of T-lymphocyte activation (Kim et al., 
2005).  
An external environmental trigger is believed to be necessary in order to meet the 
threshold in which the pool of self-reactive naïve T-cells are activated, leading to the initiation 
of insulitis, typically (though not exclusively) in patients with a genetic predisposition. The 
several suspected environmental triggers include; viral infection, dietary factors during 
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infancy (particualry cow’s milk formula), vaccination, toxins and physiological beta cell 
turnover occuring in newborns (Pirot et al., 2008). Whilst evidence points to the role of viral 
infection (Richardson et al., 2009; Wilcox et al., 2011), possibly attributed to the so-called 
‘hygiene hypothesis’ and its hypothesised link to the increase in auto-immune diseases, as a 
potential ‘trigger’ for the development of type 1 DM, studies are yet to demonstrate a direct 
causal relationship between viral candidates and diabetogenesis in vivo. 
In early insulitis, T-cell recruitment to the pancreatic islets may be potentiated by 
production of chemokines; initiating the recruitment, activation and co-stimulation of the 
immune system. Activation of antigen presenting cells (APC), such as resident dendritic cells 
and macrophages, further orchastrate the release of chemokines and pro-inflammatory 
cytokines, such as interleukin 1-beta (IL-1β) tumour necrosis factor alpha (TNF-α) and 
interferon gamma (IFN-γ), into the islet milieu (Lenzen et al., 2001; Pirot et al., 2008). NOD 
mice deficient in macrophage inflammatory protein-1α (MIP-1α), a known recruiter of 
proinflammatory cells, resulted in a reduction of insulitis and protection against diabetes 
(Cameron et al. 2000). Willcox et al., (2010) highlighted the importance of therapeutic 
interventions, if early diagnosis of pateints with recent-onset type 1 DM during early insulitis 
is achievable, identifying makers of proliferation (Ki67) in human pancreas sections from 
deceased patients with recent-onset type 1 DM, suggesting beta cell proliferation, which may 
restore functional cell mass if immunotherapy/other intervention becomes possible. In 
support of this, Sherry et al., (2006) observed similar findings, showing beta cell replication in 
NOD mice during progression to overt diabetes, effects that appeared to be stimulated in 
response to insulitus. Whilst beta cell proliferation rates declined following anti-CD3 mAb 
treatment (which binds to the CD3 T-cell co-receptor), it was suggested that recovery of 
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exisiting beta cells is possible following regranulation (Sherry et al., 2006). However, regain in 
functional capacity was not sustained, with cell loss by apoptosis observed in the follow-up 
period; this may suggest an early apoptotic-priming signal during early insultis and may 
account for the limited results with anti-CD3 mAb treatment in phase 3 clinical trials (Simmons 
et al., 2011), emphasising the need for continued development of our understanding of the 
mechanisms of beta cell apoptosis and further strategies aimed to prevent this. 
Further coordination of islet insulitis is carried out by resident dendritic cells and 
macrophages migrating to the pancreatic lymph nodes (PLNs) and recruitment of T-helper 
cells (CD4+ T-lymphocytes), with Pearly-Yafe et al., (2007) demonstrating that the removal of 
pancreatic lymph nodes 3 weeks from birth protects NOD mice against developing insulitis. 
Naïve Th0 CD4+ T-cells are activated by presentation of beta cell antigens to their MCH class II 
receptors by antigen presenting cells, allowing differentiation into Th1 cells, which enhance 
the cytotoxic immune response achieved by the release of IL-12 (Pearly-Yafe et al., 2007). 
These Th1 CD4+ T-cells further secrete cytokines such as IL-2 and IFN-γ, allowing further 
antigen presenting cells to promote the release of IL-1β and TNF-α, leading to increased levels 
of NO production within beta cells and pancreatic ductal cells (Pirot et al., 2008). This set of 
events continues to promote migration of CD8+ T-cells and production of chemokines and 
cytokines, further aggravating an attack on beta cells (Cardozo et al., 2003). The presence of 
CD8+ cytotoxic T-cells, macrophages (CD68+), CD20+ and CD138+ cells in human pancreatic 
tissue sections have been identified from 29 patients (mean age 11.7 years) with recent-onset 
type 1 diabetes (Willcox et al., 2009) showing similar findings compared to rodent models. The 
predomidant CD8+ cytotoxic T-cells during insulitis and macrophages contribute to the 
secretion of cytokines (Willcox et al., 2009), with cytotoxic CD8+ T-cells also activating the 
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extrinsic pathway of apoptosis through the Fas/FasL and perforin-granzyme B pathways, 
resulting in the activation of a caspase cascade and the inititation of beta cell apoptosis. 
Cytokines IL-1β, IFN-γ and TNF-α released from APCs bind to their cell surface receptors on 
beta cells, activating the transcription factors signal transducer and activator of transcription 
1 (STAT-1) and nuclear factor kappa B (NF-κB) leading to subsequent alterations in multiple 
regulatory gene networks, caspase activation and cell death (Pirot et al., 2008).  
 
1.1.2 Mechanisms of Beta Cell Death in Type 1 DM 
Clinical symptoms of type 1 DM appear when the functional beta cell mass has been 
depleted by 70-80%. It has been well established that the main mechanisms involved in beta 
cell apoptosis occur via the activation of the extrinsic pathway, triggered by ligands such as 
Fas and tumour necrosis factor receptor (TNFR), and the intrinsic pathway (known as the 
mitochondrial or Bcl-2-regulated pathway) (Thomas and Biden, 2009). Although initiation of 
these pathways differ, the two converge in activating common downstream cysteine-
aspartate proteases (caspases), cleaving intracellular proteins resulting in beta cell death (Yin, 
2000; McKenzie et al., 2008; Grunnet et al., 2009). The four main mechanisms believed to be 
involved in mediating beta cell death are ligation of Fas Ligand (FasL) with Fas receptors 
between CD8+ T-cells and beta cells, the release of lytic granules and pro-apoptotic proteases 
by activated CD8+ T-lymphocytes (particularly perforin and granzyme), secretion of pro-
inflammatory cytokines IL-1β, IFN-γ and TNF-α via infiltrating immune cells and increase in the 
concentration of NO and reactive oxygen species (ROS) released by infiltrating dendritic cells 
and macrophages, and from cytokine-stimulated beta cells and pancreatic ductal cells (Yoon 
and Jun, 2005). 
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1.1.3 Fas ligand and Perforin:Granzyme Pathways 
Fas (CD95) is part of the TNF-α receptor superfamily and is activated by the binding of 
FasL present on the surface of infiltrating CD8+ T-cells in pancreatic islets, leading to beta cell 
apoptosis (Kawasaki et al., 2004). The ligation of FasL with cell surface Fas receptors leads to 
the recruitment of the Fas-associated death domain (FADD) to the receptor, leading to 
mitochondrial pore formation and release of cytochrome c, as well as directly stimulating the 
auto-cleavage of pro-caspase-8. Acivated caspase-8 cleaves the effector pro-caspase-3 and 
also activates the intrinsic mitochondrial death pathway via cleavage of the BH3 protein Bid 
(Eizirik and Mandrup-Poulsen, 2001). BH3-only proteins such as Bad and tBid (activated by 
caspase-8), regulate the pro-survival Bcl-2 family, which regulates the pro-apoptotic members 
Bax and Bak and ultimately cyctochrome c release from the mitochondria via permiabilization 
of the membrane (Thomas and Biden, 2009; Wang and Youle, 2009). The release of 
cytochrome c into the cytosol from the mitochondria (in part occuring downstream of 
FasL/FasR ligation) interacts with apoptotic protease-activating factor 1 (APAF-1) and pro-
caspase-9 to form the apoptosome, a large protein complex that also contains dATP (Li et al., 
1997). The formation of the apoptosome allows processing of pro-caspase-9, which can then 
proteolytically cleave pro-caspase-3. Now in its active form, caspase-3 targets a number of 
intracellular substrates for degradation in a highly organised ATP-dependent manner, 
ultimately leading to cellular termination (Taylor et al., 2008).  
The importance of Fas/FasL in models of type 1 DM as a contributor to beta cell 
apoptosis are well established in rodent models, as Fas-deficient NOD mice failed to develop 
diabetes, despite the infiltration of lymphocytes (Suarez-Pinzon et al., 2000; Petrovsky et al., 
2002). Stimulation of beta cells with IL-1β and IFN-γ upregulates Fas expression (Kawasaki et 
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al., 2004), with Augstein et al., (2004) observing an increase in Fas expression in NIT-1 mouse 
beta cells following treatment with IL-1β and IFN-γ for 24 hours from 1.4 to 29.7% Fas-positive 
cells; a treatment that was associated with an increase in caspase-3-like activity by 2.1-fold. 
Under these conditions, the addition of FasL for 3 hours augmented cytokine effects, resulting 
in a further a 1.8-fold increase in the caspase-3-like activity (Augstein et al., 2004). Pro-
inflammatory cytokines have been shown to lead to an increased expression of the inducible 
form of nitric oxide synthase (iNOS) in beta cells, resulting in an increase in NO production. 
Interestingly, iNOS inhibition still results in an increase in Fas expression via cytokine-induced 
beta cell damage in NIT-1 beta cells and intact mouse islets (Zumsteg et al., 2000).  Similarly 
iNOS knockout mice (iNOS -/-) failed to increase nitrite production after cytokine treatment, 
though the lack of cytokine-induced iNOS activity still witnessed a 3-fold increase in Fas 
expression, suggesting this occurs in a NO-independent manner, with NF-κB activation 
(downstream of cytokine signalling) likely playing a crucial role in Fas promoter regulation (Liu 
et al., 2000). 
CD8+ T-cells also release  the cytotoxic enzymes perforin and granzyme B as a result of 
TCR recognition of self-antigens presentated on the surface of beta cells by MHC-I molecules, 
with transgenic NOD mice lacking MHC class 1 not developing invasive intra-islet insulitis (De 
Jersey et al., 2007; Pearly-Yafe et al., 2007). Perforin and granzyme B are released into the 
extracellular milieu during insulitis, where perforin initiates pore formation across the cell 
membrane in a Ca2+-dependent mechanism (Pirot et al., 2008), allowing the serine protease 
granzyme B to enter the cell, inducing apoptosis (Estella et al., 2006). Granzyme B-mediated 
apoptosis occurs only in the prescence of perforin and is associated with activation of caspases 
and cleavage of Bid, leading to the aforementioned mitochondrial distruption and activiation 
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of the intrinsic apoptosis pathway via cytochrome c release (Estella et al., 2006). Mice 
deficient in Bid were protected from apoptosis after exposure to perforin/ granzyme B by 
resisting cytochrome c release, suggesting a direct link for granzyme B and Bid in apoptosis 
induction, bypassing the activation of caspase 8 (Barry et al., 2000).  
A study by Kreuwel et al., (1999) investigated the relative contribution of Fas/FasL and 
perforin:granzyme B pathways in diabetes development in a CD8+ adoptive transfer model 
using clone-4 TCR deficient mice. It was shown that blocking the perforin:granzyme pathway 
required a 30-fold increase in CD8+ T-cells for diabetes to develop, in contrast to little effect 
in Fas/FasL deficient models, suggesting an important contribution (though not essential) of 
the perforin:granzyme pathways in diabetes development. Studies using NOD mice lacking 
perforin showed a reduced rate in the development of spontaneous diabetes from 77% in 
perforin+/+ controls compared to 16% in perforin-deficient mice, but concluded chronic 
inflammation of the islets, which led to beta cell loss regardless of perforin, due to a secondary 
effector mechanism (Kägi et al., 1997).   
 
1.1.4 Activation of Pro-Inflammatory Cytokines: IL-1β, IFN-γ 
and TNF-α 
Whilst the contribution of CD8+ T cells to the autoimmune attack against pancreatic 
beta cells represents a form of direct cell:cell killing through the ligation of T-cell receptors 
with beta cell presented antigens, cytokines as soluble effectors of the immune response are 
also well-established contributors to beta cell loss (Cnop et al., 2005; Willcox et al., 2010). 
Much evidence points to an overall pro-apoptotic effect of cytokines by the activation of 
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intracellular signalling pathways culminating in beta cell demise. The following sections 
delineate the signalling pathways mediating the response to individual cytokines and the 
importance of cytokine synergy in beta cell death.  
The release of IL-1β from CD8+ T cells activates of the IL-1β receptor (IL-1R) on the beta 
cell surface inducing the formation of a multi-protein complex structure, which includes IL-1R 
accessory protein (IL-IRAcP), toll interacting protein (Tollip), myeloid differentiation primary 
88 (MyD88), interleukin-1 receptor-associated kinase (IRAK-1) and interleukin-4 receptor-
associated kinase (IRAK-4), with IRAK-4 phosphorylating IRAK-1, resulting in further activation 
and subsequent release of this protein from the IL-1R complex (Eizirik and Mandrup-Poulsen, 
2001). IRAK-1 is now able to interact with the TNF-receptor-associated factor-6 (TRAF-6), 
enabling its phosphorylation and activation (Eizirik and Mandrup-Poulsen, 2001). In its 
activated form, TRAF-6 interplays between activating NF-κB and/or the mitogen activated 
protein kinase (MAPK) pathway (Eizirik and Mandrup-Poulsen, 2001). The phosphorylation of 
IκB kinase (IKK) by TRAF-6 leads to its activation and the phosphorylation of the inhibitory IκB 
subunit, leading to its dissociation from NF-κB and activation of the transcription factor.  
Once activated, NF-κB translocates to the nucleus and regulates transcription of 
several target genes, including the up-regulation of Fas, C-Myc and CD40, which promotes 
beta cell apoptosis. NF-κB also promotes the up-regulation of iNOS, promoting the production 
of high levels of NO which contributes directly to the activation of pro-apoptotic signalling 
pathways and the expression of pro-apoptotic genes including TRAF-2, activating transcription 
factor 4 (ATF-4), C/EBP homologous protein (CHOP)/growth arrest and DNA damage-inducible 
gene 153 (GADD153), and spliced x-box binding protein 1 (XBP-1), as part of an adaptive 
endoplasmic reticulum (ER) stress response (Eizirik and Mandrup-Poulsen, 2001; Cardozo et 
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al., 2005). Other genes altered by NF-κB activation include the down-regulation of pancreatic 
and duodenal homeobox 1 (Pdx-1), insulin gene enhancer protein-1 (Isl-1), cholecystokinin A 
receptor (CCK-A receptor) and phospholipase D1 (PLD-1), leading to decreased beta cell 
proliferation and reduced beta cell function. Pro-apoptotic activity following modifications in 
expression of NF-κB target genes is associated with an increase in Bid and its cleavage to 
activated tBid, increasing the activation and expression of pro-apoptotic Bak and Bax, leading 
to activation of the mitochondrial pathway of apoptosis initiation via the release of 
cytochrome c (Cnop et al., 2005). 
A study by Heimberg et al., (2001) showed that expression of IκB((SA)2), an inhibitor 
of NF-κB, inhibited cytokine-stimulated nuclear translocation and DNA-binding of NF-κB. 
Inhibition of NF-κB meant that increased expression of several downstream target genes of 
the pathway were prevented, namely iNOS, Fas and manganese superoxide dismutase 
(MnSOD), resulting in an increase in beta cell survival. Hohmeier et al., (1998) showed that 
stable overexpression of MnSOD in INS-1 cells ameliorated the cytotoxic effects of IL-1β by a 
reduction in NO levels, correlating with reduced nitrosative and oxidative stress, with 
inhibition of iNOS producing similar findings; this may support an important role for 
peroxynitrite in beta cell death, produced in the equimolar reaction between NO and 
superoxide. In support of this, Azevedo-Martins et al., (2003) showed in RINm5F cells that 
over-expression of MnSOD protected against cytokine toxicity, effects associated with 
reduced NF-κB and iNOS expression and that anti-sense MnSOD resulted in a 3-fold higher 
activation of NF-κB and 2-fold higher activation of iNOS compared to control, again 
emphasising the important role of toxic free radical species and the enzymes responsible for 
controlling their levels in beta cell death (Azevedo-Martins et al., 2003; Lortz and Tiedge, 2003; 
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Gurgul et al., 2004). Interestingly MnSOD overexpression in combination with hydrogen-
peroxide inactivating-catalase provided greater protection against H2O2 and menadione in 
RINm5F cells than catalase expression alone (Lortz and Tiedge, 2003), supporting sensitivity 
of beta cells to cytokine stimulated, NF-κB-dependent, oxidative/nitrosative stress.  
MAPK cascades play a crucial role in apoptosis signalling, resulting in phosphorylation 
and activation of p38 MAPK and c-jun NH2 terminal kinase (JNK) (Saldeen et al., 2001). IL-1β, 
but not IFN-γ, was shown to induce phosphorylation of p38 MAPK, JNK and mitogen- and 
stress-activated protein kinase-1 (MSK-1) in RINm5F cells (Saldeen et al., 2001). With p38 
MAPK known to activate downstream of Protein Kinase C δ (PKCδ) in some models (Chen et 
al., 1999), which is directly activated by caspase-3, inhibition of PKCδ, but not PKCα, by over-
expression of a kinase-dead (KD) mutant reduced iNOS expression, attenuated NO production 
and protected against cytokine-induced apoptosis in INS-1 beta cells, effects similarly 
observed with a PKCδ inhibitor (Carpenter et al. 2001; Carpenter et al. 2002). Interestingly, 
NF-κB activation was achieved independently of PKCδ in this model (Carpenter et al. 2002), 
despite others reporting that PKCδ stimulates NF-κB activity via the IκB kinase (Lallena et al., 
1999).   
When TNF-α binds to the TNF receptor 1 (TNF-R1) this leads to the trimerization and 
recruitment of the adaptor protein TNF receptor-associated death domain protein (TRADD) 
(Eizirik and Mandrup-Poulsen, 2001). Once the TRADD complex is formed it allows the 
recruitment of the TRAF-2 and serine/ threonine kinase Rip. TRAF-2  also activates the NF-κB  
and MAPK pathways by similar mechanisms to IL-1β, suggesting an important syngergy 
between distinct cytokine species in beta cell death (Eizirik and Mandrup-Poulsen, 2001). 
Together, Rip and TRAF-2 can induce activation of the IKK complex, activating both IKKα and 
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IKKβ isoforms unlike IL-1β (Ortis et al., 2012), and acitvates the MAPK pathway by interaction 
between the MAP2Ks: Ask-1 and MEKK-1 (Eizirik and Mandrup-Poulsen. 2001). In rat 
insulinoma cells, TNF-α preferentially phosphorylates and activates JNK and p38 MAPK similar 
to IL-1β, leading to activation of NF-κB (Saldeen et al., 2001; Ortis et al., 2008). Interestingly, 
TNF-α showed a similar level of activation of NF-κB and its subsequent downstream targets, 
however compared to IL-1β, TNF-α stimulated this at a lower rate, which lead to a delayed 
translocation of NF-κB to the nucleus compared to in response to IL-1β (Ortis et al., 2008). 
IFN-γ binding to its receptor results in receptor oligomerization, recruiting janus kinase 
(Jak) -1 and Jak2, both part of the Janus kinase family (Eizirik and Mandrup-Poulsen, 2001). 
Jak1 and 2 are then activated by transphosphorylation allowing the recruitment of the 
transcription factor STAT-1 and its subsequent phosphorylation. STAT-1 then migrates to the 
nucleus after homodimerizing and can regulate, similar to NF-κB, the expression of numerous 
cytokine-response genes containing a γ-activated sequence (GAS) in the promotor region, 
including Fas, caspases and iNOS (Battle and Frank, 2002). Further to this, STAT-1 is able to 
promote an increase in activated caspase-3 by increasing interferon regulatory factor (IRF-1) 
activity, which increases initiator caspase-1 levels, affecting caspase-3 activation (Cnop et al., 
2005). A study using IRF-1 deficient mice exposed to IL-1β (5 U/ml) and IFN-γ (1000 U/ml) 
showed a 30-50% reduction in iNOS mRNA expression and nitrite production, compared to 
the wild type (Pavlovic et al., 1999), suggesting an important role of IRF-1 in elevating iNOS 
levels under co-stimulatory conditions with IL-1β.  
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1.1.5 Synergism of Cytokines 
Although individual cytokines have an effect on beta cells, the idea that IL-1β, IFN-γ 
and TNF-α work in synergy, in alteration of multiple regulatory gene networks, promoting 
increased levels of apoptosis is more likely to be pathophysiologically relevant in the 
development of type 1 DM. Investigations into whether cytokine induced beta cell death is 
associated with changes in the expression of the surface receptors intercellular adhesion 
molecule (ICAM)-1 and activation of Fas/FasL in islets from diabetes-prone and congenic 
diabetes-resistant BB rats showed that IL-1β alone or in combination with IFN-γ and TNF-α 
decreased islet insulin content, suppressed glucose stimulated insulin secretion and enhanced 
the production of nitric oxide and DNA fragmentation (Wachlin et al., 2003).  This study also 
showed that only when islets were treated with a combination of cytokines, was there damage 
to the cell membranes, however independent of diabetes susceptibility, IL-1β was able to 
increase the amount of ICAM-1 expressed at the cell surface, and adding IFN-γ and TNF-α 
witnessed no further increase. The findings showed that IL-1β is the main stimuli for ICAM-1 
expression, promoting further recruitment of immune cells in vivo, but also that a combination 
of all three cytokines induced maximum expression of Fas on the beta cell surface, 
independent of diabetes susceptibility (Walchin et al., 2003).  
Studies in human islets also revealed differences in susceptibility to individual 
cytokines alone and in combination, such that rat beta cells have been shown to be sensitive 
to apoptosis induced by IL-1β treatment alone (Ankarcrona et al., 1994), whereas in mouse 
and human beta cells a combination of cytokines is necessary for significant beta cell loss 
(Cnop et al., 2005). In combination with IL-1β, IFN-γ induced NO and CHOP expression in 
rodent and human beta cells as part of a cytokine-induced ER stress response (Cardozo et al., 
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2005). Whilst only IL-1β alone (but not IFN-γ) was capable of inducing an ER stress response 
but not apoptosis, the combination of both cytokines markedly enhanced ER stress induction 
and apoptosis, effects in part associated with elevated iNOS expression and a reduction in ER 
chaperone expression (Cardozo et al., 2005; Pirot et al., 2006). Figure 1.1 summarises cytokine 
synergistic effects in the initiation in beta cell apoptosis and the role of the Fas/FasL and 
perforin/granzyme B pathways. 
Figure 1.1 Pathways of beta cell apoptosis in type 1 DM. Synergistic activation of cytokine signalling pathways changes in 
STAT1 and NF-κB responsive target genes including iNOS leading to increased beta cell apoptosis, reduced defense capacity 
and altered beta cell function. Mechanisms of direct cell:cell killing by the actions of CD8+ cytotoxic T-cells include ligation of 
FasL with beta cell Fas receptors initiating caspase cascade and Bid cleavage activating the intrinsic mitochondria apoptotic 
pathway synergising with cytokine activity and pro-apoptotit perforin:granzyme B in the initiation of the caspase cascade 
culminating in beta cell apoptis (adapted from Tomita, 2017). 
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1.1.6 Endoplasmic and Oxidative Stress in Type 1 DM 
The formation of NO and the interplay between different pools of ‘reactive species’ as 
a result of their high chemical reactivity, including the formation of peroxynitrite from the 
reaction between NO and superoxide, directly contributes to the activation of pro-apoptotic 
signalling pathways, including the activation of ER stress, disrupting ER calcium homeostasis 
and ER to mitochondrial calcium signalling, further promoting the release of pro-apoptotic 
cytochrome c. It is well known that NO production contributes directly to cytokine-induced 
beta cell death and dysfunction, first reported by Southern et al., (1990), with subsequent 
studies confirming a role for NO, though not essential, in cytokine-induced apoptosis and ER 
stress (Oyadomari et al., 2001; Cardozo et al., 2005; Brovkovych et al., 2011).  Oyadomari et 
al., (2001) showed that S-nitroso-N-acetyl-D, L-penicillamine (SNAP), an NO donor, increased 
cytosolic [Ca2+], and agents depleting ER Ca2+ induced pro-apoptotic CHOP expression 
downstream of ER stress. This suggests that NO depletes ER Ca2+ since overexpression of 
calreticulin showed an increase in ER Ca2+ levels, protecting cells against NO-mediated 
apoptosis. Islets from CHOP knockout mice displayed increased resistance to NO, suggesting 
that NO depletes ER Ca2+ stores, leading to ER stress, resulting in beta cell apoptosis 
(Oyadomari et al., 2001). Subsequently, Cardozo et al., (2005) demonstrated that these effects 
were mediated by inhibition of an ER Ca2+ ATPase in response to pro-inflammatory cytokines 
in rodent beta cells, an effect that was blocked using an iNOS inhibitor, confirming the role of 
NO in mediating an ER stress response in beta cells. The complex interplay between reactive 
nitrogen and oxygen species, including the formation of peroxynitrite is also an acknowledged 
contributor to cytokine toxicity. Whilst some have suggested that human islets display 
reduced sensitivity to the deleterious effects of NO (Flodstrom et al., 1997), others have 
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reported that these islets, and clonal beta cells are highly sensitive to peroxynitrite (DeLaney 
et al., 1997). More recently, Broniowska et al., (2013) found that addition of the NADPH 
oxidase activator phorbol 12-myristate 13-acetate in rat islets and insulinoma cells failed to 
stimulate peroxynitrite generation in response to cytokines; proposing that NO is the likely 
mediator of the toxic effects of the reactive nitrogen species component of cytokine-induced 
loss in viability and that beta cells do not produce peroxynitrite as a response. Furthermore 
when forced to produce superoxide using phorbol 12-myristate 13-acetate , the scavenging of 
nitric oxide by superoxide protected beta cells from nitric oxide-mediated toxicity (Broniowska 
et al., 2013). 
Disruption of ER homeostasis impairs ER folding capacity and results in the 
accumulation of misfolded proteins within the ER lumen, initiating the activation of an 
adaptive response called the unfolded protein response (UPR) (Ron and Walter, 2007). 
Transduction of the UPR by the activation of three transmembrane ER proteins; protein kinase 
RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring protein-1 (IRE-1) and 
activating transcription factor 6 (ATF-6) following dissociation of the chaperone BiP from their 
ER luminal domains. These serve to mitigate ER stress and restore ER homeostasis by  1) 
increasing ER protein folding capacity via increased  expression of ER resident chaperones and 
protein foldases, 2) controlling general protein translation to reduce demands on ER folding 
capacity, 3) up-regulation of ER-associated degradation (ERAD) genes, reducing the load of 
unfolded proteins by their unbiquitiniation, export from the ER and proteosomal degradation 
and 4) if these mechanisms fail to restore ER homeostasis, pro-apoptotic signals via the 
expression of pro-apoptotic CHOP (GADD153), JNK activation and initiation of the caspase 
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cascade, including the activation of mitochondrial-associated pathways (Ron and Walter, 
2007). 
Characteristic ER stress induction by cytokines is achieved by phosphorylation of 
eukaryotic initiation factor 2α (eIF2α) by PERK, necessary for increased ATF-4 levels and 
subsequent up-regulation of pro-apoptotic CHOP in prolonged ER stress, as well as activation 
of alternative mRNA splicing of XBP-1 by IRE1 (Pirot et al., 2006; Pirot et al., 2007). Of note, 
the ATF-6 branch of the UPR seems to be diminished following cytokine-induced ER stress, 
since Cardozo et al. (2005) demonstarted impaired ATF-6 signalling using an UPRE luciferase 
construct under the control of an ATF-6 target sequence, associated with reduced XBP-1 and 
lack of BiP induction; a key ER resident chaperone. Reduced BiP expression in response to IFN-
γ may indicate a role of this cytokine in imparing a pro-adaptive UPR reponse against IL-1β- 
induced ER stress (Pirot et al., 2006). Whilst Akerfeldt et al., (2008) reported that induction of 
ER stress is dispensible for cytokine-induced ER stress, with the chemical chaperone  
phenylbutyrate (PBA) failing to attenutate cytokine toxicity, others have reported that the 
chemical chaperone TUDCA can confer protection in both human and islet models (Brozzi et 
al., 2015). Targetting CHOP through siRNA produced similar results, suggesting an important 
contribution of ER stress in cytokine toxicity this, and observations that ER stress markers can 
be detected in pancreas sections of type 1 patients, continues to maintain interest in the 
understanding of this pathway leading to the pathogenesis of type 1 DM (Marhfour et al., 
2012; Brozzi et al., 2015).  
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1.2 Type 2 Diabetes Mellitus  
In contrast to the autoimmune destruction of pancreatic beta cells that is characteristic 
of type 1 DM, mechanisms responsible for beta cell death and dysfunction in type 2 DM are 
associated with chronic glucolipotoxicity resulting from high-fat diets and peripheral 
hyperglycaemia linked to insulin resistance in adipose and skeletal muscle. Overtime, 
persistent hyperglycaemia forms the basis of a ‘pre-diabetic’ state and eventually a diagnosis 
of type 2 DM (Donath et al., 2013). This can in part be associated with a direct glucotoxic 
effect, as seen in isolated rodent islets exposed to high glucose concentrations of 16.7 or 
33mM for 3-6 days resulting in detectable levels of significant beta cell apoptosis (Piro et al., 
2002; McKenzie et al., 2010). 
 
1.2.1 Type 1-Like Cytokine-Induced Beta Cell Apoptosis in Type 
2 DM 
Rather than two distinct subtypes, a diabetes ‘spectrum’ proposes that there may be 
characteristic traits of type 1 DM development evident in the pathogenesis of type 2 DM. The 
response to elevated circulating glucose and free fatty acids (FFAs) has been suggested to 
activate an innate inflammatory response in two proposed mechanisms; FFA-triggered 
inflammation by toll-like receptor (TLR)-dependent or TLR-independent pathways and cellular 
stress (Donath et al., 2013).  TLRs are important in recognising damage-associated molecular 
patterns (DAMP) in the development of type 2, with particular interest in the roles of TLR2 
and TLR4. In rodent islets it has been demonstrated that saturated fatty acids, such as 
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palmitate (C16:0), can activate an inflammatory response mediated by signalling through the 
TLR4/MyD88 pathway, resulting in the recruitment of monocytes and macrophages, with 
enhanced chemokine secretion (Eguchi et al., 2012). Interest has also focused on the 
importance of the NLRP3 inflammasome as a contributor to an inflammatory response in islets 
in models of type 2 DM and its activation by cellular stress as a result of high glucose and FFAs 
(Dixit, 2013), linked to the initiation of the intrinsic pathway of beta cell apoptosis (Wali et al., 
2013). Activated NLRP3 can also result in cell death via caspase activated-pyroptosis, an 
intermediate step between necrosis and apoptosis, including cytoplasmic swelling and DNA 
fragmentation (Wali et al., 2013; Man et al., 2017).  
Activation of the NLRP3-inflammasome also leads to the release of IL-1β into the islet 
milieu, leading to beta cell dysfunction via downstream effects of cytokine activation on 
intracellular mechanisms, previously discussed (Wali et al., 2013). Physiologically, elevated 
ROS as seen in type 1 DM (consequential to the effects of pro-inflammatory cytokines on 
inducing oxidative stress) and type 2 DM (from increased glucose and FFA metabolism), can 
result in activation of the anti-oxidant enzyme thioredoxin by dissociation of its interacting 
protein TXNIP. The activation of an ER stress response has been shown to result in TXNIP up-
regulation, which directly activates the inflammasome and enhances oxidative stress (Lerner 
et al., 2012). Mouse islets treated with 33mM glucose have been observed to secrete IL-1β in 
a TXNIP-dependent manner (Zhou et al., 2010) and so the idea that IL-1β is secreted by islets 
in a type 2 DM model suggests an overlap between cytokine-induced beta cell apoptosis in 
type 1 DM and type 2 DM. Another possible link is that palmitate can induce NLRP3 
inflammasome activation in immune cells, such as resident macrophages in islets, with few 
studies directly addressing the link between FFAs and NLRP3-inflammasome activation (Wen 
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et al., 2011; Wali et al., 2013).  Interestingly, lipopolysaccharide (LPS)-primed bone marrow-
derived macrophages (BMDMs), bone marrow-derived cells (BMDCs) and peritoneal 
macrophages treated with palmitate displayed increased expression of the NLRP3-
inflammasome and IL-1β production. That macrophages lacking NLRP3 showed no production 
of IL-1β in this model (Wen et al., 2011), further supports the importance of a type 2 DM 
innate inflammatory response with some similarity to type 1 DM.   
 
1.3 Free Fatty Acid-Induced Beta Cell Apoptosis 
Fatty acids are categorized dependent on carbon length; fatty acids less than 6 carbons 
are termed short-chain fatty acids (SCFA), between 6-12 carbons are termed medium-chain 
fatty acids (MCFA) and more than 12 carbons are termed long-chain fatty acids (LCFA). These 
are further classified into saturated or mono/poly- unsaturated depending on the presence 
and number of double bonds (Poudyal et al., 2013). Rising levels of obesity in the population 
are of a major concern and is one of the primary contributors to the development of type 2 
DM. Such hyperlipidemia leads to an increase in the levels of circulating non-esterified FFAs 
contributing to a reduction in beta cell mass via lipotoxicity, as wells as to the progression of 
insulin resistance in peripheral tissues (adipose, skeletal muscle). In in vitro models of type 2 
DM, saturated fatty acids, particularly palmitate (the most abundant fatty acid in human 
plasma and the major fatty acid synthesized de novo in the liver) and stearate (C18:0), are well 
established inducers of beta cell apoptosis, with effects in part mediated via induction of an 
ER stress response (Cunha et al., 2008; Diakogiannaki et al., 2008). However, the extent of 
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toxicity is dependent on chain length, with medium-chain fatty acids such as Laurate (C12:0) 
showing reduced toxicity compared to long-chain fatty acids (Newsholme et al., 2007).  
Whilst elevated saturated fatty acids contribute to beta cell death and dysfunction, 
physiological beta cell function is enhanced by low levels of FFAs via augmentation of glucose-
stimulated insulin secretion (GSIS) and depleting beta cells of intra-islet FFAs results in a 
reduction in GSIS (Stein et al., 1996).  Additionally, although long-chain saturated fatty acids 
induce beta cell apoptosis in high concentrations, mono- and poly-unsaturated species such 
as palmitoleate (C16:1), oleate (C18:1) or arachidonic acid (C20:4) are well tolerated and can 
attenuate the cytotoxicity observed in response to saturated fatty acids (Welters et al., 2004; 
Diakogiannaki  et al., 2007; Keane et al., 2011). Mechanisms resposible for these effects may 
include partioning of toxic FFA species into neutral lipids via triglyceride synthesis, with 
observations that the esterification of FFAs into triacylglycerides (TAG) in the ER appears to 
be the unlikely activator of an ER stress response by ER lipid overload, suggesting that TAG 
synthesis may be a protective mechanism againts elevated FFAs (Cuhna et al., 2008). 
 
1.3.1 Palmitate Metabolism 
When free fatty acids enter the beta cell they are activated by acyl-CoA synthetase, 
which results in them either being oxidised (via entry to the mitochondria, mediated by 
carnitine palmitoyl transferase-1, CPT-1), serving as an important energy source in cells by  β-
oxidation, or re-esterified for storage as TAG (Prentki et al., 2002). Importantly non-
metabolisable methyl-ester derivatives of fatty acids are non-toxic to beta cells, failing to 
induce ER stress, suggesting the availability of palmitate to be metabolised is key in 
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metabolically activating triggers of ER stress and lipotoxicity (Cuhna et al., 2008).  High levels 
of long-chain fatty acids and very long-chain fatty acids can also result in β-oxidation in 
peroxisomes producing hydrogen peroxide as a byproduct (Elsner et al., 2011; Plötz et al., 
2016). Given that pancreatic beta cells have been shown to lack the hydrogen peroxide 
inactivating enzyme catalase, this therefore represents an important source of FFA-induced 
oxidative stress (Lenzen et al., 1996; Tiedge et al., 1997; Elsner et al., 2011), with 
overexpression of catalase protecting against palmitate toxicity in RINm5F cells (Elsner et al., 
2011).  
In states of fasting FFAs serve as an important energy source, undergoing β-oxidation 
in the mitochondria, whereas in well-fed states, increased glucose metabolism generates ATP 
and cytosolic malonyl-CoA via acetyl-CoA-carboxylase (ACC) (Roduit  et al., 2004). Excess 
malonyl-CoA prevents β-oxidation via inhibition of CPT-1, which stops transportation of acyl-
CoA into the mitochondria, thereby allowing an accumulation of cytosolic long-chain fatty 
acids. Under pathological conditions of hyperglycaemia and hyperlipidaemia, dysregulation of 
these processes by glucolipotoxicity further increases cytosolic accumulation of FFAs, 
contributing to cytotoxicity. In support of this, over-expression of CPT-1 protected against 
glucolipotoxicity in INS-1 cells (Sol et al., 2008) and inhibition of CPT-1 in the same cell line by 
etomoxir augmented palmitate-induced cell death and its knockdown increased palmitate-
induced CHOP levels, whilst reducing eIF2α and phosphorylated-JNK, suggesting alterations in 
palmitate-induced ER stress signals under conditions affecting β-oxidation (Choi et al., 2011). 
Glucose concentrations exceeding 20mM have also been shown to potentiate palmitate-
induced cell death in INS-1 cells and dispersed human beta cells, but not MIN6 cells or intact 
islets, reflecting a contribution of glucolipotoxicity in alterations in lipid handling in beta cells 
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(El-Assaad et al., 2003; Sargsyan and Bergsten 2011). Differences between these models may 
relate to a higher expression level of ACC in INS-1 cells, thereby contributing to increased 
levels of malonyl-CoA in response to high glucose levels. Additionally, MIN6 cells display a 
higher expression level of stearoyl-CoA-desaturase 1 (SCD-1) (Lai et al., 2008; Sargsyan and 
Bergsten, 2011), potentially reflecting differences in lipid handling in terms of fatty acid β-
oxidation and TAG synthesis.  
The contribution of TAG formation in beta cell models of lipotoxicity remains unclear 
and indeed whether or not this represents a mechanism contributing to the cytoprotective 
actions of unsaturated species. In regards of studies concerning this, non-metabolisable 
methyl-ester derivatives of FFA species and the poorly metabolisable palmitate analogue 2-
Bromopalmitate (2-BP), which can be thioesterified to Coenzyme-A, but is unable to undergo 
further metabolism, have been employed. Cnop et al., (2001) demonstrated that increased 
TAG formation correlated with higher cell viability in primary rat beta cells exposed to FFAs 
and observed toxicity of 2-BP, supporting that mitochondrial oxidation is not necessary for 
palmitate toxicity. This species is also incapable of being incorportated into triglycerides and 
may suppress palmitate-TAG formation through sequestring CoA and reducing available 
substrates for TAG synthesis (Diakogiannaki et al., 2007). Listenberger et al., (2003) showed 
that the unsaturated FFA oleate protected against palmitate toxicity in CHO cells by increasing 
its incorporation into neutral lipids and others have also reported a similar increase in TAG 
formation in co-incubation with the unsaturated fatty acid palmitoleate in BRIN-BD11 cells 
however, observations that methyl-palmitoleate failed to increase TAG, despite protecting 
against palmitate toxicity, suggests TAG formation is dispensible to the cytoprotective actions 
of unsaturated FFAs (Diakogiannaki et al., 2007). Perilipin is a protein associated with 
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intracellular lipid stores, protecting lipid droplets from the action of hormone sensitive lipase, 
which is observed to be expressed in pancreatic beta cells and its over-expression in INS-1 
cells was associated with increased TAG formation and protection against palmitate toxicity 
(Borg et al., 2009). However, this view has again been challenged, with astudy showing that 
shRNA targeting perilipin did not alter the cytoprotective effects of oleate in RINm5F and INS-
1 cells (Plotz et al., 2006), despite demonstrating that a range of mono- and poly-unsaturated 
fatty acids increased total lipid droplet content.  
 The enzyme diacylglycerol acyl‐transferase (DGAT) controls the last acylation step in 
TAG formation and over-expression of DGAT-1 in beta cells has been shown to increase 
palmitate incorporation into triglycerides 2-fold, with data also suggesting that glucose is 
required for palmitate to increase triglyceride mass, presumably by increasing glycerol 
availability form enhanced glycolytic flux (Briaud et al., 2001 Kelpe et al., 2002). In one study 
in MIN6 cells treated with palmitate and stearate, DGAT-1 and DGAT-2 expression were both 
increased up to 3-fold compared to controls (Thorn and Bergsten, 2010). In contrast, this study 
also showed that DGAT-1 expression was unchanged in the presence of the unsaturated fatty 
acid oleate, despite which unsaturated species were preferentially incorporated into TAG. The 
idea that unsaturated fatty acids preferentially favour TAG formation is reported in other beta 
cell models (Moffitt et al., 2005; Diakogiannaki et al., 2007) and hepatocytes (Leamy et al., 
2016). In support of this, Montell et al., (2001) demonstrated that unsaturated fatty acids are 
preferentially channelled to TAG synthesis in muscle cells, with saturated fatty acids diverted 
towards diacylglycerol (DAG) formation and activation of PKC. Of note, PKCδ activation has 
been reported to be necessary for FFA-induced beta cell apoptosis, with PKCδ knockout mouse 
islets protected from palmitate-induced mitochondrial dysfunction (Eitel et al., 2003; Hennige 
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et al., 2009). However, this view has been challenged in BRIN-BD11 cells, with down-regulation 
of PKCδ failing to attenuate palmitate toxicity in contrast to the use of the PKCδ inhibitor 
rottlerin, with data suggesting a potential role for other rottlerin-sensitive kinases in 
promoting beta cell death (Welters et al., 2004b). Whilst limited incorporation of palmitate 
into TAG, despite the reported increase in DGAT expression, may seem counter-intuitive, the 
formation of tripalmitin (with three palmitate chains esterified to glycerol) has been shown to 
lead to ER stress induction and apoptosis in INS-1 cells (Moffitt et al., 2005). Therefore, the 
presence of unsaturated species, in combination with palmitate, may increase TAG synthesis 
from alterations in total cellular lipid content.   
Saturated FFAs can be directly converted into unsaturated species, including the 
conversion of palmitate to palmitoleate, by the enzyme SCD (Green and Olson, 2011).  SCD is 
expressed as one of four isoforms with SCD-1 and -2 being the two major isoforms expressed 
in mouse beta cells and expression of SCD-1 being up-regulated in the presence of palmitate 
or stearate but decreased in the presence of their unsaturated counterparts (Thorn and 
Bergsten, 2010). In support of the preferential incorporation of unsaturated species into TAG, 
in CHO cells, over-expression of SCD-1 was sufficient in protecting against palmitate-induced 
toxicity, associated with a 5-fold increase in TAG (Listenberger et al., 2003). However, whilst 
in palmitate-resistant MIN6 cells, SCD-1 function was found to be necessary in protecting 
against lipo-apoptosis, this was not associated with increased TAG formation (Busch et al., 
2005).  
Peroxisome proliferator-activated receptor (PPAR) α agonists have also been 
associated with increased rates of β-oxidation and peroxisomal activity, with noticeable 
increases in SCD expression (Hellemans et al., 2007).  It has been shown that agonists of PPARα 
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and Liver X Receptors (LXR), nuclear oxysterol receptors with established roles in cholesterol 
and lipid metabolism, provide long-term protection against palmitate in rodent and human 
beta cells through increased SCD (Gerin et al., 2005; Hellemans et al., 2009). LXR-β is also 
required for expression of the cholesterol transporters ABCA1 and ABCG1 and, in pancreatic 
islets, lipid droplets may result from the accumulation of cholesterol esters (Gerin et al., 2005), 
further supported by observations that SCD-dependent, palmitate-resistant MIN6 cells 
displayed increased intracellular cholesterol ester accumulation rather than TAG (Busch et al., 
2005).  
As well as being desaturated, fatty acids can also be targeted for chain extension, 
achieved in multiples of two carbon units (from acetyl-CoA), by members of the elongation of 
very long chain fatty acids (Elovl) gene family, which encode for the elongase enzyme family 
(Jakobsson et al., 2006). Fatty acid elongases can be divided into two distinct groups: 1) Elovl1, 
3 and 6, suggested to be involved in the elongation of saturated and monounsaturated very 
long chain fatty acids (VLCFA) or 2) Elovl2, 4 and 5 which are elongases of polyunsaturated 
fatty acids (PUFAs) (Jakobsson et al., 2006). Elovl-6 has been shown to be highly expressed in 
MIN6 cells and mouse islets, with comparable expression to that seen in brain and liver (Tang 
et al., 2014), with Elovl3 and Elovl7 shown to be increased in MIN6 cells in response to 
palmitate (Thorn and Bergsten, 2010). Of note, Elovl6−/− mouse islets showed a decrease in 
several fatty acid metabolism-related genes including the transcription factors sterol response 
element binding protein (SREBP) -1c and Pdx-1, as well as fatty acid synthase (FAS) and SCD-1 
(Tang et al., 2014). However, Elovl6−/− islets from mice fed a high-fat diet showed lower 
C18:0/C16:0 ratios, though also displayed an increase in SCD-1 consistent with elevated ratios 
of C18:1 to C18:0 fatty acids, suggested to be protective against lipotoxicity in this model (Tang 
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et al., 2014). In support of this, knockdown of Elovl6 in INS-1 cells partially attenuated 
palmitate-induced ER stress and caspase-9 cleavage (Green and Olson, 2011). The major 
pathways of palmitate metabolism in beta cells and the role of ROS in the contribution to 
palmitate-induced apoptosis are summarised in figure 1.2. 
 
 
 
 
 
 
 
 
 
1.3.2 Ceramide Synthesis 
Alongside the production of TAG, palmitate can also be metabolised to ceramide, 
which has been implicated in beta cell death in models of type 1 and 2 DM. The two primary 
pathways for the production of ceramide are by palmitate and serine condensation (de novo 
Figure 1.2 Major pathways of palmitate metabolism and ROS production in beta cells. (1) Preferential shuttling of cellular 
palmitoyl CoA into DAG formation leads to increase PKC activation and ROS production via NOX enzymes. These effects may, 
in part, be attenuated in the presence of unsaturated species such as oleate (OA) via increased TAG formation. (2) Entry of 
palmitoyl CoA into the mitochondria via the action of CPT1 which may increase ROS production via increased β-oxidation and 
superoxide release from the electron transport chain. (3) Elevated intracellular ROS directly contributes to a redox imbalance 
in the ER, including as a consequence of dysregulated ER calcium homeostasis promoting an ER stress response (section 
1.3.3). Inhibitory action of malonyl CoA at CPT1, potentiated under hyperglycaemic conditions may increase palmitate 
metabolism in other pathways including DAG formation contributing to extra-mitochondrial ROS (Ly et al., 2017). 
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pathway) and re-acylation of sphingosine (salvage pathway). In models of type 1 DM, 
ceramide plays a role in apoptosis following exposure to cytokines, contributing to ER stress 
induction and mitochondrial release of cytochrome c (Lang et al., 2011). In context to type 2 
DM, ceramide production occurs in response to high levels of saturated fatty acids, which 
induce the de novo sphingolipid biosynthetic pathway, leading in an increase in ceramide 
accumulation, which also contributes to insulin resistance in peripheral tissues (Bikman and 
Summers, 2011). By increasing ceramide production, palmitate contributes to the 
development of insulin resistance by decreasing glucose uptake via inhibition of protein kinase 
B (PKB)/Akt, with prolonged exposure further shown to inhibit the insulin receptor substrate-
1 (IRS1) in a protein kinase R-dependent manner (Hassan et al., 2016). Furthermore, ablation 
of ceramide production by inhibition of ceramide synthase restores whole body energy 
expenditure and improves liver β-oxidation, resulting in improved glucose homeostasis  
(Turpin et al., 2014). 
Chronic exposure of beta cells to palmitate augments ceramide synthesis, leading to 
increased ER stress and apoptosis, attenuated by inhibition of ceramide synthetase, 
highlighting its importance for pharmacological inhibition to promote beta cell survival 
(Boslem et al., 2011). Similar effects of palmitate exposure on ceramide production and 
positive results from inhibition of ceramide synthesis have also been shown in human islets to 
reduce FFA toxicity (Lupi  et al., 2002). Toxicity of ceramide has been linked to activation of 
ceramide-activated protein kinases, which may promote activation of MAPK pathways and 
JNK, leading to NF-κB activation and iNOS induction  (Shimabukuro et al., 1998a; Mathias et 
al., 1998; Listenberger et al., 2001). However, despite a known link between palmitate and 
ceramide production and that signalling pathways downstream of ceramide are known to 
33 
 
produce NO, numerous studies have shown no increase in NO production in beta cell line 
models in resposne to FFAs, however, these effects have been reported in some models, 
including islets, suggesting differences in the response to FFA toxicity between models and 
species (Cnop et al., 2001; Busch et al., 2005).  In more recent studies using MIN6 cells, both 
Boslem et al., (2011) and Watson et al., (2011) inhibited de novo ceramide synthesis using 
serine palmitoyl transferase inhibitors (SPT) and showed it had no effect on GSIS with Thorn 
and Bergsten (2010) similarly showing that palmitate-induced ER stress was not accounted for 
by ceramide de novo synthesis. Rather palmitate initiated stronger expression changes in  SCD-
1, DGAT-1 and -2 and FAS, supporting ceramide-independent mechanisms of palmitate 
toxicity (Listenberger et al., 2001). 
 
1.3.4 Endoplasmic Reticulum (ER) Stress in Type 2 DM 
Impaired insulin sensitivity and reduced secretion, together with a decline in functional 
beta cell mass in the development of type 2 DM occurs as individuals fail to compensate for 
the demand in insulin output, together with the effects of glucolipotoxicity on beta cell 
viability, which are associated with the activation of an ER stress response (Eizirik et al., 2008; 
Cnop et al., 2011). Under a high glucose load, beta cells may increase proinsulin synthesis by 
up to 10-fold to achieve regulation of glucose homeostasis, whilst maintaining normal beta 
cell function (Eizirik and Cnop, 2010). ER stress is highly regulated and normal ER function is 
associated with storage of Ca2+ three to four orders of magnitude higher than cytosolic Ca2+, 
providing an oxidative folding environment for secretory and transmembrane proteins and 
synthesis of sterols and lipids, with uptake into the ER regulated by sarco(endo)plasmic 
reticulum Ca2+ ATPase proteins (SERCA) and Ca2+ release regulated by inositol 1,4,5-
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trisphosphate (InsP(3)) and ryanodine receptors (Berridge, 2002). Alterations in ER Ca2+ 
homeostasis can lead to the induction of ER stress, as reported for the effects of cytokine-
induced NO-dependent ER stress, associated with SERCA inhibition (Cardozo et al., 2005). 
Recognition of unfolded proteins is achieved by the hydrophobic effect and the inability to 
shield hydrophobic regions of proteins during folding. Prevention of random folding and 
protection of hydrophobic regions is achieved by three distinct molecular chaperone families; 
heat shock protein (HSP) 70 (HSP70), HSP90 and lectin chaperones, which create a discreet 
folding space allowing correct conformational folded states to be obtained.  
Under mild conditions of ER stress beta cells may recover following UPR induction. 
mediating translation inhibition and degradation of mis-folded ER proteins in a pro-adaptive 
ER stress response. However, chronic exposue to glucose and FFAs, can provide an 
unrecoverable burden on beta cells with increasing demands on ER folding capacity, as well 
as direct cytotoxic factors, initiating a pro-apoptotic ER stress response from sustained 
activation of the IRE1 and PERK pathways, leading to beta cell death (Eizirik et al., 2008). The 
UPR can be divided into several phases to regulate different responses; 1) contribution to 
maintenance of homeostasis in normal (unstressed) cells, 2) co-ordinating the adaptive 
response in stressed cells and 3) induction of apoptosis after failing to resolve ER stress (Eizirik 
et al., 2008). In addition to general translational inhibition, reducing ER protein folding 
demand, mis-folded proteins are marked for degradation by stimulation of ERAD, mediated 
via export and protesomal degradation (Mehnert et al., 2010). Second to this, additional 
processes such as autophagy are activated to maintin cellular function (Kruse et al., 2006), a 
process typically stimulated in response to starvation or other forms of nutrient deprivation, 
decreasing substrates for cellular energy generation (Kadowaki et al., 2006). Autophagy also 
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serves to recycle excess or damaged intracellular organelles and under normal conditions is 
less active, acting more as a housekeeping mechanism, but plays a crucial role under stressed 
conditions, including following initiation of ER stress (Kaushik et al., 2010). Autophagy has 
previously been associated with protein and organelle turnover; however, evidence has also 
linked autophagy to having other functions in response to certain types of metabolic stress 
induced by carbohydrate and lipid derangements (Kaushik et al., 2010). Martino et al., (2012) 
has shown that autophagy is activated in INS-1 cells and isolated rat and human islets in 
response to palmitate, whilst others have suggested that this process is not necessary for 
palmitate-induced beta cell loss and that treatment of INS-1 cells with 3-methyladenine, an 
inhibitor of autophagy, showed only a modest beneficial response under these conditions 
(Choi et al., 2008).  
The three main processes involved in the initiation of the UPR are the activation of 
IRE1, PERK and ATF6, in response to dissocation of the ER chaperone BiP from their luminal 
domain, as previously outlined (section 1.1.6) and are well-established mechanisms 
associated with palmitate toxicity, with unsaturated species partially protecting against 
palmitate-induced ER stress (Cunha et al., 2008; Diakogiannaki et al., 2008). High levels of 
IRE1α are found within the pancreas and, in response to ER stress, activated IRE1α cleaves the 
unspliced form of XBP-1 mRNA via its RNase domain, excising a 26 base-pair intron, forming 
spliced (XBP1s) mRNA, with noticeable levels of XBP1s detected in INS-1 cells treated with 
palmitate after 12 hours, compared to oleate (Tsuchiya et al., 2018; Cuhna et al., 2008). 
Increased XBP1s leads to the up-regulation of genes encoding the ER-associated degradation 
proteins, glycosylation enzymes, lipid synthesis enzymes, ER chaperones and secretory 
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proteins to remodel cellular output and restore cellular physiology (Ron and Walter, 2007; 
Tsuchiya et al., 2018). 
Alongside IRE1α, PERK becomes activated in response to ER stress via the dissociation 
of BiP, linked with high-molecular-mass complexes of activated PERK and IRE1α, with 
repression of the two signalling pathways achieved by overexpression of the BiP chaperone 
(Bertolotti et al., 2000). The now active PERK results in phosphorylation of eIF2α by to prevent 
further protein overload within the ER, aiming to reduce ER stress by inhibiting translation 
initiation (Novoa et al., 2001; Wortham and Pround, 2015). Activated PERK and eIF2α further 
induces translation of ATF4, with mRNA and protein levels of ATF4 induced 8-fold after 24 
hours treatment of beta cells with palmitate, in comparison to only a 2-fold induction by the 
mono-unsaturated species oleate (Harding et al., 2003; Cuhna et al., 2008). ATF4 also 
increases expression of genes involved in ER protein folding, ERAD, amino acid biosynthesis 
and transport, antioxidant stress response, ATF3 and CHOP (Cnop et al., 2017). CHOP 
expression, in part, is largely accounted for by the PERK-eIF2α-ATF4 pathway, with pro-
apoptotic signalling downstream of palmitate-induced ER stress evident by increased CHOP 
expression; mRNA levels peaking at an 8-fold increase after 12 hours treatment and a 4-fold 
increase in CHOP protein detected after only 6 hours in INS-1 cells (Cunha et al., 2008). Similar 
observations have also been reported in MIN6 cells treated with palmitate (Laybutt et al., 
2007) and CHOP deletion in mice results in an increased expression of UPR- and oxidative 
stress- related genes, including SOD and glutathione peroxidase, reducing levels of oxidative 
damage (as assessed by measurement of protein oxidation and lipid peroxidation) and beta 
cell apoptosis (Song et al., 2008).  
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The increases in PERK phosphorylation and XBP-1 splicing, as well as downstream 
expression of the UPR target genes BiP, ATF4 and pro-apoptotic CHOP, support that fatty 
acids, such as palmitate induce beta cell apoptosis in part via ER stress (Laybutt et al., 2007). 
Mechanisms by which CHOP up-regulation can induce apoptosis may be via initiation of the 
intrinsic apoptosis pathway, with CHOP shown to lead to a decreased expression of anti-
apoptotic Bcl-2, which results in a reduction in cellular glutathione and perturbation of cellular 
redox control (McCullough et al., 2001) and CHOP up-regulation can induce expression of 
PUMA (Cazanave et al., 2010), leading to mitochondrial Bax translocation, cytochrome c 
release and caspase cleavage (Gurzov et al., 2010). Examination of the integrated role of CHOP 
and the transcription factor activating protein-1 (AP-1) in mediating PUMA induction by 
palmitate showed that knockdown of CHOP by shRNA attenuated palmitate-induced 
apoptosis in Huh-7 cells (Cazanave et al., 2010), a response associated with a reduction in 
PUMA mRNA and protein levels as well as Bax activation. Bax and Bak deficient mice have 
been shown to be resistant to ER stress-mediated apoptosis, as well as from over-expression 
of Bcl-2 which is able to block CHOP-induced apoptosis (Wei et al., 2001).  
ATF6 is released from the membrane under conditions of ER stress, where it 
translocates to the Golgi and is cleaved by site-1 and -2 proteases, which also process sterol 
response element binding proteins in response to cholesterol. Cleaved ATF6 translocates to 
the nucleus and activates ER stress-inducible promoters, of which Grp78/BiP is most 
characterised, as well as genes encoding other ER chaperone proteins and protein folding 
enzymes (Hong et al., 2004). ATF6 also directly upregulates XBP-1 mRNA, working in synergism 
with IRE1α-mediated XBP-1 splicing (Lee et al., 2002). However, whilst several branches of the 
UPR signaling pathway are present and up-regulated in beta cells in response to palmitate 
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(including activation of IRE1α, PERK, eIF2α phosphorylation, ATF-4, XBP-1s and CHOP), some 
have shown limited activation of ATF6 in INS-1 cells, suggesting impaired activation of this 
pathway under these conditions (Cardozo et al., 2005). Conversely others have reported 
increased ATF6 activation in response to palmitate in MIN6 cells (Laybutt et al., 2007), possibly 
reflective of species/cell type differences in the ER stress response. However, over-expression 
of BiP (as one of the main targets of ATF6 signaling), failed to attenuate palmitate toxicity in 
INS-1 cells (Lai et al., 2008), suggesting lipotoxicity may occur independently to ER stress 
induction, though this does not preclude a potential contribution of other ATF6 targets to the 
differences observed between INS-1 and MIN6 cell line models. 
Prolonged exposure to ER stress ultimately results in beta cell apoptosis, however 
under acute ER stress, mechanisms to counteract the UPR and translational repression upon 
restoration of homeostasis are mediated through growth arrest and DNA damage inducible 
34 (GADD34). This interacts with protein phosphatase 1c (PP1c), leading to the 
dephosphorylation of eIF2α, lifting the inhibition on general protein translation as a part of a 
pro-adaptive ER stress response, with mutated PP1c failing to dephosphorylate eIF2α and 
blocking attenuation of CHOP by GADD34 (Novoa et al., 2001). Whilst this serves as a 
mechanism to counteract UPR signalling under acute conditions, in response to prolonged ER 
stress, this may serve to allow increased expression of pro-apoptotic proteins. In a screen of 
molecules able to alter cellular ER stress signalling in PC-12 cells, salubrinal was indentified as 
an inhibitor of eIF2α dephosphorylation and protected against ER stress induced by 
thapsigargin (SERCA inhibitor) or tunicamycin (ER glycosylation inhibitior) (Boyce et al., 2005). 
Under these conditions it is likely that cells were able to maintain a level of ER chaperone 
protein expression, whilst decreasing overall protein load in the ER, leading to a pro-adaptive 
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response. In contrast, salubrinal augmented palmitate-induced ER stress and apoptosis in beta 
cells and induced apoptosis when used alone (Cnop et al., 2007), such differences when 
applied to beta cell models is likely indicative of an enhanced vulnerability to any perturbation 
in the delicate balance of pro-adaptive and pro-apoptotic ER stress signalling, given the 
secretory capacity of these cells. Nonetheless, the cytoprotective effects of unsaturated FFAs 
in models of palmitate toxicty have been associated with a reduction in ER stress markers, 
with palmitoleate also protecting against tunicamycin-induced ER stress in BRIN-BD11 cells 
(Diakogiannaki et al., 2008). Of note, this study also reported protection against salubrinal 
toxicity, suggesting that monounsataurated species may exert their effects by acting at an 
early step in the initiation of ER stress.  
 
1.3.3 Free Fatty Acid Receptors 
Alongside direct intracellular changes in lipid handling/metabolism, fatty acids also 
exert their effects through extracellular receptor activation. Several free fatty acid receptors 
have been identified, which are of interest because of their effects on promoting insulin 
secretion. One such FFA receptor, FFAR1, G-protein coupled receptor 40 (GPR40), is expressed 
on the cell surface in both human and rat beta cells and has been identified as a potential 
target for FFAs, with high mRNA expression in the pancreas (Briscoe et al., 2003; Itoh and 
Hinuma, 2005; Suckrow et al., 2014).  In in vitro  models of type 2 DM, treatment with 
saturated fatty acids results in decreased FFAR1 expression, with the effect reversed in the 
prescence of unsaturated fatty acids, protecting against lipotoxicity (Tuo et al., 2012). 
Evidence suggests that FFA-GPR40 activation in rat pancreatic beta cells increases intracellular 
calcium levels and insulin secretion via receptor activation of phospholipase C (PLC), a 
40 
 
membrane bound enzyme, in the prescence of oleate, with the PLC inhibitor U-73122 
attenuating these effects and reducing PLC-directed formation of DAG and inositol-1,4,5-
trisphosphate (IP3) (Fujiwara et al., 2005; Thore et al., 2005). GPR40 signalling has also been 
implicated in the activation of signal-regulated protein kinases 1 and 2 (ERK1/2), in mediating 
protection against palmitate-induced beta cell death, in part, via increased phosphorylation 
of ERK 1/2 in response to a GPR40 agonist (Wagner et al., 2013; Panse et al., 2015). Of note, 
some have suggested a role of GPR40 in mediating the cytoprotective actions of 
monounsaturated FFAs against lipotoxicity, with siRNA targeting GPR40 in NIT-1 partially 
preventing the decrease in apoptosis in co-incubation with oleate (Zhang et al., 2007). 
However, though this study firstly confirmed successful GPR40 silencing with three different 
siRNAs, studies on the effects of this on apoptosis induction were only carried out with one of 
silencing constructs (Zhang et al., 2007) and these observations are not consistent with the 
view that saturated FFAs are also ligands for GPR40 whereas methyl-esters of 
monounsaturates are not, and yet mediate a similar protective action (Morgan and Dhayal, 
2009). 
GPR120 also functions as a receptor for saturated and unsaturated long-chain fatty 
acids and has been shown to play a crucial role in several physiological homeostatic 
mechanisms, with modest levels of GPR120 found in pancreatic islets (Suckrow et al., 2014). 
In humans, an increase in GPR120 expression has been associated with an increase in obesity 
and, compared to lean controls, GPR120-deficient mice fed a high-fat diet developed fatty 
liver, glucose intolerance and obesity (Ichimura et al., 2012). Activation of GPR120 stimulates 
the secretion of the incretin hormone glucagon-like peptide-1 (GLP-1) and exhibits anti-
diabetic effects as shown with agonists in obese mice (Tanaka et al., 2008; Oh et al., 2014). 
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Similar to GPR40, GPR120 can induce activation of ERK 1/2, phosphoinositide-3-kinase (PI3K) 
and the serine/threonine protein kinase Akt (Hara et al., 2009), which is suggested to be the 
main mechanism for protection against serum deprivation by FFAs in intestinal epithelial cells, 
with over-expression of GPR120 cDNA reducing caspase-3 activation (Katsuma et al., 2005). 
Binding of α-linolenic acid (ALA), a natural ligand for GPR120, provoked an increase in Ca2+ in 
HEK293 cells expressing rat GPR120 (rGPR120), which shares an 85 and 98% sequence 
homology to humans and mouse, respectively (Tanaka et al., 2008). In context to beta cell 
biology, long-term administration of ALA  increased beta cell proliferation in Sprague-Dawley 
rats via enhanced GLP-1 secretion, which has been shown to reverse lysosomal dysfunction, 
known to contribute to beta cell death via release of cathepsin D and impairing autphagic flux 
(Tanaka et al., 2008; Nagasawa et al., 2018; Zummo et al., 2017). 
A role for GPR119 is of interest in type 2 DM given its contribution in animal models to 
negatively influencing food intake, reducing visceral fat mass and lowering body weight. 
(Morgan and Dhayal, 2009). GPR119 binds ethanolamides and is predominately present in 
rodent pancreas and gastrointestinal tract, with speculation that GPR119 activation may be 
mediated in part through the lipid signalling agent oleoylethanolamide (OEA), which has been 
shown to act peripherally in reducing food intake and body weight gain in rat feeding models 
(Overton et al., 2006). A direct role for GPR119 in beta cells remains controversial, with some 
beta cells reported not to express the receptor (reviewed in Morgan and Dhayal, 2009) and 
some showing that GPR119 agonists failed to protect against palmitate toxicity in BRIN-BD11 
cells (Stone et al., 2012). Activation of GPR119 has also been shown to improve glucose 
homeostasis via cAMP-mediated enchancement of GLP-1 release, improving glucose-
dependent insulin release (Chu et al., 2008), highlighting important differences between 
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direct physiological roles (if any) within beta cells in contrast to GPR119 activity possibly 
contributing to increasing the incretin effect on GSIS in vivo.  
Other G-protein coupled receptors have been identified in relation to fatty acid binding 
and activation such as GPR41 and GPR43 (Brown et al., 2003), however with GPR40, GPR119 
and GPR120 known to directly bind fatty acids and their derivatives, with well-characterised 
signalling activities, these continue to be the main focus of the GPCRs in this context (Morgan 
and Dhayal, 2009). 
 
1.4 Arachidonic Acid Metabolism 
Arachidonic Acid (AA) is a polyunsaturated fatty acid (C20:4) bound to lipid membranes 
and/or other complex lipids and constitutes >30% of the glycerolipid fatty acid mass in rodent 
islets (Ramanadham et al., 1993). AA can be esterified/released at the sn-2 position of the 
glycerol backbone of membrane phospholipids by phospholipase A2 (PLA2), recognising the 
sn-2 acyl bond of the phospholipids, resulting in their hydrolysis and the release of AA (Imig, 
2000; Luo and Wang, 2011). AA release is known to positively contribute to GSIS as part of 
normal cellular function, with inhibition of its release from the phospholipid membrane 
negatively affecting insulin secretion (Ramanadham et al., 2004). Further, inhibition or 
knockdown of iPLA2β expression, a calcium-dependent PLA2 enzyme, in INS-1 cells is 
associated with a decrease in insulin secretion and transgenic over-expression of iPLA2β 
results in an enhanced GSIS response (Song et al., 2005; Bao et al., 2006). Several other PLA2 
family members have been shown to be involved in beta cell function such as cytosolic PLA2 
(cPLA2), shown to enhance insulin exocytosis (Juhl et al., 2003). Second to this, secretory PLA2 
(sPLA2) subtypes GX- and GV- sPLA2 have differential actions, negatively regulating insulin 
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secretion by enhancing prostaglandin E2 (PGE2) production and serving to enhance GSIS, 
respectively (Shridas et al., 2017).  
AA and its metabolites have also been shown to be cytoprotective in models of lipo-
apoptosis, with over-expression of cPLA2 in MIN6 beta cells increasing endogenous AA release 
and protecting against loss in viability induced by palmitate (Papadimitriou et al., 2007). 
Similar evidence is also reported in BRIN-BD11 cells, with data suggesting that this may by 
mediated by a reduction in NF-κB, iNOS and NADPH oxidase subunit levels and a reduction in 
NO and ROS levels, respectively (Keane et al., 2011). Although this study supports the idea of 
an increase in iNOS expression and subsequent production of NO in beta cells in response to 
FFA treatment, others suggest the absence of an increase in iNOS expression and NO 
production, including in same beta cell line (Cnop et al., 2001; Welters et al., 2004a). 
Nonetheless, the contribution of oxidative stress to lipotoxicity in beta cells is well-established 
(Elsner et al., 2001) and AA (or its metabolites) may contribute to the attenuation of this 
(Keane et al., 2011). Potential mechanisms of AA action (or its metabolites) have also been 
explored, with some observations suggesting changes in the expression of genes involved in 
FFA metabolism, which may indicate AA actions in context to changes in lipid handling in these 
cells. Treatment of BRIN-BD11 cells with AA resulted in a down regulation of SCD-2 and ATP-
binding cassette, sub-family G, member 1 (Abcg1), with concomitant up-regulation of enoyl-
CoA-Hydratase (Ech1) and angiopoietin-like 4 (Angptl4); collectively suggesting a decrease in 
synthesis of fatty acids (SCD-2) and a decrease in cholesterol transport to high density 
lipoprotein (Abcg1) (Keane et al., 2011). The increase in Ech1 would allow increased entry of 
unsaturated fatty acids into the pathway of β-oxidation and an increase in Angptl4 has a 
potential to increase cholesterol synthesis. Whether increased fatty acid β-oxidation under 
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these conditions directly contributes to cytoprotection is yet to be clearly demonstrated 
however, increased cholesterol synthesis may favour the formation of cholesterol esters, 
sequestering cytotoxic palmitate, rather than TAG formation, as suggested in earlier studies 
in MIN6 cells (Busch et al., 2005).  
Arachidonic acid released from the membrane can be metabolised by three major 
routes: cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP) pathways 
producing various eicosanoids, prostaglandins and leukotrienes. Whether or not AA requires 
metabolic conversion for its cytoprotective effects remains unclear, however in BRIN-BD11 
cells the methyl ester of AA (as with monounsaturated species), which is a poor substrate for 
COX and LOX enzymes, similarly protected against palmitate toxicity. Additionally ETYA, a 
broad-spectrum inhibitor of all three pathways of AA metabolism, containing four alkyne 
groups, failed to attenuate AA action (Dhayal and Morgan, 2011); however, this analogue of 
AA has also been shown to active PPARs (Keller et al., 1993; Kliewer et al., 1995). Interestingly, 
AACOCF3 (a trifluoro-methyl-ketone derivative of AA) dose-dependently antagonised AA 
actions in BRIN-BD11 cells, suggesting that this derivative may be capable of binding to the 
same, as yet unidentified, binding site mediating AA activity (Dhayal and Morgan, 2011).    
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Although data suggests that bolus addition of exogenous AA mediates cytoprotective 
actions independent to AA metabolism, the contribution of COX and LOX metabolites of 
endogenous AA metabolism have been extensively studied in beta cell biology. The role(s) of 
CYP450-derived eicosanoids, the focus of this thesis, have received comparatively less 
attention in these models and so the following sections summarise some of the current 
understanding of COX and LOX pathways in beta cell (dys)function before considering the 
evidence for the roles of CYP450-eicosanoids in a variety of models (outlined in figure 1.3).  
 
 
1.4.1 Cyclooxygenase (COX) Derived Eicosanoids 
The major derivatives of AA from the COX pathway are prostaglandins (PGs) and 
thromboxane (TX), with AA released from the phospholipid pool by cPLA2 able to undergo 
oxidative metabolism by COX -1 and -2 to produce the endoperoxide PGH2 (Rouzer and 
Figure 1.3 AA-derived eicosanoids of COX, LOX and CYP450 pathways. AA is a precursor for metabolism by COX, LOX and 
CYP450 enzymes following its release from membrane phospholipids by the action of phospholipase enzymes (Yuan et al., 
2014). 
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Marnett, 2011). PGH2 is now a target for PG synthases, which produces a variety of active 
prostaglandins, PGE2, PGD2, PGF2α, prostacyclin (PGI2) and thromboxane A2 (TxA2) (Hao and 
Breyer, 2007). PGE2 has been identified in rat islets and has been reported to be the 
predominant product via the COX pathway in beta cells, responsible for the modulation of 
beta cell function (Tran et al., 2002), with COX-2 expression predominating over COX-1 in beta 
cells, supporting that PGE2 is most abundant COX product (Roberston, 1998). Actions of PGs 
are mediated through their binding to DP, EPs; EP1, EP2, EP3 and EP4, IP, FP and TP receptors 
(Roberston, 1998; Hao and Breyer, 2007) and in models of type 1 DM, it is known that IL-1β 
can activate COX-2 and EP3 expression via the NF-κB pathway, resulting in a decrease in GSIS, 
with the COX-2 inhibitor SC58236 promoting GSIS whereas SC58560, a COX-1 inhibitor, failed 
to inhibit PGE2 production (Tran et al., 1999; Tran et al., 2002). Further to this, the EP receptor 
promoter contains an NF-κB binding site, with studies showing that inhibition of NF-κB 
decreases EP3 receptor expression (Arakawa et al., 1996; Tran et al., 2002). Persaud et al., 
(2007) showed that COX-2 inhibition enhanced basal insulin secretion in human islets and in 
mouse models transgenic over-expression of COX-2 and PGE synthase increased PGE2, which 
resulted in deleterious effects on beta cell mass (Oshima et al., 2006), with earlier 
observations also showing that COX-2 inhibitors prevented hyperglycaemia in a streptozotocin 
(STZ) mouse model (Tabatabaie et al., 2000). A 2.5-fold increase in pancreatic PGE2 levels was 
observed in transgenic mice over-expressing COX-2 and PGE synthase-1, associated with 
decreased beta cell number (Oshima et al., 2006), however sections of the pancreas when 
examined showed no reduction in beta cell mass suggesting that PGE2 itself may not 
contribute directly to beta cell apoptosis and its effects may instead be related to effects on 
beta cell proliferation in vivo (Oshima et al., 2006; Luo and Wang, 2010).  In BRIN-BD11 cells, 
inhibition of COX-1 decreased D-glucose and L-alanine-stimulated insulin secretion (Keane et 
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al., 2011), suggesting that under these conditions whereby AA will preferentially be 
metabolised by COX-2, these metabolites also directly impair secretion. Further follow-up 
experiments with an inhibitor of COX-2 in combination with exogenously administered AA 
significantly enhanced insulin secretion, supporting evidence that COX-2 metabolites have a 
negative effect on insulin secretion.  
In type 1 DM cytokine-induced beta cell apoptosis is associated with an increase in NO 
production, which has been shown to activate COX-1 and COX-2 isoforms, resulting in an 
increase in PGE2 (Salvemini et al., 1993). Furthermore, the COX-2 promoter contains NF-κB, 
AP-1 and cAMP-response element binding protein consensus sequences and in models of 
db/db mice it has been suggested that cytokines in synergy cause beta cell death due to the 
induction of COX-2 and iNOS, enhancing oxidative stress (McDaniel et al., 1996). Earlier work 
by Rabinovitch et al., (1990) demonstrated that non-selective COX inhibitors could protect rat 
islets and INS-1 cells against the deleterious effects of pro-inflammatory cytokines, thus 
arguing for a pro-apoptotic role of AA-derived eicosanoids, including PGE2, with maximal 
effects on the prevention of beta cell death observed under conditions of COX and LOX 
inhibition. In another study, treatment of rat islets with IL-1β (1U/mL) for 40 hours resulted in 
a 7-fold increase in both PGE2 and nitrite production (Heitmeier et al., 2004). However, under 
conditions of COX-2 inhibition using SC58236, although formation of PGE2 was prevented, IL-
1β-induced increases in nitrite levels and beta cell dysfunction was unaffected, suggesting cell 
death was independent to COX-2 activity. Further studies investigating the effects of COX 
inhibitors in models of islet transplantation have since failed to demonstrate any long-term 
beneficial effects (Gysemans et al., 2003). The earlier findings of Rabinovitch et al., (1990) 
therefore contradicts others (Heitmeier et al., 2004; Papdimitriou et al., 2007); these later 
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studies used more selective COX-2 inhibitors (SC58236 and Celecoxib) than the non-specific 
inhibitors used in earlier studies and argue that whilst cytokines lead to increased expression 
of the inducible COX-2, that this does not directly contribute to cell dysfunction. A protective 
role of PGE2 has also been reported (Papdimitriou et al., 2007), and it is suggested that PGE2 
can exert autocrine and paracrine effects at cell surface prostaglandin EP receptors leading to 
cAMP generation, increased expression of the anti-apoptotic protein Bcl-2, and activation of 
the PI3K/PKB pathway and JNK activation (Heitmeier et al., 2004; Papdimitriou et al., 2007).  
 
1.4.2 Lipoxygenase (LOX) Derived Eicosanoids 
 The major products of the LOX pathway of AA metabolism are hydroxyeicosatetranoic 
acids (HETEs), particularly; 12(S)-HETE, 12(R)-HETE and 15(S)-HETE, and leukotrienes (LTs); 
LTA4, LTB4, LTC4, LTD4 and LTE4 (Persaud et al., 2007; Luo and Wang, 2011). In total, there have 
been six identified LOX isoforms in humans and seven isoforms have been reported in mice 
(Dobrian et al., 2019), with the lipoxygenases classified according to the positional insertion 
of a hydroperoxy group as 5-LOX, 8-LOX, 12-LOX and 15-LOX; 5-LOX and 12-LOX isoforms have 
been detected in human and rodent islets (Persaud et al., 2007; Mochizuki and Kwon, 2008). 
Several substrates have been proposed as a target for 12-LOX, including: AA, dihomo-γ-linoleic 
acid, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) (Ikei et al., 2012), with 12-
LOX expression identified in beta cells (Bleich et al., 1998; Kawajiri et al., 2000), and to a higher 
extent than alpha cells, as well as 5-LOX. However, lower levels of 5-LOX products have been 
identified in rodent pancreatic islets (Morgan and Laychock, 1988; Shannon et al., 1992; Chen 
et al., 2005). Although products of 5-LOX have been identified, cross-production of 5-LOX 
products could be attributed to other pathways of AA metabolism, as Bleich et al., (1998) 
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observed that 12-LOX is specifically expressed in pancreatic beta cell lines and primary cells 
from Zucker fatty rats; however 5-LOX or 15-LOX were not. AA-derived HETEs, involves the 
insertion of a hydroperoxide group producing hydroperoxyeicosatetranoic acids (HPETEs), 
which are subsequently reduced by glutathione peroxidase to form a more stable product; 
hydroxyeicosatetranoic acid; in the case of 12-LOX activity with AA, a hydroperoxide group is 
introduced at position 12 (12-HPETE), which is then reduced to 12-HETE (Haeggström et al., 
2011). Cross-production of other LOX metabolites can also occur, albeit with a lower specificity 
since 12-LOX can produce both 12-HETE and 15-HETE but at a ratio of 6:1; the role of 12-HETE 
has been extensively studied in models of rodent diabetes (Haeggström et al., 2011) and 
unlike 5-LOX, which can produce both HETEs and leukotrienes, the predominant product of 
12-LOX is 12-HETE.  
 In models of type 1 DM, cytokine-induced beta cell apoptosis is associated with 
activation of 12-LOX and its subsequent translocation from the cytosol to the cell membrane 
(Ma et al., 2010) and has been identified to be up-regulated in islets and beta cells (Bleich et 
al., 1995). Deletion of 12-LOX also protects against STZ-induced DM in mice (Bleich et al., 
1999), and in rat islets, treatment with IL-1β enhanced the production of 12-HETE via NO-
dependent mechanisms. Similarly, in a later study in human islets and mouse β-TC3 cells, 
treatment with IL-1β, IFN-γ and TNF-α increased 12-LOX activation, however it was suggested 
that the total protein levels of 12-LOX were not increased, but that increased 
expression/activity of iNOS can induce post-translational modification of 12-LOX enzymes, 
resulting in their activation (Chen et al., 2005). Evidence that cytokine-induced 12-LOX 
activation contributes to reduced insulin secretion and beta cell death was further 
demonstrated by treatment with the 12-LOX inhibitor baicalein, resulting in an inhibition of 
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12(S)-HETE production in mouse beta cells and human islets. This was associated with 
increased insulin secretion and attenuation of cytokine-induced JNK and p38 activation and 
apoptosis (Chen et al., 2005). With others reporting similar findings that p38 phosphorylation 
is increased when 12-LOX is overexpressed (Reddy et al., 2002), this suggests a contribution 
of 12-LOX and its products in cytokine-induced beta cell dysfunction. 
 
1.4.3 Cytochrome P450-Derived Eicosanoids 
 Whilst much attention has focussed on the contribution of COX and LOX metabolites 
of AA to beta cell death and dysfunction in DM models, comparatively less attention has been 
given to the contribution of metabolites of the CYP 450 pathway. Four epoxyeicosatrienoic 
acid (EET) isomers of AA can be produced by the action of distinct CYP450 enzymes, depending 
on which of the double bonds undergoes epoxidation, with two possible enantiomers for each 
(figure 1.4) 
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Figure 1.4 Structure of each EET regioisomer. Position of epoxide groups are shown identifying different structural 
characteristics of each EET (Zeldin, 2001). 
 
Different members of the CYP450 family (share 40% sequence homology) and 
subfamily (share 55% sequence homology) have different catalytic efficiencies in metabolising 
AA into EETs. CYP1A, CYP2B, CYP2C, CYP2D, CYP2G, CYP2J, CYP2N and CYP4A are known to 
contribute to EET production (Zeldin, 2001) and evidence suggests that the major CYP 
epoxygenases for the formation of EETs from AA in islets are the CYP 2C and CYP 2J isoforms 
(Imig and Hammock, 2009). The CYP isoform CYP 2C8 has been shown to produce 14(15)-EET 
and 11(12)-EET at a ratio of 1.3:1.0 yet does not produce detectable amounts of 8(9)-EET, 
whereas CYP 2C9, which has a >80% sequence identity to CYP 2C8, can produce the same EETs 
at a ratio of 2.4:1.0:0.5, respectively.  
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EETs produced by CYP450 epoxygenases are reported to have potent anti-
inflammatory properties and in transgenic mice, over-expression of the CYP 2J2 isoform 
protects against ischemia/reperfusion injury (Seubert et al., 2004). Similarly Wang et al., 
(2014) showed that CYP 2J2-derived EETs suppress ER stress using an in vivo model of heart 
failure in mice over-expressing CYP 2J2, an effect that was associated with restored SERCA2a 
expression and increased expression of catalase and MnSOD. Although the protective effects 
of EETs against ER stress induced by pro-inflammatory cytokines in in vitro models of type 1 
DM have not been studied, it is tempting to speculate that elevation of EETs either through 
exogenous administration or from over-expression of CYP 2J2 or 2C11 (the rat homolog of 
human 2C8) may reduce ER stress in these models. Particularly since cytokine-induced ER, 
stress is associated with reduced expression of SERCA2a in an NO-dependent manner in beta 
cells (Cardozo et al., 2005). Similarly, EETs have also been shown to exert anti-inflammatory 
effects through the inhibition of NF-κB by acting upstream of its activation by IKK (Node et al., 
1999), suggesting the possibility that targeting EETs may impair cytokine-induced beta cell 
death through an inhibitory effect on NF-κB activation, acting upstream of the transcription 
factors’ effects on global gene expression changes, contributing to beta cell apoptosis. In 
endothelial cells, inhibition of NF-κB was achieved by treatment with 11(12)-EET, and 8(9)-EET 
with 11(12)-EET and 14(15)-EET inhibiting endothelial apoptosis through activation of the 
PI3K/Akt pathway, subsequently inhibiting ERK1/2 dephosphorylation (Spiecker and Liao, 
2005). Other mechanisms have also been implicated with EET action, such as 11(12)-EET being 
shown to stimulate angiogenesis through activation of EphB4-coupled PI3K/Akt pathways 
(Webber et al., 2008), as well as activating sphingosine kinase-1 mediating cell proliferation 
and angiogenesis (Yan et al., 2008). Studies in cardiomyocytes have also reported similar 
findings through the activation of the pro-survival PI3K/Akt pathway, and have shown 
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activation of the myocardial KATP channels by decreasing their sensitivity to ATP (Wang et al., 
2006). Relevant to the aetiology of type 2 DM, over-expression of CYP 2J2 in mice models of 
obesity-induced insulin resistance recovered insulin sensitivity via effects on an endothelial 
NOS isoform (Xu et al., 2011) and Bettaieb et al., (2013) suggest that EETs may protect liver 
cells against high fat diet-induced ER stress and metabolic dysfunction. Whilst more recent 
studies have demonstrated that CYP 2J2 overexpression restores glucose tolerance and 
improves hepatic insulin resistance in db/db mice, a model for dyslipidaemia (Li et al., 2015), 
no studies have directly assessed a potential cytoprotective activity of EETs in pancreatic beta 
cells under lipotoxic conditions. 
EETs are further metabolised by soluble epoxide hydrolase (sEH) into corresponding 
vicinal diols, dihydroxyeicosatrienoic acids (DHETs), metabolites with considerably reduced 
biological activity than EETs (Imig and Hammock, 2009). A study by Zeldin et al., (1993) has 
shown that rates of hydration by cytosolic soluble epoxide hydrolase favours 14(15)-EET 
producing 4.5 µmol of product/mg of protein/min in comparison to 11(12)-EETs and 8(9)-EETs 
showing only 1.6 and 1.5, respectively. Inhibitors of sEH are suggested to exert beneficial 
properties in the treatment of cardiovascular disease, owing to increased levels of biologically 
active EETs. Further to this, inhibition of sEH lowers blood pressure in various animal models 
however, little is known about the involvement of sEH and blood glucose control in DM 
models. Studies have shown that in STZ-induced diabetes in mice, sEH knock-out or 
pharmacological inhibition improves glucose tolerance and increases plasma insulin 
concentrations, likely as a result of increased GSIS and preserved beta cell mass possibly owing 
to the anti-inflammatory properties of EETs (Luo et al., 2010; Chen et al., 2013). This suggests 
that beta cells express appreciable levels of sEH, with Luo et al., (2010) reporting that mouse 
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islets express sEH at 0.93ng/μg protein and confirmed sEH expression in NIT-1 clonal beta cells 
by Western blotting. That sEH inhibitors protect liver and adipose cells of mice fed high-fat 
diets against ER stress (Bettaieb et al., 2013) and improve functional beta cell mass in STZ-
induced DM models suggests that this approach may protect clonal beta cells against 
physiological inducers of beta cell death in models of type 1 (pro-inflammatory cytokines) and 
type 2 (lipotoxicity) DM.   
The fate of EETs is not solely by sEH metabolism and they can also be metabolised by 
acyl transferases, resulting in their incorporation into cellular EET-phospholipids. Glutathione 
S-transferases are also able to utilize EETs and form glutathione conjugates and EETs can be 
further oxidised by prostaglandin G/H synthase (PGHSs) and P450s resulting in the formation 
of epoxyprostaglandins, diepoxides, THF-diols and epoxy-alcohols. Additionally, intracellular 
fatty acid binding protein (FABP) can bind EETs and DHETs and control their metabolism, 
activity and targeting (Zeldin, 2001). EETs and DHETs are also able to feed into mitochondrial 
and peroxisomal β-oxidation pathways, forming shortened-chained fatty acids, including 7(8)-
dihydroxy-hexadeadienoic acid 7(8)-DHHD, which is reported to display comparable effects 
on vascular function as 11(12)-EET/DHET (Fang et al., 1996). Additional β-oxidation products 
also include shortened-chain epoxide derivatives, the levels of which may be enhanced in 
models investigating effects of sEH inhibition (Fang et al., 2001; Fang et al., 2004) 
It has been proposed that EET mechanisms of action may involve binding to cell surface 
receptors and activation of intracellular mechanisms, binding to intracellular lipid binding 
proteins, or by their incorporation into cellular phospholipids (Spector and Norris, 2007). 
Extensive data has suggested that an extracellular mechanism, in part, may be one of their 
modes of action, with data suggesting a selective EET receptor of the G-protein coupled 
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receptor family, with activation of an intracellular signal transduction pathway associated with 
increased intracellular cAMP (Yang et al., 2008).  A radiolabelled 14(15)-EET analogue has been 
shown to bind at the plasma membrane in U937 cells, increasing cAMP, an effect that was 
competitively inhibited by 14(15)-EET and 14(15)-EEZE (a reported EET antagonist). Although 
the molecular identity of any such receptor remains elusive, a recent study screening EET 
action at 105 known GPCRs failed to identify a single high-affinity receptor, instead 
demonstrating activity at a number of low-affinity prostaglandin (PG) receptors (including 
PTGER2, PTGER4, PTGFR, PTGDR and PTGER3IV), concluding that EETs may signal through 
multiple GPCRs (Liu et al., 2017). Whilst the role of PGE2 in insulin secretion (which signals 
through PTGER2, PTGER4 and PTGER3IV) remains unclear, activation of these receptors (and 
PTGDR by PGD) leads to increased cAMP, supporting a possible role in EET-Gαs signalling 
(Wong et al., 2000; Yang et al., 2008).  
Other proposed mechanisms are that EETs bind to receptors for other lipid-soluble 
agonists that also function to activate intracellular signalling pathways and that EETs have 
characteristics of long-chain fatty acids and can undergo similar metabolic processing. Several 
studies have shown the involvement of an intracellular mechanism through incorporation into 
phospholipids and binding to cytoplasmic FABPs and PPARγ (Widstrom et al., 2003; Spector et 
al., 2004; Liu et al., 2005). In particular, PPARγ activation has become a well-established target 
for EETs in a number of non-beta cell models, mediating anti-inflammatory activity, which in 
part has been attributed to reduced NF-κB activation (Liu et al., 2005). Of note, PPARγ is the 
target of the thiazolidinedione (TZD) class of insulin sensitizers used in the treatment of type 
2 DM, which mediate their action via association with the PPARγ ligand binding domain, 
facilitating heterodimerisation with the retinoid X receptor (RXR) and increasing the 
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expression of lipogenic genes, improving dyslipidaemia. Although the significance of PPARγ 
expression and/or activity in beta cells remains unclear, TZDs have been reported to protect 
beta cells from both cytokine and palmitate toxicity (Saitoh et al., 2008; Hong et al., 2018), 
which may indicate EETs could display similar activity in these models. However, others have 
demonstrated lack of efficacy of TZDs in this context, with an inhibitory action of over-
expression of PPARγ on insulin secretion (Cnop et al., 2002; Nakamich et al., 2003).  
Incorporation of EETs into membrane phospholipids has also been shown at the sn-2 
position of the glycerol backbone; however, it is uncertain whether this represents an 
important mode of action of EETs, with studies showing that release of EETs from 
phospholipids can be achieved without stimulation necessary for PLA2 activation (Spector et 
al., 2004). It has been suggested that incorporation of EETs into phospholipids may occur to 
control alterations in properties of the cell membrane, temporarily allowing functional 
changes to protein domains (Spector et al., 2004). Coronary endothelial cells treated with 
N,N’-dicyclohexyurea (DCU), a selective inhibitor of sEH, increased cellular levels of 14(15)-
EET and its conversion into phospholipids (Fang et al., 2001). Functionally, incorporation of 
EETs into phospholipids may serve to decrease the concentration of unesterified EETs, 
representing an important mechanism for controlling EET actions through sequestration into 
the phospholipid pool. EET-containing phospholipids are also the precursors for the 
production of 2-epoxyeicosatrienoylglycerols (2-EG), containing 11(12)-EET or 14(15)-EET, 
likely mediated via phospholipase C hydrolysis and diacylglycerol lipase cleavage of the sn-1 
fatty acid (Chen et al., 2008). These products have been suggested to display 
endocannabinoid-like activity, similar to the endogenous AA-derived anandamide 
(arachidonylethanolamide), with 2-14(15)-EG shown to activate epidermal growth factor 
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receptors via ligand release upon binding to cannabinoid receptors CB1 and CB2 (Chen  et al., 
2008). Interestingly, these effects are not known to mediate free EET action, with no activity 
at cannabinoid receptors reported (Chen  et al., 2008) and given that CB receptors signal 
through Gi/o-coupled mechanisms, inhibiting adenylate cyclase and decreasing cAMP, the 
significance of the 2-EG products for mediating EET action in vivo and in vitro remains unclear, 
especially since any extracellular receptor activity of EETs has been attributed to Gαs coupled 
receptors and increased cAMP (Wong et al., 2000; Yang et al., 2008). Both CB1 and CB2 
receptors have been shown to be expressed in RINm5F cells and in BRIN-BD11 cells and 
anandamide, an endogenous CB receptor ligand, has been shown to protect against palmitate 
toxicity however, in this model effects were blocked by inhibition of fatty acid amide hydrolase 
(FAAH), suggesting these effects were mediated by conversion of anandamide to arachidonic 
acid rather than its direct receptor binding (Stone et al., 2012).  
Earlier work in rat islets reported that EETs have beneficial effects on promoting insulin 
and glucagon release (Falck et al., 1983) however, later data in INS-1 cells contradicted these 
observations suggesting that free-EETs have an inhibitory action on insulin secretion (Klett et 
al., 2013). In this model, expression of acyl-CoA-synthase-4 (Acsl4) was reported to control 
the ratio between membrane-esterified and free EETs, suggesting that this may be a 
mechanism of sequestering EETs into phospholipids, which promoted GSIS. However, the 
scarcity of additional data on potential mechanisms of direct EET action between the 
publication of these two studies highlight the need for further studies in this area, as 
acknowledged in earlier (Luo and Wang, 2011) and more recent (Xu et al., 2016) reviews on 
the role of eicosanoids in beta cell function. A further link between EETs and beneficial effects 
on islet function was reported by Luo et al., (2010), whereby a possible EET contribution was 
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assessed through pharmacological inhibition of sEH or its knock-down, which restored 
normoglycaemia and increased plasma insulin levels in STZ-induced diabetes in mice, 
associated with increased beta cell mass. Together with data showing islet expression of CYP 
2C11 in rodent models (Chen et al., 2013), this suggests that EETs could also protect beta cells 
against pathophysiologically relevant inducers of beta cell death in models of type 1 (pro-
inflammatory cytokines) and type 2 (lipotoxicity) DM. 
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1.5 Aims 
Studies over the last three decades have firmly established pro-inflammatory 
cytokines, hyperglycaemia and dyslipidaemia as direct contributors to loss of functional beta 
cell mass by apoptosis in the pathogenesis of type 1 and type 2 DM. Similarly, in models of 
type 2 DM the cytoprotective effects of mono- and poly-unsaturated FFAs are also well-
documented, including that of AA. Whilst mechanisms of AA action in this context continue to 
be defined, the contribution of the COX and LOX pathways and the products produced from 
the endogenous metabolism of AA have been widely studied in beta cell biology. However, 
evidence for the potential functional role(s) of CYP450-derived EETs and their less active 
vicinal diols (DHETs) in in vitro models of type 1 and 2 DM is lacking, therefore the specific 
aims of this thesis are to: 
 confirm the cytotoxic effects of pro-inflammatory cytokines and the saturated 
FFA palmitate in BRIN-BD11 cells, establishing appropriate in vitro models for 
further investigations, as well as confirming existing knowledge on the 
protective effects of AA in this context. 
 investigate the cytoprotective effects of EETs and DHETs in models of 
lipotoxicity and explore potential mechanisms of action through 
pharmacological modulation of known potential targets of eicosanoids and FFA 
signalling. 
 determine whether EET action is associated with changes in lipid handling in 
BRIN-BD11 cells and the contribution of known pathways of FFA metabolism 
through pharmacological inhibitor studies. 
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 investigate the cytoprotective effects of EETs and DHETs against pro-
inflammatory cytokine toxicity and whether any effects of EET action are 
associated with changes in cytokine signalling, particularly activation of NF-κB. 
 investigate whether manipulation of endogenous EET levels through over-
expression of the rat CYP 2C11 epoxygenase or pharmacological inhibition of 
sEH can recapitulate effects of exogenously applied EETs.  
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Chapter Two 
 
Methods 
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2 Methods 
2.1 Cell Culture 
The rat pancreatic beta cell line, BRIN-BD11 (a gift from Professor Noel Morgan, 
University of Exeter), was used in this study. Derived by electrofusion of RINm5F cells with 
New England Deaconess Hospital (NEDH) rat pancreatic islets (McClenaghan et al., 1996), 
BRIN-BD11 cells are glucose-responsive, insulin secreting cells commonly used in in vitro 
studies of cytotoxicity in models of type 1 (pro-inflammatory cytokine toxicity) and type 2 
(lipotoxicity) DM. BRIN-BD11 cells were routinely cultured in 75cm2 tissue culture flasks at 
37oC in a humidified atmosphere of 5% CO2: 95% air in RPMI-1640 medium supplemented 
with 10% foetal bovine serum (FBS), 2mM L-glutamine, 100U/mL penicillin and 100µg/mL 
streptomycin (complete medium). Cells were used between passages 23-38, with stock 
cultures (~1x106 cells/mL) stored at -196oC in liquid nitrogen in complete media supplemented 
with 40% FBS and 10% dimethyl sulphoxide (DMSO).  
A BassAire P5HB culture hood was used for all cell culture work, with laminar flow 
maintained at 100 Pascals and surfaces cleaned with 70% industrial methylated spirit (IMS). 
All materials were sterile and culture reagents pre-warmed to 37oC before use. Cells were 
passaged at ~80% confluency, with spent medium removed from 75cm2 tissue culture flasks 
and discarded into Virkon (1% w/v). Following this, excess phosphate buffer saline (PBS, pH 
7.4) was washed over the cells to remove residual medium and cells were then trypsinized 
using 0.25% Trypsin: EDTA for 3 minutes at 37oC at 5% CO2. Confirmation of trypsinisation was 
observed under an inverted microscope, with cells washed over and suspended in 10mL fresh 
RPMI-1640 complete medium to inactivate residual trypsin. Cells were then centrifuged at 
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1200xG for 6 minutes, with spent medium discarded in Virkon and cells re-suspended in 10mL 
fresh RPMI-1640 medium and used to seed new flasks, or sub-cultured (section 2.1.1) for 
further studies.  
 
2.1.1 Sub-cultures 
Cells were sub-cultured into 96-well (15,000 cells/well in 200µL), 24-well (50,000 
cells/well in 500µL) and 6-well (200,000 cells/well in 2mL) plates, or 25cm2 tissue flasks (1 
million cells/flask in 5mL) dependent on assay protocol (see relevant sections). Following 
preparation of cell suspension (as described in section 2.1), a 10µL sample of the cell 
suspension was mixed with 10µL of 0.4% Trypan blue and cell number determined using a 
haemocytometer with coverslip, counting the number of unstained viable cells in each of the 
four corner 4x4 grids. Total viable cell number was then determined according to equation 1 
and cell suspensions diluted to the appropriate density for seeding. Cells were then incubated 
for 24 hours prior to treatment in complete medium, unless otherwise stated. 
Eq. 1    𝐶𝑒𝑙𝑙𝑠 𝑝𝑒𝑟 𝑚𝐿 = 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 × 2 × 104 
 
2.2 Preparation of Fatty Acid-Albumin Complexes 
Stock solutions of FFAs were prepared as follows; sodium palmitate (C16:0) (Sigma 
Aldrich), a long-chain saturated fatty acid, was dissolved in 50% ethanol (EtOH) (v/v) at 70oC 
to a concentration of 50mM. Similarly, Oleate (C18:1) (Sigma Aldrich), a mono-unsaturated 
fatty acid, was dissolved in filter-sterilised water to 50mM. Arachidonic Acid (C20:4) (Sigma 
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Aldrich), a poly-unsaturated fatty acid, and 2-bromopalmitate (Sigma Aldrich), an analogue of 
palmitic acid, were prepared in 90% ethanol (v/v) to a concentration of 90mM.  
Fatty acid-free Bovine Serum Albumin (BSA) (Sigma Aldrich) was prepared in deionised 
water and filter-sterilised using a 0.22µm filter in preparation for complexing with fatty acids. 
Within pathological conditions the ratio of free fatty acids (FFAs) to albumin can rise as high 
as 6:1 and whilst cellular models of beta cell lipotoxicity employ a range of FFA:BSA treatment 
ratios, Oliveira et al. (2015) report a ratio of 3.3:1 to be optimum, as using a ratio greater than 
5:1 could exceed FFA solubility, especially with long-chain fatty acids, introducing artefacts in 
cultures and enhanced detergent-like effects of FFAs on cell membranes, whilst lower ratios 
will limit FFA delivery. Therefore, all FFAs used in this thesis were complexed to BSA at a final 
ratio of 3.3:1 using 5mM FFA: 10% BSA, unless otherwise stated, followed by incubation for 1 
hour at 37oC. Once formed, complexes were aliquoted, stored at -20oC and used within one 
month. 
Epoxyeicosatrienoic acids (EETs) (Caymen Chemical): (±)5(6)-, (±)8(9)-, (±)11(12)- and 
(±)14(15)- and dihydroxyeicosatrienoic acids (DHETs) (Caymen Chemical): (±)8(9)-, (±)11(12)- 
and (±)14(15)- were supplied at 100µg/mL (0.32mM) in 100% ethanol. To concentrate the 
fatty acids (thus avoiding higher residual ethanol concentrations in cell treatment), a stream 
of nitrogen gas at <10L/min was used to evaporate the ethanol and all EET/DHET isomers were 
reconstituted in 100% ethanol, purged under nitrogen, to a stock concentration of 3.2mM and 
prepared in BSA at a final concentration of 100µM: 0.2% BSA (maintaining a molar ratio 3.3:1).  
An analogue of (±)14(15)-EET with the addition of a methyl sulphonamide group: (±)14(15)-
EET-SI (Caymen Chemical) was supplied at 100µg/mL (0.32mM) in 100% methyl acetate. 
Following the procedure of evaporation under nitrogen for EETs and DHETs, (±)14(15)-EET-SI 
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was reconstituted to a stock concentration of 3.2mM in ethanol and similarly prepared in BSA 
to a final concentration of  100µM: 0.2% BSA (molar ratio 3.3:1).  
 
2.3 Cell Treatment  
Treatment with the pro-inflammatory cytokines, IL-1β (100U/mL), IFN-γ (20U/mL) and 
TNF-α (500U/mL) (PeproTech EC), was used as a model of cytokine toxicity in type 1 DM, with 
preliminary dose response data establishing optimum conditions in this model (see Chapter 
3). To mimic lipotoxicity induced by long-chain saturated FFAs, cells were treated with 
palmitate:BSA complexes to a final concentration of 250µM palmitate (unless otherwise 
stated), with AA used in co-incubation in both models at concentrations up to 80µM. 
Cytoprotective effects of EETs and their derivatives were routinely studied at a final 
concentration of 10µM (unless otherwise stated). Control cultures were treated with 
corresponding concentrations of EtOH (or other vehicle) and BSA (see relevant chapters). 
Further investigations utilised a range of pharmacological inhibitors/antagonist to 
explore potential mechanisms of EET/DHET and AA action, as summarised in Table 2.1 (see 
relevant chapters). The concentrations indicated were based on preliminary dose response 
data (screened using the MTT assay (section 2.4.1)) under control and/or palmitate-treated 
conditions, to ensure appropriate low toxicity profiles and limiting any enhancement of 
toxicity in response to palmitate treatment. Stock concentrations of all agents were prepared 
in appropriate solvents (water, EtOH or DMSO) according to supplier specifications, with 
control cultures in viability studies treated with the appropriate vehicle.  
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Table 2.1 Pharmacological inhibitors/antagonists used in the study of EET action.  
Compound Target Concentration used 
(µM) 
DC260126 (Tocris) GPR40 1.25, 2.5 
AH7614 (Tocris) GPR120 1.25, 2.5 
GW6471 (Tocris) PPARα 1.25, 2, 2.5 
GSK3787 (Tocris) PPARβ/δ 1.25, 2, 2.5 
T0070907 (Tocris) PPARγ 1.25, 2, 2.5 
HX531 (Tocris) RXR 1.25, 2.5 
Etomoxir (Tocris) CPT1 50 
Xanthohumol (Tocris) DGAT 5 
A939572 (Tocris) SCD-1 2 
t-AUCB (Cayman Chemical) sEH 10 
TPPU (Cayman Chemical) sEH 10 
OBBA (Tocris) cPLA2 1.25, 2.5 
 
2.4 Cell Viability Assays 
2.4.1 MTT Assay 
The MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyltetrazolium bromide) (Sigma 
Aldrich) assay was used to determine cell viability following the procedure outlined by 
Mossman, (1983), with some modifications. The MTT assay largely reflects mitochondrial 
activity whereby viable cells with active mitochondria reduce the tetrazolium salt to a blue-
purple formazan product, which can then be solubilised in DMSO (Mossman, 1983). Initially 
thought to be catalysed by enzymes of the respiratory chain (notably succinate-tetrazolium 
reductase), the conversion of MTT to formazan has since been shown to also occur outside 
the mitochondria (Berna and Dobrucki, 2002). Nonetheless, this is regarded as being relative 
to the number of viable (respiring) cells and therefore the absorbance of solubilised formazan 
measured at 540nm is proportional to, and a quantitative measure of, cell viability. A 5mg/mL 
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MTT stock solution was prepared in PBS (pH 7.4) and diluted in complete RPMI-1640 medium 
to a final assay concentration of 0.5mg/mL. Following treatment with test agents, spent media 
was removed from the wells of a 96-well plate and cells were treated with 100µL/well dilute 
MTT solution, followed by incubation for 4 hours at 37oC with 5% CO2. Following incubation, 
the MTT:media solution was replaced with 100µL/well DMSO and plates gently agitated on a 
rocking platform. Absorbance was measured at 540nm using a BioTek EL800 plate reader, with 
data expressed as mean percentage cell viability +/-SEM, as compared to vehicle-treated 
control (see relevant chapters), with absorbance values corrected using a cell-free blank. 
 
2.4.2 Neutral Red Assay 
The Neutral red (Sigma Aldrich) assay was used to determine cell viability following the 
procedure outlined by Repetto et al., (2008), with some modifications. The neutral red assay 
provides a quantitative measure of viable cells in culture by assessing the cells’ ability to 
incorporate the supravital dye neutral red within lysosomes, with absorbance of solubilised 
neutral red deposits being proportional to cell viability (Repetto et al., 2008). A 0.33% (w/v) 
neutral red stock in PBS (pH 7.4) was diluted in complete RPMI-1640 medium to a final assay 
concentration of 0.03% and used at 100µL/well, following treatment of 96-well plates with 
test agents and removal of treatment media. Plates were then incubated for 2 hours at 37oC 
with 5% CO2 and following this, cells were washed in PBS and neutral red deposits dissolved 
in 100µL 50% ethanol: 1% acetic acid (v/v), with plates gently agitated on a rocking platform. 
Absorbance was measured at 540nm using a BioTek EL800 plate reader, with data expressed 
as mean percentage cell viability +/-SEM, as compared to vehicle-treated control (see relevant 
chapters), with absorbance values corrected using a cell-free blank. 
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2.4.3 Trypan Blue Vital Dye Exclusion 
Trypan blue (Sigma Aldrich) is a diazo dye that has widely been used to identify viable 
and non-viable cells. The negatively charged dye is not retained in viable cells, with preserved 
membrane integrity and actively exclude the dye, but is retained in dead/dying cells with 
membrane damage (Tran et al., 2011). This technique remains a commonly used, reliable 
method for the determination of cell viability, as a measurement of altered plasma membrane 
integrity, a method complementary to assays associated with the measurement of other 
indicators of cell death, such as the MTT and neutral red assays. 
This assay was used to determine viable and non-viable cells from 24-well plates, 
unless otherwise stated, following treatment with test agents. Cells were harvested for 
counting by removal of spent media (containing detached cells) into correspondingly labelled 
tubes and the remaining cell monolayer washed in PBS (pH 7.4) (1X volume), with any cells 
detaching in the PBS wash solution being combined with the corresponding well media. 
Remaining attached cells were trypsinized at 37oC with 5% CO2 in 0.25% Trypsin: EDTA (1X 
volume) and following detachment, the corresponding spent media/ PBS was used to inactive 
residual trypsin, with each well washed using the mix to collect the total cell population, which 
was then centrifuged at 1200xG for 6 minutes. The pelleted cells were then concentrated by 
resuspension in 200µL and the cell suspension diluted 1:2 with Trypan blue (0.4%) and 
examined by a haemocytometer, with cells retaining the dye considered non-viable. Total and 
viable cell numbers were determined as described in section 2.1.1, using triplicate wells per 
treatment condition.  
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2.4.4 Assessing Apoptosis by Flow Cytometry  
Apoptosis is a mechanism to arrest cell growth and activate regulatory pathways of 
cell death. In this thesis, two complementary flow cytometry apoptosis assays were used to 
measure apoptosis induction in treated cells; i) the MUSE™ Annexin V & Dead Cell Assay and 
ii) MUSE™ MultiCaspase assay. 
During apoptosis, intracellular signalling events result in characteristic changes such as 
phosphatidylserine (PS), which is usually localised internally on the plasma membrane of 
healthy cells, being externalised to the cell surface (Muse protocol a, 2016). Annexin V is a 
calcium-dependent phospholipid binding protein that has a high affinity for PS. Along with 
Annexin V, a dead cell marker 7-amino-actinomycin D (7-AAD) is incorporated into the assay 
reagent and can identify damage to cell membranes, whereby it is omitted from viable cells 
that retain membrane integrity. Flow cytometry analysis using the MUSE™ analyser scores 
cells after incubation with the assay reagent according to the following populations; non-
apoptotic cells: Annexin V (-) and 7-AAD (-), early apoptotic cells: Annexin V (+) and 7-AAD (-)  
late stage apoptotic and dead cells: Annexin V (+) and 7-ADD (+) and mostly nuclear debris: 
Annexin V (-) and 7-ADD (+). 
Following the manufacturer’s protocol; cells were harvested as described in section 
2.4.3, re-suspended to a concentration of 1x105 to 1x107cells/mL and diluted 1:2 in Annexin V 
& Dead Cell Reagent to a final concentration of 1x104 to 5x105cells/mL. Samples were 
protected from light, incubated at room temperature for 20 minutes and measured using the 
Muse™ Cell Flow Cytometry Analyser, with data expressed as mean percentage total 
apoptosis using triplicate samples per treatment condition from three independent replicates. 
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Further to PS externalisation, pro-apoptotic signals associated with activation of 
caspases were also assayed by flow cytometry using the Muse™ MultiCaspase kit, to 
determine total activate caspases (caspase-1, 3, 4, 5, 6, 7, 8 and 9) in treated cells. This assay 
simultaneously determines total count and percentage of cells with caspase activity by 
utilising a derived VAD-peptide in combination with a dead cell dye (Muse protocol b, 2016). 
Using Flourescent-Labelled Inhibitor of Caspases (FLICA) the VAD-peptide binds to activated 
caspases resulting in a fluorescence signal proportional to the number of active caspases in 
cells. Similar to the Annexin V assay, the dead cell dye (7-AAD) determines membrane 
structural integrity and cell death by increasing fluorescence intensity, compared to viable 
cells that actively excludes the dye (Muse protocol b, 2016). The MUSE™ analyser scores cells 
after incubation with the reagent according to the following populations: Live cells: Caspase 
(-) and 7-AAD (-), Caspase (+) cells exhibiting pan caspase activity: Caspase (+) and 7-AAD (-), 
Late stage of Caspase activity cells: Caspase (+) and 7-AAD (+) and Necrotic cells: Caspase (-) 
and 7-AAD (+). 
Following manufacturer’s protocol: cells were harvested as described in section 2.4.3 
and re-suspended in 1X Caspase Buffer. MultiCaspase Reagent working solution was added to 
each corresponding tube and incubated for 30 minutes at 37oC with 5% CO2. Following this, 
the samples were diluted 1:4 with Caspase 7-AAD working solution to a final concentration of 
1x105 to 1x106cells/mL and incubated at room temperature for 5 minutes, protected from 
light and measured using the Muse™ Cell Flow Cytometry Analyser, with data expressed as 
mean percentage total caspase activity using triplicate samples per treatment condition from 
three independent replicates. 
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2.4.6 Griess Assay 
The Griess assay was used to determine nitrite levels in cell supernatants as an indirect 
assessment of iNOS activity following cytokine treatment. Nitrite present within the culture 
media reacts with the amino group of sulphanilamide under acidic conditions forming a 
diazonium cation, which couples with N-Naphylethylenediame (NEDA) to form a 
corresponding azo dye, which can be measured at 540nm (Tsikas, 2007).  
Sodium nitrite (NaNO2) standards were produced across the range 0-100µM, these 
were then dispensed (100µL/ well) in duplicate onto a 96-well plate. Alongside this, culture 
media from cytokine-treated 96-well plates was also transferred to a fresh 96-well plate. To 
all wells (standards and samples), 50µL Griess solution A (1% Sulphanilamide (w/v) in 5% 
ortho-phosphoric acid (v/v)) was added, immediately followed by 50µL Griess solution B (0.1% 
NEDA (w/v)). Absorbance was measured at 540nm using a BioTek EL800 plate reader and 
nitrite levels in cytokine-treated supernatants determined (µM) relative to the standard 
calibration graph plotted (calibration data was collected each time the assay was carried out, 
with a representative plot shown in Appendix A, figure A.1).  
 
2.5 Quantification of Intracellular Lipid Droplets 
A Lipid Droplet Fluorescence Assay Kit (Caymen Chemical) was used to quantify 
intracellular lipid droplets using the lipophilic lysochrome Nile Red, which strongly fluoresces 
in the hydrophobic environment of intracellular neutral lipids.  Following manufacturer 
protocol, cells were treated in 24-well plates with palmitate (250µM), alone or in combination 
with EETs (10µM), for 24 hours and then harvested as described in section 2.4.3. Treatment 
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with 250µM oleate was used a positive control, as referenced in the manufacturer protocol. 
Cell samples were re-suspended in Assay Buffer before being centrifuged at 1200xG for 5 
minutes, after which the cell supernatant was aspirated and cells re-suspended in Fixative 
Solution. After incubation for 10 minutes at room temperature, samples were centrifuged for 
a further 5 minutes at 1200xG, and the supernatant aspirated. Assay Buffer was added to wash 
the samples, which were again centrifuged at 1200xG for 5 minutes before the addition of Nile 
Red Staining Solution. Samples were then incubated at room temperature for 15 minutes, 
protected from light, before proceeding to aspirate the staining solution. Samples were then 
washed again and further centrifuged at 1200xG for 5 minutes and the supernatant discarded. 
Samples were re-suspended in Assay Buffer before fluorescence intensity was measured by 
FITC (ex/em 485/535) using a Guava® easyCyte™ Flow cytometer. Results were analysed using 
FLOWJO V10 software by conversion of the histogram plot into a cumulative distribution 
function plot and mean fluorescence corrected against control, expressed as fold change +/-
SEM. 
 
2.6 Plasmid Preparation 
The plasmid vectors used in this study were obtained commercially. The pNL3.2.NF-
κB-RE[NlucP/NF-κB-RE/Hygro] reporter vector was purchased from Promega, supplied at 20µg 
and reconstituted at 100ng/µL in deionised water (section 2.7.2). pCMV6-Cyp2c11 (untagged 
ORF)-Rat cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) (Cyp2c11) and 
pCMV6-Entry mammalian vector with C-terminal Myc-DDK tag (empty vector) were 
purchased from OriGene, supplied at 10µg and reconstituted at 100ng/µL in deionised water 
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(section 2.7.3). Prior to transfection in BRIN-BD11 cells, transfection ready plasmids were 
prepared according to the following sections.  
 
2.6.1 Preparation of Luria-Bertani (LB) agar plates and liquid medium 
Lennox LB with agar (Sigma Aldrich) was supplied as a powder and reconstituted to 
35g/L in deionised water. After reconstitution, the LB solution was autoclaved at 121oC, cooled 
slightly before making additions of antibiotic (either 50µg/mL ampicillin or kanamycin, 
depending on the resistance gene encoded by the plasmid; see Appendix B) and poured into 
sterile petri dishes and allowed to solidify. 
LB Broth (Lennox) (Sigma Aldrich) was supplied as a powder and reconstituted to 20g/L 
in deionised water. After reconstitution, the LB solution was autoclaved at 121oC, cooled 
slightly before making additions of antibiotics (as stated above). 
 
2.6.2 Transformation of Chemically Competent Cells  
Alpha-Select Chemically Competent Bronze-Efficiency E.coli Cells (Bioline) were 
supplied transformation ready. All aseptic techniques were performed in a Triple Red J Bio 
Microbiology Fume Culture Hood.  Following manufacturer protocol; cells were thawed on ice 
and 50µL cell samples aliquoted into sterile pre-chilled microcentrifuge tubes. A sufficient 
amount of vector (2-5µL at 100ng/µL) was added to the cell suspension, gently mixed and 
incubated on ice for 30 minutes. Samples were heat shocked at 42oC for 30 seconds and 
immediately returned to ice for 2 minutes. The transformation reaction was diluted 1:20 with 
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SOC medium, mixed thoroughly and placed in a shaking incubator at 37oC, medium speed 
(~250rpm) for 60 minutes to allow recovering of the cells post-transformation and facilitate 
expression of antibiotic resistance genes prior to plating. Bacterial cultures were plated onto 
LB agar (+/- antibiotic, as indicated in 2.6.1 and dependent on the resistance gene encoded by 
the plasmid) using a lawn method and incubated for 24 hours at 37oC. Successful, antibiotic 
resistant, colonies were individually collected and transferred to 5mL LB liquid medium (+/- 
antibiotic) and further incubated for 24 hours at 37oC before being diluted 1:250 in LB liquid 
medium (+ antibiotic) to expand the cultures for plasmid purification.   
 
2.6.3 Zyppy™ Plasmid Miniprep Kit   
The Zyppy™ plasmid miniprep kit (Zymo Research) was used to prepare sample 
plasmids for sequencing before further colony expansion and Maxiprep purification. Following 
manufacturer protocol; bacterial cultures were grown in LB liquid medium (+/- antibiotic) as 
described in section 2.6.2 and samples of the initial 5mL culture were centrifuged at 13,000xG 
at room temperature. Bacterial cultures were lysed using 7X Lysis Buffer before adding 
Neutralisation Buffer and samples centrifuged for 4 minutes. The supernatant was transferred 
into provided Zymo-Spin IIN Column with Collection Tube and centrifuged for a further 15 
seconds. Following this, the flow-through was discarded and Endo-Wash Buffer added to the 
column to remove residual endotoxins and centrifuged again for 30 seconds. After this, 
Zyppy™ Wash Buffer was added to the column and further centrifuged for 1 minute before 
plasmid DNA was eluted by the addition of 30µL Zyppy™ Elution Buffer direct to the column 
matrix and centrifuging. Isolated plasmid DNA was then quantified using a Thermo Scientific 
Nanodrop™ 1000 spectrophotometer, with samples then diluted to 10µg/µL and sent for 
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sequencing (MWG Eurofins) using pre-supplied forward and reverse sequencing primers for 
the pCMV6 vector (Origene).  
 
2.6.4 GeneJET Plasmid Maxiprep Kit   
GeneJET Plasmid Maxiprep Kit (Thermo Scientific™) was used for high yield 
transfection-ready (endo-free) plasmid isolation from 250mL LB liquid cultures, prepared as 
described in section 2.6.2. Following manufacturer protocol; bacterial cultures were grown in 
250mL LB liquid medium (+ antibiotic) and plasmid DNA harvested using GeneJET Plasmid 
Maxi Prep protocol using a low speed centrifugation method (up to 5,000xG). Bacterial 
cultures were centrifuged at 5,000xG for 10 minutes at room temperature, with cell 
supernatant discarded and pellets re-suspended in Resuspension Solution and mixed before 
adding a 1X volume of Lysis Solution; samples were then lysed (SDS/alkaline lysis) for 3 
minutes at room temperature before adding Neutralization Solution to re-anneal plasmids. 
Following this, Endotoxin Binding Reagent was added to isolate endotoxins, preventing their 
subsequent binding to spin column matrix, allowing isolation of transfection-ready 
(endotoxin-free) plasmids. Samples were gently mixed by inverting, incubated at room 
temperature for 5 minutes and further centrifuged at 5,000xG for 40 minutes after the 
addition of a 1X volume (equal to neutralisation solution) of 96% ethanol to pellet cell debris 
and chromosomal DNA. The supernatants were decanted into fresh tubes, avoiding 
transferring or disturbing the white precipitate, samples were then transferred to a spin 
column and centrifuged (~20mL at a time until the entire sample volume was processed) for 
3 minutes at 2,000xG in a swinging bucket rotor. Plasmid DNA bound to the column matrix 
was then washed twice using Wash Solution I (low concentration of chaotropic salts in 
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isopropanol to remove residual protein), followed by Wash Solution II (containing ethanol to 
remove salt prior to elution), centrifuging for 2 minutes at 3,000xG after each wash and 
discarding the flow-through. Finally, plasmid DNA was eluted in a fresh tube using 1mL Elution 
Buffer and incubating the samples at room temperature for 2 minutes before proceeding to 
centrifuge at 3,000xG for 5 minutes. Plasmid yield was quantified using a Thermo Scientific 
Nanodrop™ 1000 spectrophotometer, with an A260/A280 ratio of 1.8-1.9 indicating a high 
purity. Isolated plasmid DNA was then stored at -20oC until use. 
 
2.7 Plasmid Transfection  
2.7.1 Lipofectamine® 2000 Transfection 
Preliminary investigations using NanoJuice® Transfection Kit (Merck), Lipofectamine® 
2000 Transfection Reagent (Invitrogen™) and Lipofectamine® 3000 Transfection Reagent 
(Invitrogen™) were trialled to determine the optimum method for plasmid transfection in 
BRIN-BD11 cells using the Green Fluorescence Protein (GFP)-expressing plasmid pmaxGFP (gift 
from Dr Mirna Maarabouni, Keele University). Both NanoJuice® and Lipofectamine®3000 
failed to produce successful transfections (data not shown), in comparison to ~56% 
transfection efficiency using Lipofectamine® 2000.  Having established an appropriate ratio of 
Lipofectamine® 2000: plasmid DNA (see Appendix A, figure A.2), cells were routinely 
transfected according to the following manufacturer protocol. BRIN-BD11 cells were cultured 
to 70-90% confluency prior to transfection. Lipofectamine® 2000 was diluted in Opti-MEM® 
(Gibco®) medium separate to Opti-MEM® (Gibco®) medium containing plasmid DNA. The 
dilute DNA and Lipofectamine® 2000 solutions were combined at a ratio of 1:1 and incubated 
77 
 
at room temperature for 5 minutes to allow transfection complexes to form before addition 
to cell cultures at the following final concentration ratios of lipofectamine® 2000:plasmid DNA; 
96-well plates: 0.3µL: 0.1µg/ well, 24-well plates: 1.5µL: 0.5µg/ well and 6-well plates: 7.5µL: 
2.5µg/ well. Cells were incubated at 37oC with 5% CO2 for 24 hours before being re-plated 
and/or treated for cell viability assays (see section 2.7.2 and 2.7.3). 
 
2.7.2 NF-κB-NanoLuc® Reporter Vector Assay  
A pNL3.2.NF-κB-RE[NlucP/NF-κB-RE/Hygro] reporter vector (Promega) expressing the 
NanoLuc® luciferase under the control of five copies of the NF-κB response element was used 
in combination with Nano-Glo® Luciferase Assay System to determine NF-κB activation 
following cytokine treatment in BRIN-BD11 cells. NanoLuc® luciferase is a small enzyme 
(19.1kDa) that reports luminescence in the presence of Nano-Glo® substrate using a novel 
coelenterazine analogue (furimazine) that produces a high intensity, glow-type, ATP-
independent luminescence reaction (Promega technical manual, 2015). BRIN BD11 cells were 
seeded onto 96-well black plates and transfected with the pNL3.2.NF-κB-RE vector as 
described in section 2.7.1 for 24 hours before treatment with test agents (see Chapter 5) for 
a further 24 hours. Following treatment, plates were equilibrated to room temperature for 10 
minutes before Nano-Glo® Luciferase Assay Reagent (equal to 1X culture volume) was added 
and gently mixed. Plates were incubated for 3 minutes before measuring luminescence using 
the Promega Glomax® Multi-Detection System (E9032). Data was expressed following 
manuscript calculation as fold induction of NF-κB, as compared to control (equation 2).  
Eq 2.    𝐹𝑜𝑙𝑑 𝐼𝑛𝑑𝑢𝑐𝑡𝑖𝑜𝑛 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑙𝑖𝑔ℎ𝑡 𝑢𝑛𝑖𝑡𝑠 𝑜𝑓 𝑖𝑛𝑑𝑢𝑐𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑙𝑖𝑔ℎ𝑡 𝑢𝑛𝑖𝑡𝑠 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑒𝑙𝑙𝑠
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2.7.3 Cytochrome P450 2C11 (CYP 2C11) Stable Transfection 
pCMV6-Cyp2c11 and pCMV6-Entry plasmids were prepared for transfection as 
described in section 2.6 (with the addition of kanamycin) and after confirmation of successful 
cloning by sequencing, BRIN-BD11 cells were seeded onto 6-well plates and transfected with 
either the pCMV6-Cyp2c11 vector or pCMV6-Entry vector as described in section 2.7.1. After 
48 hours, cells were passaged and serially diluted across the range 1:125-1:2000 in fresh RPMI-
1640 media containing Geneticin (G-418; Roche) at a concentration of 1µg/mL. Cells were 
incubated in the presence of G-418 for two weeks with media replaced every 2-3 days until 
formation of islands appeared. Following distinct island formation, several large, isolated 
colonies were collected individually by trypsin:EDTA detachment using a cloning ring, and 
further seeded into 24-well plates in the presence of G-418. Cells were continuously 
monitored for 2-3 weeks, with media changed every 2-3 days, and then further sub-cultured 
into 96-well plates at one cell/well by serial dilution. After this, cells were progressively 
cultured in G-418-containing media until the cultures were scaled to confluent 75cm2 tissue 
culture flasks, yielding G418 resistant BRIN-BD11 cells stably expressing CYP 2C11. Four stable 
cell lines transfected with pCMV6-Cyp2c11 vector and two transfected with pCMV6-Entry 
were isolated, these were designated as C11-1, C11-2, C11-3 and C11-4, or pCMV6-EV1 and -
EV2, with stable expression of CYP 2C11 confirmed by Western blotting (section 2.8).  
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2.8 Western Blotting 
2.8.1 Preparation of BRIN-BD11 Cell Lysates 
For specific details on the application of Western blotting and cell treatment 
conditions, see relevant chapters. Following treatment, total BRIN-BD11 cell samples were 
collected from culture plates or flasks and pelleted (750,000 cells), as described in section 
2.4.3, and the resulting cell pellets washed twice in excess ice-cold PBS, centrifuging at 1200xG 
for 6 minutes. Following this, protease inhibitor (Sigma Aldrich) was diluted 1:10 in RIPA Buffer 
(Sigma Aldrich) and cells re-suspended in 30µL of RIPA/ protease inhibitor cocktail and 
incubated at 4oC for 5 minutes before being centrifuged at 13000xG for 10 minutes to pellet 
cell debris. After centrifugation, 20µL of cell supernatant (corresponding to the lysate of 
500,000 cells) was removed and diluted with 4X Laemmli Buffer (BIO-RAD) containing 10% β-
mercaptoethanol, resulting in a loading sample of 500, 000 cells in 1X Laemmli, with samples 
heated to 95oC for 4 minutes and briefly centrifuged.  
 
2.8.2 SDS-PAGE 
A Precision Plus Protein™ Dual Colour Standards (BIO-RAD) ladder was used to confirm 
migration of proteins, transfer quality of proteins and molecular weight confirmation for all 
western blot samples.  
Samples were loaded into 10-well Mini-PROTEAN® TGX™ gels (BIO-RAD) at either 10 
or 12% polyacrylamide (depending on target protein), in a BIO-RAD Mini-PROTEAN® Tetra 
System tank containing 1X Tris-Glycine-SDS running buffer (Fisher Scientific™) and separated 
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by electrophoresis using a Consort EV231 system at 150 Volts for 1 hour at room temperature 
until separated. Materials for an overnight Western blot transfer were prepared as follows: 
one PVDF Transfer membrane (0.45µm; Thermo Scientific™) was briefly soaked in 100% 
methanol for 20 seconds, this and two Whatman™ Chromatography grade 3mm filter papers, 
and two filter pads supplied with the BIO-RAD Mini-PROTEAN™ 3 Cell overnight transfer tank 
were then were pre-soaked for at least 20 minutes in 1X NuPAGE™ Transfer Buffer (Thermo 
Scientific™) before assembly.  
After successful protein migration, the gel cassette was removed, the gel rinsed in 
transfer buffer to remove residual SDS and the gel placed onto the PVDF membrane and 
sandwiched between two filter papers and two filter pads. The membrane unit cassette was 
loaded into a BIO-RAD Mini-PROTEAN™ 3 Cell overnight transfer tank in 1X NuPAGE™ Transfer 
Buffer (Thermo Scientific™) with an ice pack and stirring bead and transferred using a Consort 
EV231 system at 30 Volts, 90mA for 16 hours at 4oC. 
 
2.8.3 Western Blot 
After transfer of the samples to PVDF membranes, blots were processed for immuno-
detection using the following protocol; all samples were incubated at room temperature 
unless otherwise stated. The membrane was removed from the overnight transfer unit and 
washed in excess 1X TBS (Fisher Scientific™) to remove residual transfer buffer. The 
membrane was incubated in 5% non-fat milk (w/v TBS) or 5% goat serum (v/v TBS) blocking 
solution for 1 hour and gently rocked at slow speed (~15rpm) using a Gyro-platform rocker. 
Following this, the membrane was washed three times in excess 1X TBS (Fisher Scientific™) to 
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remove residual blocking solution, before adding 1% blocking solution containing primary 
antibody, dependent on target protein (see relevant chapters), covered and incubated 
overnight at 4oC with gentle rocking at slow speed. Following primary antibody incubation the 
membrane was washed in 1X TBS (Fisher Scientific™) or 1X TBS Tween®-20 Buffer (Thermo 
Scientific™) three times for 5 minutes whilst gently rocked at slow speed. After washing, the 
secondary antibody (HRP-conjugated polyclonal goat anti-mouse secondary (Dako, P0447) at 
1:1000), was added in 5% blocking solution, covered and further incubated overnight at 4oC 
with gentle rocking at slow speed. Following secondary antibody incubation, the membrane 
was washed five times for 5 minutes in 1X TBS (Fisher Scientific™) or 1X TBS Tween®-20 Buffer 
(Thermo Scientific™) before adding Clarity™ Western ECL Substrate (BIO-RAD) and incubating 
for 5 minutes protected from light. Once incubated, the membrane was imaged using a C-
DiGit® Blot Scanner (LI-COR®), set at high-sensitivity for all Western blot samples.  After the 
membrane was scanned, the membrane was then washed in excess 1X TBS (Fisher Scientific™) 
before the addition of Restore™ PLUS Western Blot Stripping Buffer (Thermo Scientific™) for 
10 minutes and gently rocked at slow speed. The stripped membrane was then washed three 
times in excess 1X TBS (Fisher Scientific™) before being re-blocked in 5% blocking solution for 
30 minutes. The membrane was then washed in excess 1X TBS (Fisher Scientific™) before the 
addition of a mouse monoclonal anti-β-Actin (Sigma Aldrich, A2228, clone AC-74) at 1:1000 
dilution in 1% blocking solution. Following a 1 hour incubation, the membrane was again 
washed three times in 1X TBS (Fisher Scientific™)  for 5 minutes before being incubated with 
the corresponding polyclonal goat anti-mouse secondary (Dako, P0447) at 1:1000 in 5% 
blocking solution for 2 hours. Following this, the membrane was washed five times in 1X TBS 
(Fisher Scientific™) before proceeding to incubate with Clarity™ Western ECL Substrate (BIO-
RAD) for 5 minutes protected from light. Once incubated, the membrane was imaged using a 
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C-DiGit® Blot Scanner (LI-COR®). Results were analysed using the LI-COR® software supplied 
and expressed as relative ratio of protein of interest against β-Actin expression.  
 
2.9 Real Time-Polymerase Chain Reaction (RT-PCR) 
2.9.1 RNA Extraction and Purification  
BRIN-BD11 cells were seeded in 24- or 6-well plates and, following treatment with 
250µM palmitate, alone or in combination with EETs (10µM), cells were harvested for RNA 
extraction using Direct-zol™ RNA MiniPrep (Zymo Research). Following manufacturer’s 
protocol, all centrifugation steps were performed at 13000xG for 30 seconds. To isolate RNA 
from the total cell population, spent media from treated wells was centrifuged at 12000xG for 
6 minutes to pellet any detached cells. The remaining adhered cells were lysed directly in the 
culture plate using TRIzol® (Zymo Research), an acid-guanidinium-phenol based reagent that 
functions to solubilise biological compounds and denature proteins, in the process of cell lysis, 
whilst isolating RNA, DNA and protein, which was then transferred to the isolated pellet from 
the culture media. After lysing the cells in Trizol, an equal volume of ethanol (100% v/v) was 
added and the samples were transferred to a Zymo-Spin™ IIC Column with collection tube and 
centrifuged to bind nucleic acids to the silica-based column matrix, eliminating inaccuracies 
with phase separation and precipitation-based methods of RNA isolation. The column was 
then transferred to a new collection tube and RNA Wash buffer was added and samples 
centrifuged to remove residual protein before proceeding with DNase I treatment to remove 
genomic DNA contamination. DNase I (6U/µL) was diluted with DNA Digestion Buffer at a 1:16 
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ratio, before directly applying to the column matrix (80µL/column) and incubated at room 
temperature (20-30oC) for 15 minutes. 
The column was then washed twice to eliminate digested DNA, discarding the flow-
through, using Direct-Zol™ RNA PreWash, followed by a final addition of RNA Wash Buffer to 
remove PreWash buffer salts and centrifuged. Sample tubes were then centrifuged (empty) 
for 2 minutes to ensure complete removal of residual wash buffers before columns were 
transferred to new collection tubes ready for sample elution in 30µL of DNase/RNase-Free 
Water, directly added to the column matrix before centrifugation. Samples were quantified 
using Thermo Scientific Nanodrop™ 1000 spectrophotometer, with a ratio of A260/A280 of 
1.8-2.1 indicating a high purity RNA sample. Integrity of the eluted RNA was confirmed by 
preparation of 1µg RNA/sample in a 1X DNA loading buffer (Bioline) and separation on a 1% 
(w/v) agarose mini-gel in 1X tris-acetate-EDTA buffer (TAE) containing ethidium bromide for 
20 minutes at 100V alongside a 1,000kBp DNA ladder (Biolone). Gels were visualised using a 
Syngene U:Genius 3 UV Transilluminator and RNA integrity/purity confirmed by a 2:1 ratio of 
the 28S and 18S rRNA bands, the absence of high molecular weight gDNA bands or band 
smearing (see Appendix A, figure A.3). Samples were then stored at -80oC or used immediately 
for cDNA synthesis. 
 
2.9.2 cDNA Synthesis by Reverse Transcription      
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used to 
synthesise cDNA from RNA for RT-PCR. Following manufacturers protocol; all materials were 
kept on ice, including RNA samples (thawed on ice if stored at -80oC) throughout. A 2X RT 
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master mix was prepared with the following components: 2X RT Buffer, dNTP Mix (4mM), 2X 
RT Random Primers, MultiScribe™ Reverse Transcriptase (50U/reaction), RNase Inhibitor 
(20U/reaction) and Nuclease-free H2O to a total of 10µL per reaction. The 2X RT master mix 
was kept on ice whilst RNA samples were prepared to a final concentration of 1µg/10µL, which 
was then gently mixed with 10µL of the 2X RT master mix. Samples were loaded into an 
Eppendorf Mastercycler® nexus (thermal cycler) and conditions set to:  Step 1 – 25oC for 10 
minutes, Step 2 – 37oC for 120 minutes, Step 3 – 85oC for 5 minutes and Step 4 – hold at 4oC 
indefinitely. Samples were stored long-term at -20oC.  
 
2.9.3 QuantiNova™ SYBR® Green PCR Kit      
QuantiNova™ SYBR® Green PCR kit was used to determine gene expression in cDNA 
samples. SYBR® Green I dye binds to the minor groove of any double-stranded DNA with 
excitation producing a strong fluorescence with minimal background noise from unbound 
SYBR® Green I dye (Life Technologies Protocol, 2012). Following manufacturers protocol; a 
reaction master mix was prepared in a 1X SYBR Green PCR Master Mix containing; QN ROX 
Reference Dye for normalisation of fluorescence signal (low-ROX), Forward primer (as 
desired), Reverse primer (as desired), template cDNA was diluted into the reaction master mix 
to a final concentration of 10ng and reaction volume made up to 20µL in Nuclease-free H2O. 
PCR amplification and real-time quantification of fluorescence was carried out using an AriaMx 
Real Time PCR System G8830A (Agilent Technologies) under the following cycling conditions; 
PCR initial heat activation for 2 minutes at 95oC, followed by 2-step cycling (denaturation for 
5 seconds at 95oC and annealing/extension for 10 seconds at 60oC) over 40 cycles. Specificity 
of the amplification was then determined by melt curve analysis. 
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Efficiency for each target gene was determined using a standard curve of real-time PCR 
data across the range of 0.01, 0.1, 1 and 10ng. All primers had an efficiency between 90-110% 
and showed no visible primer-dimer formation, as determined by specificity of amplification 
from melt curve analysis, showing a single peak (see Appendix A, figure A.4 and table A.2).  
All data was analysed using the AriaMx qPCR software to compare Ct values for the 
gene of interest (GOI) in treated samples with vehicle-treated controls, relative to the 18S 
rRNA gene as a normaliser (equation 3), deriving a value for ΔΔCt (equation 4) with data 
expressed as fold change in expression (as compared to control; equation 5).  
Eq. 3    ∆𝐶𝑡  𝑠𝑎𝑚𝑝𝑙𝑒 =  𝐶𝑡 𝐺𝑂𝐼 − 𝐶𝑡 18𝑆 𝑟𝑅𝑁𝐴 
∆𝐶𝑡  𝑐𝑜𝑛𝑡𝑟𝑜𝑙 =  𝐶𝑡 𝐺𝑂𝐼 − 𝐶𝑡 18𝑆 𝑟𝑅𝑁𝐴 
 
Eq. 4     ∆∆𝐶𝑡 =  ∆𝐶𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 − ∆𝐶𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 
Eq. 5     𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =  2−∆∆𝐶𝑡  
 
To confirm suitability of 18S rRNA as a normaliser relative to the GOIs, comparative 
efficiency plots were produced for each GOI by plotting the mean ΔCt between the 18S rRNA 
gene and the GOI from the standard curve data against input amount of RNA (see Appendix 
A, table A.2). Whilst absolute comparison between ΔCt values for any given input amount of 
RNA target should be identical, the slope of these comparative efficiency plots produced 
values <0.1, which is considered acceptable deviation when using the ΔΔCt method for RT-PCR 
expression analysis, thereby confirming suitability of the 18S rRNA gene for normalisation in 
this study.    
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2.9.4 Primer Design       
Primers were designed using Primer-BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) provided by National Centre for 
Biotechnology Information (NCBI) and integrated DNA technologies, with primer specificity 
further confirmed using NCBI-BLAST.  
Table 2.2 Primers used in the study of EET action 
Target Primers Sequences (5’ to 3’) Length of Product (bp) 
18S Forward 
Reverse 
GCAATTATTCCCCATGAACG (20) 
GGCCTCACTAAACCATCCAA (20) 
123 
CPT1 Forward 
Reverse 
CAGCTCGCACATTACAAGGA (20) 
TGCACAAAGTTGCAGGACTC (20) 
128 
Elovl6 Forward 
Reverse 
ACACGTAGCGACTCCGAAGAT (21) 
AGCGCAGAAAACAGGAAAGACT (22) 
145 
Ech1 Forward 
Reverse 
TGTGGTCTCTGGTGCAGGAAAG (22) 
GGTATCGGCTGATGAGGTCTCG (22) 
134 
DGAT1 Forward 
Reverse 
TGCTCTTTTTCACCCAGCTT (20) 
TTGAAGGGCTTCATGGAGTT (20) 
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2.10 Statistical Analysis 
All experiments were performed as three independent replicates, unless otherwise 
stated. Results expressed as mean +/- SEM. Data was tested for normality and level of 
significance was calculated by using one-way ANOVA followed by Tukey’s test post hoc and 
where appropriate a two-way ANOVA  followed by Bonferroni’s post hoc (GraphPad Prism 7). 
A P value of less than 0.05 (P<0.05) was regarded as significant.  
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Chapter Three 
 
Preliminary Investigations  
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3 Preliminary investigations into cytotoxic effects 
of cytokines and palmitate in BRIN-BD11 cells 
 
3.1 Introduction 
 Broadly classified, DM is mainly characterised into type 1 DM and type 2 DM. Type 1 
DM occurs as a result of an autoimmune attack on pancreatic beta cells within the islets of 
Langerhans, reducing functional cell mass by 70-80% by the time of diagnosis and is 
characterised by the infiltration of immune cells, mainly CD4+ and CD8+ T-cells and 
macrophages, in a process termed insulitis (Willcox et al., 2009). Type 2 DM is often associated 
with chronic glucolipotoxicity, influenced by high-fat diets and increased insulin resistance in 
adipose and skeletal muscle, typically forming the foundation of a pre-diabetic 
hyperglycaemic state before progressing to overt type 2 DM (Donath et al., 2013). 
Understanding the mechanisms responsible for targeted beta cell destruction in the 
development of type 1 DM and the sensitivity of beta cells to pro-inflammatory cytokines, 
oxidative and nitrosative stress, and the glucolipotoxic environment in the milieu of islet beta 
cells in the pathogenesis of both main forms of DM remains a major aim of diabetes research. 
The establishment of a range of in vitro pancreatic beta cell line models, as well as ex vivo 
islets and primary cells, and in vivo animal models continue to advance these aims.  
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3.1.1 In vitro models of type 1 DM  
 The main mechanisms believed to be involved in beta cell demise via apoptosis 
induction in type 1 DM include: 1) ligation of Fas Ligand (FasL) expressed by infiltrating CD8+ 
with cell surface Fas Receptors, 2) the release of pore-forming perforins and the granzyme B 
serine protease, 3) secretion of pro-inflammatory cytokines; IL-1β, IFN-γ and TNF-α by 
infiltrating immune cells and 4) increase in NO and ROS (Yoon and Jun, 2005). 
 In models of type 1 DM, it is well-established that pro-inflammatory cytokines are the 
main soluble mediators involved in beta cell death. Treatment with these cytokines has been 
shown to increase apoptosis in a range of pancreatic beta cell lines and primary islets and is, 
in part, mediated by the alteration in expression of NF-κB and STAT1 target genes, 
downstream of cytokine receptor activation, including the upregulation of iNOS and 
subsequent NO production (Cnop et al., 2005). The contribution of NO to beta cell dysfunction 
was first reported by Southern et al., (1990) and has since been observed to mediate, in part, 
pro-apoptotic cytokine-induced cell death (Ankarcrona et al., 1994; Eizirik et al., 1996; 
Cardozo et al., 2005); although both NO-dependent and NO-independent effects are known. 
In INS-1 cells subjected to IL-1β and IFN-γ, microarray analysis showed alteration in expression 
of 698 genes over 1, 2, 4, 8, 12 and 24 hours treatment, with several apoptosis-related genes 
altered within 2-4 hours, preceding increased iNOS expression (typically occurring within 6 
hours of cytokine treatment). Alternatively, between treatment times of 8-24 hours, 46% of 
gene analyses were altered because of NO production and were classified as NO-dependent 
despite which, inhibition of NO production failed to attenuate cytokine toxicity (Kutlu et al., 
2003).  
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The extent of pro-inflammatory cytokine toxicity, and indeed the contribution of iNOS 
expression to cytokine-induced beta cell apoptosis, is variable between different model 
systems, as well as being influenced both by concentration (and type) of cytokines 
administered and treatment periods across a range of beta cell and islet models. In rat RINm5F 
cells, studies on the contribution of individual cytokines in mediating beta cell death showed 
that IL-1β and IFN-γ alone, but not TNF-α, increased beta cell death by activation of the 
intrinsic mitochondrial pathway (Holohan et al., 2007). Synergistic actions of IL-1β and IFN-γ 
were also demonstrated to be central to beta cell death, supporting previous studies carried 
out in RINm5F cells and isolated rat primary beta cells, and human beta cells (Rabinovitch and 
Suarez-Pinzon, 1998; Eizirik and Mandrup-Poulsen, 2001). Whilst earlier studies in the same 
cell line reported that IL-1β and TNF-α (but not IFN-γ) alone increased iNOS expression and 
induced apoptosis (Ankarcrona et al., 1994; Cetkovi-Cvrlje and Eizirik, 1994), other studies in 
murine insulinoma cells showed TNF-α has synergistic effects with IFN-γ in causing beta cell 
death in the absence of IL-1β (Chang et al., 2004). It is clear, therefore, that cytokine synergy, 
through costimulatory activation of numerous pro-apoptotic signalling pathways, is essential 
in beta cell death and more closely reflects the in vivo autoimmune attack on beta cells. 
Cytokine-induced iNOS expression has been shown to be mediated by NF-κB 
activation, downstream of IL-1β binding to its receptor (Flodstrom et al., 1996; Kutlu et al., 
2003), with consensus sequences for NF-κB identified in the iNOS promoter region (Xie et al., 
1994). Further synergistic contribution of IFN-γ activated pathways in mediating iNOS 
expression, such as IRF-1 and STAT1 are also well-established; with consensus sequences for 
IRF-1 also identified in the iNOS promoter region (Xie et al., 1994) and IRF-1-/- mice have been 
shown to produce little or no NO, with iNOS mRNA barely detectable when treated with IFN-
91 
 
γ (Kamijo et al., 1994). This cross-talk between pathways indicates that IFN-γ may potentiate 
IL-1β mediated iNOS expression by enhancement of NF-κB action in this context. Whilst iNOS 
expression and NO production can be considered as a classical ‘hallmark’ of cytokine action in 
beta cells, the contribution of this radical as a mediator of beta cell death in type 1 DM remains 
unclear. Exogenous treatment of beta cells with chemical NO donors has been shown to 
induce cytotoxicity comparable to cytokine-stimulated endogenous NO production (Eizirik  et 
al., 1996) and the ER stress response in rodent beta models exposed to cytokines appears NO-
dependent (Oyadomari et al., 2001; Cardozo et al., 2005). However, iNOS inhibition may only 
partially rescue clonal cells and islets from cytokine toxicity (Kutlu et al., 2003) and cytokine 
effects in human islet models are largely NO-independent (Eizirik et al., 1994; Zhong et al., 
2018). Nonetheless, recent studies aimed at the development of novel and more 
potent/selective iNOS inhibitors and their effects on cytokine toxicity in rodent beta cell lines 
and islet models (Zhong et al., 2018), as well as observations that improved siRNA delivery 
into human islets targeting iNOS induced a modest reduction in apoptosis in response to 
cytokine treatment (Li and Mahato 2007), continues to maintain interest in its role in models 
of type 1 DM.  
 
3.1.2 In vitro models of type 2 DM 
In contrast to the autoimmune attack on pancreatic beta cells in type 1 DM, type 2 DM 
is partly associated with glucolipotoxicity, with chronic elevation of long-chain fatty acids 
(particularly palmitate (C16:0)) alongside prevailing hyperglycaemia directly contributing to 
declining functional beta cell mass. Although mechanisms responsible for glucolipotoxicity-
induced beta cell apoptosis are not fully understood, elevated glucose levels lead to increased 
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cytosolic malonyl-CoA, with a direct inhibitory action on CPT1 decreasing entry of long-chain 
fatty acyl-CoA groups into the mitochondria for oxidation.  
Accumulation of cytosolic acyl-CoA, largely from cellular lipid overload, increases the 
rate of fatty acid metabolism in other pathways including de novo ceramide synthesis and 
peroxisomal β-oxidation. This latter pathway leads to increased production of H2O2, which, 
coupled to very low expression of the H2O2-detoxifying oxidoreductase enzyme, catalase in 
beta cells (Tiedge et al., 1997), directly provides a mechanistic link between lipotoxicity, ROS 
generation and oxidative stress. In support of this Elsner et al., (2011) showed that 
peroxisomal and cytosolic over-expression of catalase could protect RINm5F beta cells against 
palmitate toxicity, suggesting that this represents a major route of palmitate-induced ROS, in 
addition to the possible contribution of mitochondria-derived ROS from the release of 
superoxides in the respiratory chain, with enhanced palmitate oxidation. That over-expression 
of CPT1 has been shown to protect against lipotoxicity in INS-1 cells further supports extra-
mitochondrial fatty acid metabolism as a main contributor to lipotoxicity (Sol et al., 2008).  
One well-established mechanism of lipotoxicity is the activation of ER stress and 
initiation of the UPR by palmitate overload in beta cells (Cnop et al., 2008; Diakogiannaki et 
al., 2008). In INS-1 cells, palmitate treatment has been shown to induce a marked elevation in 
the activation and/or increased expression of the three main branches of the UPR (Cuhna et 
al., 2008), with similar effects also observed in MIN6 beta cells (Laybutt et al., 2007), as well 
as human islets (Lai et al., 2008). Similarly, the cytoprotective actions of mono- and poly-
unsaturated fatty acids have also been associated with a reduction in palmitate-induced ER 
stress markers (Diakogiannaki et al., 2008). However, over-expression of the ER resident 
chaperone BiP failed to attenuate palmitate toxicity in INS-1 cells, nor alter palmitate 
93 
 
sensitivity in MIN6 cells (Lai et al., 2008), highlighting that whilst ER stress initiation may be a 
factor in lipotoxicity, it is not the sole mediator of beta cell apoptosis under these conditions.   
Similar to the action of cytokines in mediating beta cell death in cellular models of type 
1 DM, species and cell type-specific variation in the response of clonal cell lines and ex vivo 
islets to the lipotoxic action of palmitate are also noted in a number of studies. The 
phenomenon of glucolipotoxicity, whereby hyperglycaemia potentiates lipotoxicity (possibly 
via effects on decreased mitochondrial β-oxidation) has been reported in several studies 
utilising the rat beta cell line INS-1 (El-Assaad et al., 2003; Sargsyan and Bergsten, 2011). In 
contrast however, Sargsyan and Bergsten., (2011) showed that whilst high glucose markedly 
enhanced palmitate-induced DNA fragmentation and caspase activation in INS-1 cells, such 
effects were not evident in MIN6 cells. Similarly, human islets also displayed reduced 
sensitivity to glucose-augmented lipotoxicity, suggesting important species/model system 
differences. However, El-Assaad et al., (2003) reported comparable enhancement in dispersed 
human islets exposed to palmitate and 25mM glucose, as assessed by Hoechst and TUNEL 
staining, to that observed in INS-1 cells. Differences between these two models likely reflects 
additional protection afforded by the intact islet architecture; this may be attributable to 
higher antioxidant enzyme capacity facilitating ROS clearance in intact islets, given the likely 
contribution of peroxisomal H2O2 to lipotoxicity (Elsner et al., 2011).  
Differences between the rat INS-1 and mouse MIN6 cell line models may also reflect 
differential lipid handling between the two models, with palmitate oxidation rates less 
affected by high glucose in MIN6 compared to INS-1, effects associated with higher acetyl-CoA 
Carboxylase activity in INS-1 cells (Sargsyan and Bergsten, 2011). Similarly both human islets 
and MIN6 cells have been shown to express higher levels of SCD-1 compared to INS-1 cells (Lai 
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et al., 2008), which converts toxic saturated fatty acid species to the more well-tolerated 
monounsaturated species. Such differences in lipid handling may also explain variation in 
palmitate doses and/or exposure times in a range of studies in these cell lines used to model 
lipotoxicity, whereby concentrations of palmitate exceeding 400µM over longer incubation 
periods of 48 hours in MIN6 cells witness a comparable reduction in cell viability to that seen 
with 125-250µM over 24 hours in INS-1 cells when assessed by MTT reduction assays. 
 
3.1.3 BRIN-BD11 cells a model for cytotoxicity studies 
The BRIN-BD11 rat pancreatic beta cell line, used in the current study, was established 
in the mid-1990’s, producing a more glucose-responsive cell line from parental RINm5F cells 
(which continue to also be extensively utilised despite poor secretory capacity), by 
electrofusion with NEDH rat islet beta cells (McClenaghan et al., 1996). BRIN-BD11 cells in 
contrast, display an enhanced GSIS profile, owing to high expression of GLUT2 and a higher 
glucokinase:hexokinase ratio, facilitating enhanced glucose uptake, glucose oxidation and ATP 
production necessary for stimulus-secretion coupling; with similarly enhanced activity in 
responses to amino acids and hypoglycaemic agents (McClenaghan et al., 1996; McClenaghan 
and Flatt 1999). These properties have been exploited in functional studies into the roles of 
novel insulinotropic peptides with potential clinical utility, with activity related to GLP-1 
signalling and the GLP-1 mimetic exendin-4 (O’Harte et al., 2016; Long et al., 2018).  
BRIN-BD11 cells have also been utilised as a model for the study of lipotoxicity and, to 
a lesser extent, pro-inflammatory cytokine toxicity. Establishing cytotoxic effects of palmitate 
in BRIN-BD11 cells treated with 250µM palmitate, studies have shown comparable effects to 
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that seen in INS-1 and primary rodent islets in the extent of cytotoxicity, as assessed utilising 
a range of cell viability assays including trypan blue vital dye exclusion staining, caspase 
activation and Annexin V/PS staining (Welters et al., 2004; Dhayal  et al., 2008). Furthermore, 
this cell line has also been employed in studies investigating the cytoprotective actions of 
mono- and poly-unsaturated fatty acids against palmitate toxicity, defining important 
structural characteristics for cytoprotection in terms of chain length and number and 
configuration of double bonds (Dhayal and Morgan 2008; Dhayal et al., 2008). Potential 
mechanisms of action have also been reported, both in terms of ameliorating palmitate-
induced ER stress (Diakogiannaki et al., 2008) and defining potential requirements for a fatty 
acid binding site(s) in as yet undefined receptor(s) (Dhayal and Morgan 2008). Mechanisms of 
cytoprotection afforded by AA, relevant to the current study, have also been explored in this 
cell line (Dhayal and Morgan 2008; Keane et al., 2011), with these studies exploring the 
dependence of AA-derived COX and LOX metabolites and, whilst their contribution to the 
cytoprotective effects of AA is minimal (Dhayal and Morgan 2008), COX1 metabolites may 
positively contribute to augmentation of insulin secretion in co-incubation with AA and 
palmitate (Keane et al., 2008).  
In contrast to RINm5F, INS-1 and MIN6 clonal beta cells, comparatively fewer studies 
have fully established the actions of pro-inflammatory cytokines in the BRIN-BD11 cell line.  
Nonetheless beta cell dysfunction, loss in cell viability and induction of apoptosis have been 
reported, with this rat cell line shown to respond modestly to IL-1β used alone (Gao et al., 
2003), in agreement with the sensitivity of the parental RINm5F cells to this singular cytokine 
treatment (Ankarcrona et al., 1994; Holohan et al., 2008). Similarly, synergistic action of 
cytokines is also evident, with a combination of IL-1β and IFN-γ increasing cell death to ~40% 
96 
 
as assessed by vital dye staining (Welters et al., 2004) and reducing cell viability as assessed 
by neutral red up-take (Hsu et al., 2012). Furthermore, a combination of IL-1β, IFN-γ and TNF-
α produced a 5-fold increase in apoptosis as assessed by flow cytometry (Cunningham et al., 
2005).  
Of note, the contribution of iNOS and NO production in BRIN-BD11 cells to cytokine 
(and palmitate) toxicity remains unclear. Whilst numerous studies report an increase in nitrite 
levels in cytokine-treated BRIN-BD11 cells (Gao et al., 2003; Welters et al., 2004; Cunningham 
et al., 2005; Hsu et al., 2012), inhibition of iNOS activity by L-NAME failed to attenuate cytokine 
toxicity in one study, despite reducing cytokine-stimulated nitrite production (Hsu et al., 
2012), whereas Cunningham et al., (2005) observed a 31% decrease in cytokine-induced 
apoptosis. Of note, in those studies reporting on the cytoprotective effects of palmitoleate 
(Welters et al., 2004), alanine (Cunningham  et al., 2005), or novel plant extracts (Hsu et al., 
2012) against cytokine toxicity, all were suggested to occur by mechanisms independent to 
NO production and similarly in BRIN-BD11 cells, the iNOS inhibitor 1400W failed to attenuate 
a cytokine-induced decrease in insulin secretion, in contrast to effects in mouse islets in the 
same study (Michalska et al., 2010). Collectively, this may suggest that BRIN-BD11 cells display 
a comparatively reduced sensitivity to cytokine-derived NO and nitrosative stress than some 
other beta cell line models, though studies in this regard are limited. Interestingly though, a 
dual inhibitor of iNOS and NADPH oxidase displayed a markedly enhanced protection against 
cytokine-induced apoptosis compared to iNOS inhibition alone, despite comparable reduction 
in nitrite levels (Cunningham et al., 2005), suggesting a more important combination of NO 
and ROS together in mediating cell death under these conditions. Similar effects have been 
also been reported in vivo, whereby the dual iNOS inhibitor and peroxynitrite scavenger 
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guanidinoethyldisulphide decreased diabetes incidence in NOD mice and protected against 
cytokine toxicity in isolated islets (Suarez-Pinzon et al., 2001).  
In lipotoxicity models, although the contribution of ROS production is a well-
established mediator of palmitate toxicity (Elsner et al., 2011; Keane et al., 2011), the role of 
NOS-derived NO remains unclear. However, the general consensus indicates NO-
independency with most studies failing to detect an increase in palmitate-induced NO 
accumulation, including in BRIN-BD11 cells (Welters et al., 2004; Cnop et al., 2005). 
Interestingly though, Keane et al., (2011) observed a significant increase in NO production in 
BRIN-BD11 cells treated with palmitate concentrations above 100µM, an effect attenuated by 
co-incubation with 100µM AA, in disagreement with other studies in these cells (Welters et 
al., 2004).  
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3.2 Aims 
The aim of this chapter is to establish a model system in BRIN-BD11 cells, 
characterising cell death in response to pro-inflammatory cytokines and the lipotoxic actions 
of palmitate, confirming validity of the model in context to previous studies and establishing 
appropriate conditions for further investigations. Specifically the aims are to: 
 characterise the response of BRIN-BD11 cells to pro-inflammatory cytokines 
alone and in combination as a model of cytokine synergy and determine 
appropriate optimum conditions for further study. 
 confirm the dose-dependent action of palmitate in BRIN-BD11 cells and 
determine appropriate optimum concentrations. 
 investigate a dose-response relationship for the cytoprotective effects of the 
polyunsaturated FFA, arachidonic acid (AA). 
 compare a range of assays for the measurement of cell viability and apoptosis 
for use in models of inflammatory cytokine and lipo- toxicity. 
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3.3 Methods 
Cell viability was determined using MTT, neutral red and trypan blue vital dye exclusion 
assays, or apoptosis quantification by flow cytometry using the MUSE™ Annexin V and Dead 
Cell Assay (Chapter 2.4). As a model of cytokine-toxicity, BRIN-BD11 cells were treated with 
IL-1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL), alone or in combination, with the 
Griess assay used for the quantification of nitrite in cell supernatants, as a measure of 
cytokine-induced iNOS expression. Additionally, cytokine-induced iNOS expression was 
determined by SDS-PAGE/Western blotting using cell lysates (500,000 cells) from cultures 
treated with the combination of all three cytokines for 6 or 24 hours. Lysates were separated 
on 10% resolving gels and, after transfer to PVDF, membranes were blocked in 5% goat serum 
(v/v TBS) and probed with a mouse monoclonal anti-iNOS (1:500 in TBS), subsequent steps 
were carried out as described (Chapter 2.8, using 1X TBS Tween®-20 Buffer for washing), with 
expression levels quantified relative to β-actin. For the study of palmitate-induced lipotoxicity, 
palmitate:BSA complexes were prepared at a ratio of 3.3:1, as described (Chapter 2.2) and 
diluted into 1% FBS-supplemented RPMI-1640 media to final concentrations ranging from 
31.25µM-1000µM. Cytoprotective effects of AA in both models were also explored using 
AA:BSA complexes (molar ratio 3.3:1) at final concentrations ranging from 0.625µM-100µM 
in combination with palmitate or cytokines. In all treatments with fatty acids, control cultures 
were treated with 0.5% BSA (w/v) and 0.25% ethanol (v/v).  
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3.4 Results 
To establish the effect of known cytotoxic mediators of pancreatic beta cell death and 
dysfunction in DM pathogenesis in BRIN-BD11, preliminary investigations into the effects of 
cytokines and the saturated fatty acid palmitate were established. Cytokines are well-known 
contributors to pancreatic beta cell dysfunction and loss in type 1 DM with evidence 
suggesting an overall pro-apoptotic effect by subjecting beta cells to cytokines activating 
intracellular pathways culminating in beta cell demise (Collier et al., 2011) 
Initial preliminary studies dosing a range of concentrations of IL-1β, IFN-γ and TNF-α 
(data not shown) established suitable concentration ranges to investigate cytokine synergy in 
the current model. BRIN-BD11 cells were then treated with concentrations of IL-1β (100U/mL), 
IFN-γ (20U/mL) and TNF-α (500U/mL), alone and in combination, for 24 and 48 hours, with 
cell viability initially assessed using the MTT assay (figure 3.1).   
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Figure 3.1. Cell viability in BRIN-BD11 cells exposed to cytokines assessed by MTT assay. Cells were treated with IL-1β 
(100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL), alone and in combination, for 24 and 48 hours. Cell viability was assessed 
by MTT assay, with values represented as mean (+/- SEM), n=3. *P<0.05 relative to time matched controls. #P<0.05 relative 
to corresponding treatment at 24 hours, as determined by two-way ANOVA and Bonferroni’s post-test. 
 
 The cytotoxic effects of cytokines when treated in combination for 24 and 48 hours 
resulted in a decrease in cell viability when assayed by MTT. Treatment with IL-1β (100U/mL), 
IFN-γ (20U/mL) and TNF-α (500U/mL) alone for 24 and 48 hours showed no significant 
difference in cell viability (P>0.05). However, in combination, significant loss in cell viability 
was evident with IL-1β plus IFN-γ, IFN-γ plus TNF-α and all three cytokines together after 48 
hours (P<0.05), supporting previous studies of synergism. However, treatment with the 
combination IL-1β plus TNF-α failed to increase cytotoxicity, suggesting the role of cytokine 
synergism was most potent following co-stimulatory activation of NF-κB and STAT1.  The 
combination of IL-1β plus IFN-γ treatment after 24 hours resulted in no significant decrease in 
cell viability, however, after 48 hours, viability was significantly decreased to 73.5% (+/-5.0) 
(P<0.05). Analysis of IFN-γ plus TNF-α showed similar results to that of IL-1β plus IFN-γ with 
no significance at 24 hours but a significance at 48 hours 74.2% (+/-4.7) (P<0.05) and 
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treatment with IL-1β plus IFN-γ plus TNF-α for 48 hours witnessed maximal loss in cell viability, 
decreasing to 66.9% (+/-5.9).  
To further confirm activation of known pathways mediating cytokine toxicity, BRIN-
BD11 cells were also assayed for nitrite production as a hallmark of cytokine toxicity; this 
method can be used as an indirect analysis reflecting an increase in iNOS levels (figure 3.2). 
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Figure 3.2. Nitrite production in BRIN-BD11 cells exposed to cytokines assessed by Griess assay. Cells were treated with IL-
1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL), alone and in combination, for 24 and 48 hours. Nitrite production was 
assessed by Griess reagent. Values are represented as mean (+/- SEM), n=4. *P<0.05 relative to time matched controls. 
#P<0.05 relative to corresponding treatment at 24 hours, as determined by two-way ANOVA and Bonferroni’s post-test.   
 
 In general, an increase in nitrite production correlated with the decrease in cell viability 
(figure 3.1). All treatments after 24 and 48 hours showed a significant increase in nitrite 
production (P<0.05), except TNF-α alone, with the largest increase seen with the combination 
of all three cytokines after both 24 and 48 hours to 14.5µM (+/-0.8) and 22.2µM (+/-1.1), 
respectively, confirming cytokine synergism. Furthermore, confirmation that IL-1β and TNF-α 
acting through similar intracellular mechanisms, with IL-1β being the predominant activator 
of the NF-κB pathway, is shown by the combination treatment of IL-1β and TNF-α witnessing 
103 
 
the smallest increase in nitrite production of all cytokines in combination. Interestingly and in 
agreement with cell viability data (figure 3.1), treatment with IL-1β plus IFN-γ in combination 
produced similar results for 24 hours; 12.2µM (+/-0.7) and 48 hours; 21.4µM (+/-1.5) when 
compared to treatment with all three cytokines at both time points. 
 Given the lack of a significant effect of cytokine combinations on loss in cell viability 
over 24 hours and the modest decrease in viability at 48 hours, as assessed by the MTT assay, 
cell viability was further assessed under the same treatment conditions using the neutral red 
assay (figure 3.3). 
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Figure 3.3. Cell viability in BRIN-BD11 cells exposed to cytokines assessed by neutral red assay. Cells were treated with IL-
1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL,) alone and in combination, for 24 and 48 hours. Cell viability was 
assessed by neutral red assay. Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to time matched controls. 
#P<0.05 relative to corresponding treatment at 24 hours, as determined by two-way ANOVA and Bonferroni’s post-test. 
 
 Treatment with IL-1β plus IFN-γ in combination resulted in a significant decrease in 
viability after 24 hours to 66.9% (+/-2.9) (P<0.05), in contrast to the MTT assay which showed 
no difference after 24 hours (P>0.05). At 48 hours cell viability continued to decrease to 23.7% 
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(+/-5.9) compared to control (P<0.05); an almost 80% reduction in cell viability compared to 
only 25% reduction when assayed by MTT. Treatment with IFN-γ plus TNF-α for 24 hours 
similarly showed a decrease to 55.7% (+/-8.0) when compared to control (P<0.05), again such 
a reduction in cell viability by 45% was not witnessed when assayed by MTT. Treatment with 
the combination of all three cytokines also showed a significant decrease in cell viability at 
both time points compared to control (P<0.05); at 24 hours there was a decrease in cell 
viability to 43.6% (+/-0.5), reducing to 13.9% (+/-3.4) at 48 hours. Comparing the data 
obtained between the two assays (figure 3.1 and 3.3), discrepancy in the results in terms of 
the extent of loss in cell viability could be accounted by differences in assay sensitivity in the 
current cell model, emphasising the need to use multiple methods, as reported by Fotakis and 
Timbrell, (2006). 
To further confirm cytokine effects on BRIN-BD11 cell viability, total and viable cells 
were assayed manually using trypan blue vital dye exclusion, as an extension to the automated 
colorimetric MTT and neutral red assays. As IL-1β plus IFN-γ in combination showed the 
highest decrease in cell viability, this combination was used along with IL-1β and IFN-γ alone 
and the combination of all three cytokines (figure 3.4). 
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Figure 3.4. Total and viable cell number in BRIN-BD11 cells exposed to cytokines assessed by trypan blue vital dye exclusion. 
Cells were treated with IL-1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL), alone and in combination, for (A) 24 hours 
and (B) 48 hours. Total and viable cell numbers were assessed by trypan blue vital dye exclusion. Values are represented as 
mean (+/- SEM), n=3. *P<0.05 relative to time matched controls as determined by two-way ANOVA and Bonferroni’s post-
test. 
 
 Treatment with IL-1β and IFN-γ alone for either 24 or 48 hours witnessed no significant 
decrease in either total or viable cell number compared to control (P>0.05) confirming results 
of previous assays. When treated with a combination of IL-1β plus IFN-γ viable cell number 
decreased from 1.45 x106 cells/mL (+/-0.13) to 0.85 x106 cells/mL (+/-0.11) (P<0.05) after 24 
hours, with a decrease from 2.21 x106 cells/mL (+/-0.11) to 0.69 x106 cells/mL (+/-0.19) after 
48 hours (P<0.05). Furthermore, the addition of TNF-α further decreased viable cell number 
to 0.69 x106 cells/mL (+/- 0.08)(P<0.05) after 24 hours and decreasing from 2.21 x106 cells/mL 
(+/-0.11) to 0.45 x106 cells/mL (+/-0.14) after 48 hours. These results therefore confirm 
findings from the neutral red data (figure 3.3), suggesting that the MTT assay (figure 3.1) under 
these conditions lacks sensitivity. Of note, as with previous assays, the inclusion of TNF-α leads 
to further decreases in viable cell number, though the effects are not significantly different to 
the combination of IL-1β plus IFN-γ, suggesting near maximal effects under these conditions. 
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Finally, to confirm the increase in nitrite production as a hallmark of iNOS expression, 
cells were treated with the combination of all three cytokines and assessed for iNOS 
expression by Western blotting after 6 and 24 hours (figure 3.5). 
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Figure 3.5. Relative density of iNOS/β-actin expression in BRIN-BD11 cells exposed to cytokines for 6 and 24 hours assessed 
by Western blotting. Cells were treated with IL-1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) for 6 and 24 hours and 
cells harvested for SDS-PAGE/Western blotting. Panel (A) represents relative density ratio of iNOS/β-actin Values are 
represented as mean (+/- SEM), n=3. *P<0.05 relative to control and #P<0.05 relative to 6 hour, as determined by one-way 
ANOVA and Tukey’s post-test. Panel (B) represents the western blot from independent replicate lysates.  
  
iNOS expression was significantly increased relative to control at after both 6 and 24 
hour incubation, such that  iNOS expression was increased 10-fold compared to control after 
(A) 
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131 kDa iNOS 
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6 hours, with a further 3.5-fold significant increase from 6 to 24 hours (P<0.05). It is clear 
therefore that whilst iNOS expression is detectable after 6 hours, a further increase in 
expression is observed after 24 hours.  
Following characterisation of cytokine-induced beta cell death as an in vitro models of 
type 1 DM, BRIN-BD11 cells were further investigated to establish their response to palmitate 
(C16:0), a long-chain saturated fatty acid thought to be a major contributor to lipotoxicity in 
type 2 DM. BRIN-BD11 cells were treated with increasing concentrations of palmitate from 
31.25µM to 1000µM, resulting in a dose dependent effect on cell viability, as assessed by MTT 
assay (figure 3.6).  
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Figure 3.6. Cell viability in BRIN-BD11 cells exposed to palmitate assessed by MTT assay. Cells were treated with increasing 
concentrations of palmitate from 31.25µM to 1000µM for 24 hours and cell viability was assessed by MTT assay. Values are 
represented as mean (+/- SEM), n=3. *P<0.05 relative to control as determined by one-way ANOVA and Tukey’s post-test. 
 
All concentrations of palmitate resulted in a significant decrease in cell viability, from 
31.25µM – 82.6% (+/-5.6) to 1000µM – 17.7% (+/-4.2) (P<0.05) compared to control. At a 
concentration of 250µM cell viability was reduced to 43.3% (+/-3.9), decreasing to 27.1% (+/-
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2.9) with 500µM, yielding the largest decrease in cell viability between treatment groups of 
~16%. Given the discrepancy between the MTT assay data and other assays obtained in the 
cytokine model, the neutral red assay was used to assess cell membrane integrity in response 
to the same palmitate dose range (figure 3.7) 
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Figure 3.7. Cell viability in BRIN-BD11 cells exposed to palmitate assessed neutral red assay. Cells were treated with 
increasing concentrations of palmitate from 31.25µM to 1000µM for 24 hours and cell viability was assessed by neutral red 
assay. Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to control as determined by one-way ANOVA and 
Tukey’s post-test. 
A similar dose-dependent response was observed across all concentrations of 
palmitate, confirming data from the MTT assay. Treatment with 250µM and 500µM palmitate 
witnessed a decrease in cell viability to 28.4% (+/-1.7) and 22.2% (+/-0.6), respectively, 
compared to control (P<0.05). However, unlike the data from the MTT assay, the highest 
decrease in cell viability between treatments was from 62.5µM to 125µM, and 125µM to 
250µM, both witnessing ~20% loss in cell viability, again this may be reflective of a higher 
sensitivity of the neutral red assay. However, possibly owing to treatment of cells with 
palmitate requiring a reduction in serum composition of the media from 10% to 1% (to 
account for the levels of BSA in FBS, ensuring the palmitate:BSA complex ratio was maintained 
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at 3.3:1), this appeared to affect the ability of the cells to remain adhered to the wells 
following incubation in neutral red, causing potential loss of cells during the washing and 
solubilisation steps. As such, this may account for the apparent stunting of the dose response 
at concentrations exceeding 250µM, whereby cell viability decreased from 28.4% (+/-1.7) to 
22.2% (+/-0.6) at 500µM, compared to ~2-fold decrease in the MTT assay across the same 
doubling of the palmitate concentration.     
 The lipotoxic response in BRIN-BD11 cells treated with palmitate was then further 
investigated across the range 62.5µM to 500µM and assessed for total and viable cell number 
by trypan blue vital dye exclusion (figure 3.8). 
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Figure 3.8. Total and viable cell number in BRIN-BD11 cells exposed to palmitate assessed by trypan blue vital dye 
exclusion. Cells were treated with increasing concentrations of palmitate from 62.5µM to 1000µM for 24 hours with total 
and viable cell numbers assessed by trypan blue vital dye exclusion. Values are represented as mean (+/- SEM), n=3. *P<0.05 
relative to corresponding control. #P<0.05 relative to corresponding total cells as determined by two-way ANOVA and 
Bonferroni’s post-test. 
Increasing concentrations of palmitate resulted in a significant decrease in both total 
and viable cell number for all treatments compared to control (P<0.05). Treatment with 
250µM observed the highest decrease in both total and viable cells, with viable cells reducing 
from 1.06 x106 cells/mL (+/- 0.11) in control to 0.140 x106 cells/mL (+/- 0.01) (P<0.05), ~9-fold 
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decrease, and overall supports data from the MTT and neutral red assays showing a dose-
dependent decrease in cell viability in BRIN-BD11 cells treated with palmitate.  
To confirm effect of palmitate treatment in BRIN-BD11 cells in terms of apoptosis 
induction, the percentage of Annexin V positive cells thereby displaying PS externalisation in 
response to 250µM palmitate was assessed by flow cytometry (figure 3.9). Additionally, any 
effect on the cells of the necessary reduction in FBS composition of the media from 10% to 1% 
was also compared.   
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The apoptosis profile for cells cultured in 10% and 1% FBS-supplemented media shows 
basal apoptosis rates for BRIN-BD11 cells of 5.7% (+/-0.9) and 14.5% (+/-1.6), respectively, 
suggesting a significant increase in response to serum reduction. However treatment with 
250µM palmitate shows a further increase in total apoptosis from the 1% FBS-supplemented 
control from 14.5% (+/-1.6) to 25.6% (+/-1.3) (P<0.05). Comparison of panel (B) and (C) shows 
Figure 3.9. Comparative analysis of BRIN-BD11 cells cultured in 10% and 1% FBS-supplemented media and palmitate 
assessed by Annexin V & Dead Cell assay. Cells were treated for 24 hours +/- 250µM palmitate in 1% FBS-supplemented 
media, or 10% FBS-supplemented complete media and the total apoptosis profile (A) was assessed by flow cytometry using 
the Muse™ Annexin & Dead Cell kit. Panels (B) to (D) show representative apoptosis profiles of cells under each treatment 
condition. Values in panel (A) are represented as mean percentage apoptosis (+/- SEM), n=3. *P<0.05 relative to control. 
#P<0.05 relative to 1% FBS and determined by one-way ANOVA and Tukey’s post-test. 
 
112 
 
a modest increase in late apoptosis/dead (upper right quadrant), from 3.1% to 7.8%, 
respectively, whereas comparison of panel (C) to (D) shows an increase in late apoptosis/ dead 
from 7.8% to 22.5%, ~3-fold increase. Between panels (B), (C) and (D), there is a clear increase 
in percentage late apoptosis/dead as seen in the upper right quadrant, which shows a clear 
increase in apoptosis induction due to the cytotoxic effects of palmitate compared to control. 
To conclude, preliminary findings of palmitate treatment in BRIN-BD11 cells suggests 
that the data presented from MTT, neutral red, trypan blue vital dye exclusion and Annexin & 
Dead Cell assays supports evidence from others that BRIN-BD11 cells respond to palmitate in 
a dose-dependent manner (Welters et al., 2004; Dhayal and Morgan 2008; Keane et al., 2011). 
Due to the inherent difficulties of treatment of cells in media supplemented with 1% serum in 
processing of the neutral red assay, this assay was not used further in these models.  
 Whilst the current data (and others) support the lipotoxic action of palmitate in BRIN-
BD11 cells, it has also established that mono- and poly- unsaturated species such as 
palmitoleate (C16:1) or oleate (C18:1) are well tolerated and can ameliorate the cytotoxic 
effects observed in response to saturated fatty acids (Welters et al., 2004; Diakogiannaki et 
al., 2007; Keane et al., 2011). The main focus of this thesis is the cytoprotective effects of AA-
derived eicosanoids (specifically EETs) against palmitate and cytokine toxicity (subsequent 
chapters). Therefore, the effects of AA in co-incubation with palmitate was first confirmed as 
part of these preliminary investigations by treating BRIN-BD11 cells with increasing 
concentrations of AA against fixed concentrations of 250µM and 500µM palmitate (figure 
3.10). 
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Figure 3.10. Cell viability in BRIN-BD11 cells exposed to palmitate against increasing concentrations of AA assessed by MTT 
assay. Cells were treated with increasing concentrations of AA (0.6125µM to 40µM) against a fixed dose of either 250µM (A) 
or 500µM (B) palmitate for 24 hours. Cell viability was assessed by MTT assay, with results represented as mean (+/- SEM), 
n=3. *P<0.05 relative to control and #P<0.05 relative to palmitate alone as determined by one-way ANOVA and Tukey’s post-
test. 
 
Treatment with 250µM palmitate in combination with increasing concentrations of AA 
dose-dependently increased cell viability with respect to palmitate treatment alone, 
increasing from 27.9% (+/- 8.3) with 0.6125µM AA to 71.7% (+/- 1.5) with 5µM AA, though this 
remained significantly lower than control. Co-incubation with concentrations of AA at 10µM 
and above resulted in no significant difference between treatments and control (P>0.05), 
these were also the only concentrations of AA where significant protection against palmitate 
toxicity was observed (P<0.05 vs. palmitate alone), despite the trend in increased viability 
observed in co-incubation with 0.625-5µM AA. Similarly, a 2-fold increase in the concentration 
of palmitate to 500µM in co-incubation with the same range of AA concentrations, resulted in 
a dose-dependent increase in cell viability, however whilst concentrations of AA above 5µM 
significantly increased cell viability compared to palmitate treatment alone, all combined 
treatment groups resulted in a cell viability that remained significantly lower than untreated 
control (P<0.05). Whilst a clear dose-dependent effect of AA was observed, the highest 
C
o n
tr
o l 0
0 .
6 1
2 5
1 .
2 5 2 .
5 5 1 0 2 0 4 0
0
2 0
4 0
6 0
8 0
1 0 0
2 5 0 M  P a lm it a t e
A A  (M )
C
e
ll
 v
ia
b
il
it
y
 (
%
 c
o
n
tr
o
l)
*
*
*
*
# #
#
*
C
o n
tr
o l 0
0 .
6 1
2 5
1 .
2 5 2 .
5 5 1 0 2 0 4 0
0
2 0
4 0
6 0
8 0
1 0 0
5 0 0 M  P a lm it a t e
A A  (M )
C
e
ll
 v
ia
b
il
it
y
 (
%
 c
o
n
tr
o
l)
* *
*
*
*
*
* *
##
#
#
(A) (B) 
114 
 
maximum effect of AA was achieved with a concentration of 10µM therefore, to further 
confirm these effects, cell viability was assessed using the MTT assay with a palmitate dose 
response against a fixed concentration of 10µM AA (figure 3.11). 
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Figure 3.11. Cell viability in BRIN-BD11 cells exposed to increasing concentrations of palmitate +/- 10µM AA assessed by 
MTT assay. Cells were treated with increasing concentrations of palmitate (31.25µM to 1000µM) +/- 10µM AA for 24 hours. 
Cell viability was assessed by MTT assay with results expressed as mean cell viability (+/- SEM), n=3. *P<0.05 relative to 
corresponding control and #P<0.05 relative to corresponding palmitate treatment group as determined by two-way ANOVA 
and Bonferroni’s post-test. 
 
Treatment with 10µM AA in co-incubation with increasing concentrations of palmitate 
supports the previous data showing a dose-dependent decrease in cell viability in treatment 
with palmitate alone, with all concentrations significantly decreasing cell viability compared 
to control (P<0.05). Co-incubation with 10µM AA resulted in a significant increase in cell 
viability against all palmitate concentrations from 62.5µM to 1000µM compared to 
corresponding palmitate treatment alone (P<0.05). Interestingly, treatment with 10µM AA 
also significantly increased cell viability in co-incubation with 1000µM palmitate from 7.8% 
(+/-2.9) to 45.1% (+/-3.6) (P<0.05), though with all palmitate concentrations above 250µM in 
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co-incubation with 10µM AA cell viability remained significantly lower than untreated controls 
suggesting partial protection (P>0.05). 
The data collected with the MTT assay in cells co-incubated with palmitate and AA 
showed that regardless of higher AA concentrations cell viability did not exceed ~80% 
therefore, and as with previous data, the trypan blue vital dye exclusion assay was used to 
assess total and viable numbers in cells treated with palmitate in co-incubation with 1µM, 
5µM and 10µM AA (figure 3.12); this, and all subsequent data with palmitate was collected 
using a fixed concentration of 250µM. 
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Figure 3.12. Total and viable cell number in BRIN-BD11 cells exposed to 250µM palmitate co-incubated with 1µM, 5µM 
and 10µM AA assessed by trypan blue vital dye exclusion. Cells were treated with 250µM palmitate co-incubated with either 
1µM, 5µM or 10µM AA for 24 hours before total and viable cell numbers were determined using trypan blue vital dye 
exclusion assay. Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to control. #P<0.05 relative to total cells as 
determined by two-way ANOVA and Bonferroni’s post-test. 
 
Treatment with 250µM palmitate significantly decreased both total and viable cells 
compared to control from 1.15 x106 cells/mL (+/-0.09) to 0.68 x106 cells/mL (+/-0.09), roughly 
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2-fold, and 0.92 x106 cells/mL (+/-0.07) to 0.07 x 106 cells/mL (+/-0.03) cells/mL, roughly 9-fold 
(P<0.05), respectively. Treatment with 250µM palmitate in the presence of 1µM AA produced 
a similar, significant decrease in total and viable cells compared to control, with 1µM AA failing 
to protect against palmitate toxicity (P>0.05). Increasing the concentration of AA from 1µM to 
5μM resulted in a significant increase in viable cell number from 0.13 x106 cells/mL (+/- 0.03) 
to 0.66 x106 cells/mL (+/-0.13), respectively, an increase of ~5-fold (P<0.05). Similar 
observations were seen in increasing the concentration of AA from 5µM to 10µM with viable 
cells increasing from 0.66 x 106 cells/mL (+/-0.13) to 1.05 x106 cells/mL (+/-0.12) (P<0.05), a 
further increase of ~1.6-fold in viable cells.  
Comparing total and viable cells treated with 250μM palmitate in the presence of 
10μM AA respective to untreated controls, there is no significant difference (P>0.05). 
However, there is a modest increase in viable cell number from 0.92 x106 cells/mL (+/- 0.07) 
to 1.05 x106 cells/mL (+/- 0.12), in contrast to the maximum cell viability of ~80% observed in 
the MTT assay (potentially indicative of limitations of the MTT assay in this context) and 
perhaps suggesting a protective effect of AA against the effects of the lower serum levels in 
this model. To further confirm the protective effects of AA against palmitate toxicity, the 
Annexin V & Dead Cell assay was used to determine the percentage of cells undergoing 
apoptosis (figure 3.13).    
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Figure 3.13.  Comparative analysis of BRIN-BD11 cells exposed to 250µM palmitate co-incubated with 1µM, 5µM and 10µM 
AA assessed by Annexin V & Dead Cell assay. Cells were treated for 24 hours with 250µM palmitate in combination with 
increasing concentrations of AA (1µM, 5µM or 10µM) and the total apoptosis profile (A) was assessed by flow cytometry using 
the Muse™ Annexin V & Dead Cell kit. Panels (B) to (F) show representative apoptosis profiles of cells under each treatment 
condition. Values in panel A are represented as mean percentage apoptosis (+/- SEM), n=3. *P<0.05 relative to control. 
#P<0.05 relative to palmitate alone as determined by one-way ANOVA and Tukey’s post-test. 
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Confirmation of the protective effects of AA are evident from the apoptosis profiles 
with 5µM and 10µM AA in the presence of 250µM palmitate producing a significant decrease 
in percentage apoptosis from 22.8% (+/-1.9) with 250µM palmitate alone to 14.3% (+/-0.7) 
and 8.4% (+/-0.6) (P<0.05), respectively; to values not significantly different from control 
(P>0.05). As with previous flow cytometry representative apoptosis profiles (figure 3.9), there 
is a clear population of apoptotic cells within the upper right quadrant showing basal levels of 
apoptosis (figure 3.13 panel: B, upper right quadrant).  Increasing clusters of apoptotic cells 
were observed when treated with 250µM palmitate (panel: C, upper right quadrant) and 
reduced with increasing concentrations of AA (panels: D and E, upper right quadrant) to below 
basal levels when co-incubated with 10µM AA (panel: F, upper right quadrant). This 
corresponds with the modest increase in viable cell number under the same conditions (figure 
3.12), suggesting that AA can compensate for the increase in basal apoptosis exerted by using 
media supplemented with 1% FBS in these models (figure 3.9). The final preliminary 
investigation into the protective effects of AA therefore determined the total and viable cell 
numbers in BRIN-BD11 cells treated under these conditions with 10µM AA alone, alongside 
co-incubation with 250µM palmitate (figure 3.14).  
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Figure 3.14. Total and viable cell number in BRIN-BD11 cells exposed to 250µM palmitate and 10µM AA alone and in co-
incubation assessed by trypan blue vital dye exclusion. Cells were treated with 250µM palmitate and 10µM AA individually 
or in combination for 24 hours before total and viable cell numbers were assessed by trypan blue vital dye exclusion. Values 
are represented as mean (+/- SEM), n=3. *P<0.05 relative to corresponding control. #P<0.05 relative to total cells as 
determined by two-way ANOVA and Bonferroni’s post-test. 
 
Treatment with 10µM AA alone witnessed no increase in total cell number compared 
to control conditions (P>0.05) however, there was a significant increase in viable cell number 
from 1.01 x106 cells/mL (+/-0.05) to 1.20 x106 cells/mL (+/-0.01), ~1.2-fold increase (P<0.05), 
supporting the suggestion that AA can protect cells against lower serum levels under these 
conditions. Additionally this result also confirms, as previously seen, that AA protects against 
palmitate toxicity with no significant difference between the combined treatment group and 
the control, suggesting that AA completely ameliorates palmitate toxicity, with over a 10-fold 
increase in viable cell number.   
Further to the protective effects of AA in an in vitro model of type 2 DM, protective 
effects of AA were then investigated in the type 1 DM model of cytokine toxicity in BRIN-BD11 
cells. Preliminary investigations into any dose-dependent protective effects of AA against 
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cytokine-induced beta cell death was assessed by MTT assay against the combination of IL-1β 
(100U/mL) plus IFN-γ (20U/mL), or with the inclusion of TNF-α (500U/mL) for 24 and 48 hours, 
with nitrite levels also determined using Griess assay (figure 3.15 A-D). Additionally, effects of 
AA on the combination of all three cytokines, representing the most patho-physiologically 
relevant combination, were also assessed by trypan blue vital dye exclusion assay in 
combination with 80µM AA. Due to the additional contribution of BSA from media 
supplemented with 10% FBS, for the purpose of this data all treatments were in 1% FBS-
supplemented media, in accordance with the previous model whereby AA is delivered to cells 
complexed to BSA, maintaining the molar ratio of 3.3:1.  
 
 
 
 
 
 
 
 
 
Figure 3.15 Effects of AA on cytokine-induced loss in cell viability and nitrite production assess by MTT and Griess assay. 
Cells were treated with a combination of IL-1β (100U/mL) and IFN-γ (20U/mL) with or without TNF-α (500U/mL) in co-
incubation with AA at increasing concentrations for 24 or 48 hours. Cell viability was assessed by MTT assay (panels A and C), 
with nitrite levels quantified using Griess reagent (panels B and D). Values are represented as mean (+/- SEM), n=3. *P<0.05 
relative to corresponding control. #P<0.05 relative to corresponding cytokines alone as determined by two-way ANOVA and 
Bonferroni’s post-test. 
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Figure 3.16 Effects of AA on cytokine-induced BRIN-BD11 cell death assessed by trypan blue vital dye exclusion. Cells were 
treated with cytokines in combination of IL-1β (100U/mL) and IFN-γ (20U/mL) and TNF-α (500U/mL) in co-incubation with 
80µMAA 24 (A) or 48 (B) hours. Total and viable cell numbers were assessed by trypan blue vital dye exclusion. Values are 
represented as mean (+/- SEM), n=3. *P<0.05 relative to control. #P<0.05 relative to total cells as determined by two-way 
ANOVA and Bonferroni’s post-test. 
 
As with previous data, minimal loss in cell viability was observed in treatment with 
cytokines over 24 hours, as assessed by MTT assay, with a significant decrease observed after 
48 hours. Increasing concentrations of AA in combination with IL-1β plus IFN-γ over 48 hours 
witnessed a significant increase in cell viability from 42.9% (+/8.1) with cytokines alone to 
70.2% (+/-4.7) with 40µM AA (P<0.05). No increase in protection was observed upon 
increasing concentrations of AA further, suggesting that higher concentrations of AA may be 
needed to ameliorate cytokine-induced beta cell death, as compared to the effects seen at 
10µM AA with palmitate. Though similar to the palmitate model, AA effects seem to plateau 
at 70-80% cell viability (figure 3.15), suggesting a limiting factor that prevents any further 
increase in the observed cell viability. In contrast, effects of AA on cell viability in treatment 
with combined IL-1β and IFN-γ were not mirrored by a decrease in nitrite accumulation, 
suggesting any effects are NO-independent. However, with inclusion of TNF-α, whilst 
producing comparable overall effects on loss in cell viability with combined IL-1β and IFN-γ, 
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AA failed to ameliorate the cytotoxic effects of all three cytokines, though an overall trend in 
increasing cell viability up to 70-80% was also noted (figure 3.15, panel: C), which again may 
reflect limitations of the MTT assay in this model. However, when total and viable cell numbers 
(figure 3.16) were determined by trypan blue vital dye exclusion, the combination of all three 
cytokines alone showed a significant decrease in cell populations compared to control 
(P<0.05), an effect not reversed in the presence of 80µM AA (P>0.05 compared to cytokine 
treatment alone).  
The fact that 80µM AA failed to ameliorate cytokine-induced cytotoxicity likely reflects 
distinct modes of action dependent upon the nature of the apoptotic stimuli between the type 
1 and type 2 models established. Interestingly, after 48 hours there was a significant increase 
in total and viable cell numbers with 80µM AA treatment alone compared to control (P<0.05), 
increasing from 1.69 x106 cells/mL (+/-0.06) and 0.98 x106 cells/mL (+/-0.02) to 2.46 x106 
cells/mL (+/-0.04) and 2.31 x106 cells/mL (+/-0.03) (P<0.05), respectively. Again, this likely 
reflects protection against serum withdrawal under these culture conditions and/or a pro-
proliferative effect of AA at this higher concentration. This therefore may explain the observed 
protective effect noted with IL-1β and IFN-γ in combination with 20µM AA and above, when 
assessed by MTT assay, suggesting an overall lack of effect of AA against cytokine toxicity in 
the current model.  
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3.5 Discussion 
 The aims of this chapter were to characterise the response of BRIN-BD11 cells to pro-
inflammatory cytokines and the saturated fatty acid palmitate (C16:0), establishing model 
systems reflecting cytokine toxicity associated with the development of type 1 DM and 
lipotoxicity in the pathogenesis of type 2 DM. Additionally, this chapter also established the 
cytoprotective effects of AA in these models, in agreement with previous studies in this cell 
line (Keane et al., 2011), as well as comparative differences in methods used to assess cell 
viability. BRIN-BD11 cells were selected for this study owing to their favourable growth 
characteristics, long-term stability in culture and expression of appropriate cell-type markers 
and characteristics of beta cell function (McClenaghan et al., 1996).    
 Cell viability obtained following treatment of BRIN-BD11 cells with IL-1β (100U/mL), 
IFN-γ (20U/mL) and TNF-α (500U/mL) alone resulted in no significant decrease in cell viability 
when assessed by MTT and neutral red assay, or by trypan blue vital dye exclusion for total 
and viable cells, suggesting singular cytokine treatment has minimal effect on cell viability 
under these conditions. Whilst parental RINm5F cells have been shown to respond to singular 
treatment with IL-1β or IFN-γ (Ankarcrona et al., 1994; Holohan et al., 2008), the 
concentrations used were considerably higher than those in the current study, with effects of 
IL-1β apparent only at concentrations of 180-540U/mL (Holohan et al., 2008), and others have 
reported minimal effects of these cytokine treatments alone in BRIN-BD11 cells (Hsu et al., 
2012). In agreement with others, treatment of BRIN-BD11 cells with cytokines in combination 
markedly enhanced the cytotoxic response, with loss in cell viability witnessed over 24-48 
hours incubation across all assay formats used, supporting cytokine synergy (Rabinovitch and 
Suarez-Pinzon, 1998; Chen et al., 2000; Eizirik and Mandrup-Poulsen, 2001; Hsu et al., 2012).  
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Cytokine synergism was most evident in treatment combinations with either IL-1β or 
TNF-α plus IFN-γ, or the combination of all three cytokines, with the combination of IL-1β plus 
TNF-α producing a markedly reduced effect on loss in cell viability in both the MTT and neutral 
red assays. Minimal synergism with this cytokine combination compared to when either 
cytokine was combined with IFN-γ is likely due to TNF-α receptor binding activating similar 
pathways to IL-1β; particularly downstream activation of NF-κB. Saldeen et al., (2001) showed 
that in rat insulinoma cells TNF-α signalling preferentially leads to phosphorylation and 
activation of JNK and p38 MAPK, similar to IL-1β signalling, whereas in contrast, IFN-γ receptor 
binding leads to the activation of STAT-1. Concomitant activation of STAT-1 and NF-κB then 
coordinate changes in gene expression associated with orchestrated beta cell death in part 
mediated via an enhanced cellular stress response, associated with increased oxidative and 
nitrosative stress (Cnop et al., 2005). Maximum iNOS expression and nitrite production are 
achieved under these conditions, as shown by the highest nitrite levels recorded with 
combined cytokine treatments, with the exception of IL-1β plus TNF-α, in the current model. 
Additionally a reduction in beta cell defence capacity is also thought to contribute to cytokine 
toxicity, with IFN-γ shown to synergise with IL-1β in the induction of ER stress via 
downregulation of the ER chaperone BiP (Pirot et al., 2006). Synergistic action of TNF-α plus 
IFN-γ in the absence of IL-1β, as observed in the current study, have also been reported by 
others (Chang et al., 2004), effects suggested to be mediated by activation of IRF-1 
downstream of IFN-γ/STAT-1 sensitising MIN6 and islet beta cells to TNF-α (Suk  et al., 2001).  
In the current model, nitrite levels and increased iNOS expression correlated with the 
degree of cytokine-induced loss in cell viability, with highest nitrite levels observed when 
cytokines were used in combination. Although cytokine-induced iNOS expression and 
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production of the NO radical are considered a classical feature of cytokine action in pancreatic 
beta cells, with exogenous NO donors (in part) mimicking cytokine toxicity (Eizirik et al., 1996; 
Oyadomari et al., 2001; Cardozo et al., 2005), inhibition of iNOS only partially protects against 
cytokine-induced beta cell death in vitro and may only delay onset of DM in in vivo models 
(Lindsay et al., 1995). Establishing the NO-dependency of cytokine toxicity was not a focus of 
the data presented here however, Hsu et al., (2012) have shown that the iNOS inhibitor L-
NAME failed to attenuate cytokine toxicity in BRIN-BD11, in agreement with unpublished data 
in our group (Cunningham and Watson, unpublished observations) and others on the lack of 
a protective effect of iNOS inhibition against cytokine-induced loss in insulin secretion in these 
cells (Michalska et al., 2010).  
The current data also highlights important differences in sensitivity between assays 
used to measure the cytotoxic response of the cells, as observed in the comparison between 
the MTT and neutral red assay. The use of the MTT assay solely to determine cell viability, like 
other assays, is limited by its mode of action; MTT data direct correlate with cell viability by 
assessing the cells’ ability to reduce the tetrazolium salt into a blue formazan product 
(Mossman, 1983) and although non-mitochondrial MTT reduction has also been reported 
(Bernas and Dobrucki, 2002), the assay is largely considered a measure of cellular metabolic 
activity. In contrast, the neutral red assay measures cellular ability to incorporate the cationic 
neutral red dye into the lysosomal matrix in viable cells with retained membrane integrity, 
which is considered proportional to cell viability (Griffon et al., 1995), therefore it was 
considered as an appropriate comparator to the MTT assay in the current study.  
Previous studies observed an increase in the sensitivity of neutral red over the MTT 
assay (Fotakis and Timbrell, 2006) which was also evident in the current study when 
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comparing the extent of loss in cell viability in BRIN-BD11 cells in response to combined 
cytokine treatments, with a significant reduction in cell viability over 24 hours observed in the 
neutral red assay in contrast to the MTT assay, where effects were not noted until after 48 
hours. This apparent higher sensitivity of the neutral red assay was also confirmed by trypan 
blue vital dye exclusion assay, again demonstrating a significant reduction in cell viability with 
cytokine combinations over 24 hours. Given that these assays both reflect cell membrane 
integrity, this agreement is not surprising but considering that cytokine toxicity is largely 
considered to occur by apoptosis, an ATP-dependent process, retained mitochondrial 
respiratory capacity (as evidenced by the MTT assay) suggests loss in membrane integrity as 
an early event in cell death in this model. However, given the closer agreement between the 
MTT and neutral red assays when cells were treated with palmitate (which was also associated 
with increased apoptosis markers), this may suggest differences in assay sensitivity are 
dependent on the nature of the apoptotic stimuli applied. Additionally, this may be reflective 
of differential sensitivity between cell types, since Kiely et al., (2007) also reported no loss in 
cell viability in BRIN-BD11 cells exposed to cytokines in combination, when assessed using the 
MTT assay with concentrations broadly consistent with those in the current study, concluding 
that mitochondrial capacity is relatively resistant to cytokine-induced effects in these cells 
(though apoptosis levels were increased).  
Data from treatment of BRIN-BD11 cells with the saturated fatty acid palmitate 
produced a typical dose-dependent decrease in cell viability when assessed by MTT, neutral 
red, trypan blue vital dye exclusion and total apoptosis. Results obtained are broadly 
consistent with other observations in BRIN-BD11 cells (Welters et al., 2004; Dhayal and 
Morgan 2008), as well the INS-1 and RINm5F rat beta cell lines (Cuhna et al., 2008; Elsner et 
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al., 2011), with a concentration of 250µM palmitate reducing cell viability to ≤ 50%. 
Mechanistically, palmitate toxicity is associated with induction of an ER stress response 
following lipid overload and increased oxidative stress (Laybutt et al., 2007; Cuhna et al., 2008; 
Diakogiannaki et al., 2008; Elsner et al., 2011). Although a contribution of palmitate-induced 
NO production and nitrosative stress remains unclear, in the current study the Griess assay 
failed to detect any increase in nitrite levels in BRIN-BD11 cells at all palmitate concentrations 
used (data not shown); discrepancy between other studies in this regard may be related to 
methods in which palmitate treatment was carried out (Welters et al., 2004; Keane et al., 
2011).  
Owing to inherent difficulties in the aqueous solubility of long-chain fatty acids when 
applied to these in vitro studies, palmitate was first complexed to BSA at a molar ratio of 3.3:1, 
which also mimics in vivo transport of fatty acids where, under physiological conditions an 
average of two fatty acid modules are bound to BSA (Oliveria et al., 2015). Under 
pathophysiological conditions this ratio can exceed 5:1 (with six fatty acid binding sites located 
in BSA), however culture models approaching these higher ratios should be avoided to 
minimise detergent-like effects on cell membranes from higher unbound fatty acid levels. 
Whilst it was not feasible to determine the total unbound fatty acid concentrations in the 
current model, Oliveria et al., (2015) showed that treatment of INS-1 cells with a 
palmitate:BSA complex (3.3:1) at a final palmitate concentration of 500µM resulted in 
unbound palmitate concentrations of 27nM. However, Cistola and Small (1991) suggested 
unbound FFAs could be greater than 400nM under similar conditions, though others report 
that at a 6:1 molar ratio, the estimated unbound FFA is in the region of 300nM (Chu et al., 
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2010); levels which induced apoptosis when applied to MIN6 cells, not resulting from non-
specific detergent effects as previously described (Jeffrey et al., 2008; Gwiazda et al., 2009).  
  A further consideration in these models is the contribution of BSA present in FBS in 
supplemented cell culture media, in the region of 0.25% (Oliveria et al., 2015; Alsabeeh et al., 
2018), therefore direct application of palmitate:BSA complexes to cells under these conditions 
would alter the molar ratio, increasing variability between data sets. Whilst some studies 
therefore conduct palmitate treatments under serum-free conditions, this was poorly 
tolerated in the current model and so media was supplemented with 1% FBS; a level providing  
a low endogenous BSA content, whilst supporting cell health under control conditions (El-
Assaad et al., 2003 Alsabeeh et al., 2018). The effect of low serum conditions was explored in 
the current data, showing a modest increase in the basal apoptosis rate of control cultures; 
though this may reflect the higher sensitivity of the flow cytometry method used for apoptosis 
assessment, as trypan blue vital dye exclusion and MTT assays suggested no significant 
difference in total or viable cells under these conditions (data not shown). Additionally, the 
apoptosis profiles also confirmed that palmitate-induced loss in cell viability in BRIN-BD11 
cells is associated with a significant increase in the percentage of cells scored as apoptotic.  
The focus of this thesis is on the cytoprotective effects of AA-derived eicosanoids 
(EETs; subsequent chapters) and therefore the protective effect of AA against palmitate and 
cytokine toxicity was first established. BRIN-BD11 cells treated with 250µM palmitate co-
incubated with AA, ameliorated palmitate toxicity with all treatments from 62.5-1000μM in 
preliminary MTT dose responses and trypan blue vital dye exclusion assays, confirming 
previous studies by Keane et al., (2011) who showed co-treatment with 10μM AA reduced cell 
death from 70% (250μM palmitate alone) to ~15% after 24 hours in BRIN-BD11 cells. These 
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effects are also consistent with the cytoprotective actions of AA in other beta cell models 
including INS-1, MIN6 and HIT-T15 cell lines, as well as mouse islets (Papadimitriou et al., 2007; 
Dhayal and Morgan, 2008; Cho et al., 2012). Effects of AA were also established in the current 
model at a higher (500µM) palmitate dose which, as with 250µM palmitate, demonstrated a 
dose-dependent effect of AA, with concentrations greater that 5μM significantly protecting 
BRIN-BD11 cells against palmitate toxicity This data also indicated that a 2-fold increase in 
palmitate concentrations required a similar 2-fold increase in the concentration of AA 
required to achieve a comparable increase in cell viability. 
Further confirmatory assays with trypan blue vital dye exclusion showed that at a 
concentration of 5μM AA there was no significant difference compared to control for total 
and viable cell numbers, which was not evident from the MTT assays where, regardless of AA 
concentration, co-incubation with palmitate did not result in viability exceeding 70-80%. This 
again may reflect variability between methods of assessing cell viability, in this case possibly 
attributed to changes in mitochondrial activity as a result of altered intracellular lipid handling. 
Therefore, this emphasises the importance of additional assays to more clearly establish the 
extent of cytoprotection, as witnessed by the reduction in palmitate-induced apoptosis levels 
below control in the current data. This also additionally supports that AA may protect against 
the effects of serum withdrawal (though necessary under these treatment conditions), and is 
in agreement with similar data reporting this effect of mono-unsaturated species in BRIN-
BD11 cells (Welters et al., 2004). Similarly, the observation that 80µM AA treatment alone 
markedly increased total and viable cell numbers over control also highlights this protective 
effect and is agreement with others that 100µM (but not 50µM) may increase proliferation in 
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BRIN-BD11 cells (Keane et al., 2011); though this study assessed these effects using a WST-1 
assay (comparable to the MTT assay) rather than absolute cell number.  
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3.6 Conclusion 
 The data collected in this chapter reports preliminary investigations into the cytotoxic 
effects of cytokines and palmitate in in vitro models of type 1 and 2 DM, establishing these 
model systems in BRIN-BD11 cells for further investigations. Reflecting the most 
pathophysiologically relevant cytokine profile, treatment of BRIN-BD11 cells with IL-1β 
(100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) in combination for 24 and 48 hours was 
selected for use in subsequent chapters. Alongside this, the data confirms appropriate 
cytotoxicity profiles, assessed using several methods and showing that loss in cell viability 
coincides with cytokine-induced nitrite accumulation and iNOS expression, as a marker for 
cytokine action. Lipotoxicity profiles confirmed previous studies in this cell line, with 
concentrations of 250-500µM producing appropriate responses for use in further studies. 
Prior to commencing studies into the cytoprotective action of AA-derived EETs in these 
models, this chapter also corroborates earlier work demonstrating that this polyunsaturated 
fatty acid can attenuate palmitate toxicity.  
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Chapter Four  
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4 Cytoprotective effects of epoxyeicosatrienoic 
acids and their derivatives in in vitro models of type 
2 DM 
 
4.1 Introduction 
 Prolonged exposure to elevated fatty acids are well-known to cause a reduction in beta 
cell mass, associated with inhibition of GSIS. In rat islets, incubation with 1mM palmitate 
resulted in hallmark events of apoptosis; increase in expression of apoptotic genes, ceramide 
formation, increase in caspase activity and DNA fragmentation (Shimabukuro et al., 1998), 
with pro-apoptotic action well-established in a number of beta cell line models (Karaskov et 
al., 2006; Lai et al., 2008; Dhayal and Morgan, 2011). Hyperglycaemia may also promote the 
cytotoxic effects of palmitate, consequential to dyslipidaemia, in a process of glucolipotoxicity 
(El-Assaad et al., 2003; Maedler et al., 2003; Maris et al., 2012; Sargsyan and Bergsten, 2011). 
In contrast, (poly)-unsaturated species are well-tolerated and attenuate the cytotoxicity of 
saturated FFAs, therefore understanding the mechanisms of these differential responses in 
models of type 2 DM continues to be a major aim of diabetes research and in this thesis, gives 
rise to investigations into the actions of the hitherto largely unexplored EETs and DHETs in this 
context. 
 Polyunsaturated fatty acids in models of type 2 DM have been extensively studied, 
with species such as AA showing protective characteristics in many in vitro beta cell lines 
(Papadimitriou et al., 2007; Dhayal and Morgan, 2011; Keane et al., 2011). Metabolism of AA 
can occur by three major routes: the cyclooxygenase (COX), lipoxygenase (LOX) pathways, 
which have been extensively studied, and to a lesser extent, CYP450 enzymes. The latter route 
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results in the production of epoxyeicosatrienoic acids (EETs) comprising of four main isomers: 
5(6)-EET, 8(9)-EET, 11(12)-EET and 14(15)-EET, with two enantiomers of each (R,S), which have 
been shown to exert protective actions in several models, including in maintaining vascular 
tone and the attenuation of inflammation. The conversion of EETs to their less active vicinal 
diols (DHETs) represents the major route of EET metabolism however, due to earlier reports 
on their lack of activity, a view which has been challenged by some (Lu et al., 2001; Suzuki et 
al., 2008), investigations into their actions in several models is lacking. In particular, little 
attention has focused on the role(s) of CYP450-derived EETs/DHETs in DM models, in contrast 
to the more well-studied contributions of COX and LOX metabolites (Xu et al., 2016).  
 Studies in the 1970s into the regulation of GSIS by AA were conducted with a primary 
focus on one of the three major routes of AA metabolism: the COX pathway (Robertson, 2017). 
AA is esterified at the sn-2 position of the glycerol backbone of membrane phospholipids and 
is released via hydrolysis by the action of PLA2 (Imig, 2000), which is known to be expressed in 
human and rodent islets, as well as beta cell lines (Loweth et al., 1995). The released AA can 
be metabolised by COX-1 and -2 to produce prostaglandins (PGs) and thromboxane (TX) (Hao 
and Breyer, 2007), with COX-2 predominately expressed in islets (Sorli et al., 1998). 
Prostaglandins have several biological roles including in inflammation and the regulation of 
insulin release from pancreatic beta cells. The production of a number of COX metabolites, 
including PGD2, PGE2, PGF2α, PGI2 and TXA2 act as signalling molecules and exert their action 
on cells though GPCRs, with 50-60% of current drug targets used in treatment of type 2 DM 
known to be associated with GPCR signalling (Lundstrom, 2009). Radiolabelled AA has been 
reported to predominately produce PGD2, PGE2, PGF2α, PGI2 in rat islets (Carboneau  et al., 
2017) and some have suggested that PGE2 may protect against STZ-induced DM in mice 
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(Vennemann et al., 2012) and PGI2 has been shown to enhance GSIS in rat islets (Gurgul-
Convey et al., 2012).  In contrast, in BRIN-BD11 cells, AA metabolism by COX-2 has been 
suggested to directly impair insulin secretion following co-incubation with a COX-2 inhibitor 
and exogenously administered AA. Although this data suggests a negative impact of COX-2 
metabolites on insulin release in beta cells, studies in human islets have shown conflicting 
results (Persaud et al., 2007) and others have similarly reported that PGE2 inhibits GSIS in 
rodent islets and beta cell lines, compared to human islets (Heitmeier et al., 2004). These 
observations were similarly confirmed by Sandberg and Jansson (2014), showing that 2 hour 
incubation with several COX-2 inhibitors produced no deleterious effects on insulin secretion 
in islets however, 2 day incubation in the presence of indomethacin did result in a slight 
increase in GSIS and in basal insulin secretion in co-incubation with the COX-1 inhibitors, SC 
560 and FR122047. Differences between these in vivo, ex vivo and in vitro models may arise 
due to differences in expression levels of PLA2 (Loweth et al., 1995) or COX isoforms and/or 
sensitivity in terms of downstream PG signalling.  
Further to the metabolism of AA by the COX pathway, AA can also be metabolised by 
LOX to produce hydroxyeicosatetranoic acids (HETEs) and leukotrienes (LTs), with 12-LOX 
shown to be specifically expressed in pancreatic cells and Zucker fatty rat islets, predominately 
producing 12-HETE (Haeggström et al., 2011).  12-LOX expression and the contribution of 
subsequent lipid-derived signalling species have been reported in several models including 
neurodegenerative disease, stroke, cardiovascular disease and insulin resistance (Hernadez-
Perez  et al., 2017). Implications of the contribution of 12-LOX have been studied in context of 
whole body metabolism and the impact in respect to high-fat-diets and obesity in knockout 
mice, with evidence that 12-LOX knockout reduced insulin resistance, enhanced beta cell 
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function and improved glucose tolerance (Sears et al., 2009). The production of 12-HETE has 
been proposed to regulate mitochondrial dysfunction and an increase in oxidative stress, 
including in models of cytokine-induced beta cell death, with inhibition of 12-LOX protecting 
against beta cell apoptosis (Bleich et al., 1997). 
With much attention focused on AA metabolism by the COX pathway in DM models 
and, to a lesser extent, the LOX pathway, evidence for the contribution of CYP450 metabolites 
remains lacking, especially in beta cell lines in cytotoxicity studies relevant to type 1 and 2 DM. 
Cytochrome P450s are classified according to their sequence homology and ability to 
metabolise a variety of endogenous ligands, including AA; primarily 2C and 2J isoforms are 
expressed in humans and are known AA-directed epoxygenases, producing EETs, with pro-
inflammatory cytokines reported to decrease 2C activity in human hepatocytes (Abdel-
Razzack et al., 1999). The second class of AA-directed CYPs hydroxylate substrates at or near 
the ω-terminus, with prominent isoforms 4A and 4F expressed in humans and are known as 
CYP ω-oxidases producing 20-hydroxyeicosatetreaneoic acid (20-HETE) (Capdevila and Falck, 
2001). CYP isoforms 2C and 2J metabolise AA in the presence of oxygen and NADPH to yield 
four EET isomers and high levels of CYP 2J have been reported in both human and rat islets 
(Zeldin et al., 1997), as well as high levels of 2C11 (the rat homolog of human CYP2C8) also 
found in rat islets (Chen et al., 2013). Comparison between expression levels of the two major 
AA-directed CYP epoxygenases in rat tissues observed high levels of 2C11 in islets compared 
to kidney, in contrast to 2J where higher levels of this isoform and the EET-metabolising sEH 
were observed in the kidney as determined by Western blotting (Chen et al., 2013). This 
observation is important and suggests that EET production in islets in vivo may exert important 
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biological activity and that manipulation of EET production/metabolism could be an attractive 
strategy in controlling beta cell (dys)function.   
 The production of EETs has been shown to induce potent anti-inflammatory effects 
and repress ER stress in in vivo models of heart failure (Wang et al., 2014), as well as important 
roles in regulating vasodilation, functioning as endothelial-derived hyperpolarizing factors, 
inhibiting sodium transport in nephrons and the inhibition of vasodilation in renal arterioles 
(Zhao and Imig, 2003). EETs are further metabolised by several pathways including β-
oxidation, entry into phospholipids by acyl transferases, binding to intracellular fatty acid-
binding proteins (FABP), conversion into less active diols (DHETs) by sEH, proposed to be the 
main metabolic fate, glutathione conjugation of EETs by glutathione S-transferases, 
subsequent oxidation by prostaglandin endoperoxide H synthase (PGHS) and chain elongation 
(Zeldin, 2001). Since sEH-directed metabolism to DHET represents the major route of EET 
metabolism, producing products with reduced activity and that can be rapidly conjugated and 
excreted (Deng et al., 2010), the use of sEH inhibitors in cardiovascular models have been well 
studied, showing protective actions of sEH inhibition in decreasing EET hydration making them 
attractive for the development of novel therapeutics in cardiovascular disease (Imig, 2006). 
Of relevance to DM models, sEH knockout or inhibition augmented GSIS in mouse islets and 
reduced STZ-induced apoptosis (Luo et al., 2010), with similar observations reported by others 
(Chen et al., 2013), though direct activity of EETs in these models is yet to be properly 
established (Xu et al., 2016).  
Of the EETs produced, 14(15)-EET has been reported to represent the major product 
of CYP450 action, comprising 44% of the total EETs detected in samples from human kidney 
cortex, followed by 11(12)-EET at 33% and 8(9)-EET at 23%, with the group reporting difficulty 
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in obtaining levels of 5(6)-EET owing to its reactivity due to the proximity of the epoxide to the 
carboxylic acid group, facilitating rapid hydration to DHET (Karara et al., 1990). Esterification 
of EETs at the sn-2 position into membrane phospholipids, with 90% of EETs sequestered in 
this way, likely represents an important mechanisms of controlling available free-EETs 
mediating biological activity, with concentrations in the region of 1nM available (Karara et al., 
1991; Bernstrom et al., 1992). Of note, this has also been suggested as mechanism of 
regulating EET levels with effects on the control of insulin secretion and whilst some have 
suggested that free-EETs negatively regulate GSIS (Klett et al., 2013), others have reported 
stimulatory actions (Flack et al., 1993) though further direct evidence is limited.  
Mechanisms of EET action are still not fully defined, though as FFA derivatives, much 
of their biological activity is associated with binding interactions and/or metabolic processes 
that are known to be involved in lipid homeostasis/signalling, including processes relevant to 
lipotoxicity in beta cells, though evidence for EET action in this context is lacking. FFAR1 or 
GPR40 has been identified as a medium- and long-chain fatty acid receptor and more recently 
EETs have been shown in GPR40-over-expressing HEK293 cells to bind GPR40, significantly 
enhancing proliferation associated with increased EGFR expression and phosphorylation of 
ERK (Ma et al., 2015), though this is inconsistent with a more recent study which failed to 
identify potent EET binding at a single high-affinity GPCR target (Lui et al., 2017). Nonetheless, 
GPR40 could represent an important site for EET action in beta cells, with known activities of 
this receptor in mediating beta cell responses to FFAs. Previous studies using NIT-1 beta cells 
have shown that GPR40 siRNA transfected cells observed an increase in apoptosis compared 
to mock transfections when treated with 500µM oleate co-incubated with 500µM palmitate 
(Zhang  et al., 2007). As with previous studies, ERK 1/2 phosphorylation was associated with 
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oleate treatment and GPR40 knockdown showed reduced levels of ERK 1/2 phosphorylation, 
furthermore, oleate activation of the ERK-MAPK pathway was associated with GPR40 
activation and termed GPR40-dependent, although treatment with palmitate alone was 
GPR40-independent, the protective actions of oleate were markedly diminished following 
GPR40 knockdown (Zhang  et al., 2007; Alquier  et al., 2009). In support of this, studies in mice 
models  have shown that oleate acts through GPR40-dependent mechanisms in the activation 
of protein kinase D (PKD), with rottlerin, a PKD inhibitor, completely blocking GSIS, which was 
further confirmed using islets from Prkd1flox/flox  mice bearing PKD1 allele flanked by Lox-P 
sites, with Ad-Cre used to delete segments of DNA flanked by LoxP sites, showing a 75% 
reduction in PKD1 expression at the protein level and reducing potentiation of oleate on GSIS 
(Ferdaoussi  et al., 2012). 
 Further to potential activation of GPR40 by EETs, FFAR4 (GPR120) has also been shown 
to have a high affinity for long-chain saturated fatty acids (14-18 carbons) and unsaturated 
fatty acids (16-22 carbons), as well as potentially binding EETs (Park et al., 2018). GPR120 
signals through Gαq/11, activating phospholipase C (PLC), increasing IP3, which is associated 
with an increase in intracellular calcium levels, increasing DAG and subsequent activation of 
PKC (Wellendorph et al., 2009; Vangaveti  et al., 2010). GPR120 expression has been identified 
in monocytes and adipocytes, though is mainly expressed in the gastrointestinal tract, where 
it may serve to potentiate the incretin effect (Hirasawa et al., 2005) and in pancreatic beta 
cells, GPR120 expression has been identified at the mRNA level in INS-1 and BRIN-BD11 cells 
and human islets (unpublished studies by Dhayal and Morgan; Dhayal and Morgan, 2009). In 
STC-1 intestinal cells, several long-chain fatty acids have been reported to increase cell viability 
and reduce caspase 3-activity, with linoleic acid shown to preferentially bind GPR120 over 
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GPR40, whereby knockdown of GPR120 showed a decrease in inhibition of caspase-3 activity, 
which was also associated with changes in ERK, c-Jun, JNK, p38 MAPK and Akt activation 
(Katsuma et al., 2005).  
Whilst extracellular (GPCR) binding by EETs may mediate some of their biological roles, 
a single high-affinity receptor site is yet to be identified (Lui et al., 2017), including establishing 
whether or not this could be mediated via activation of GPCRs with known 
expression/biological activity in beta cells, one of the well-established roles of EETs is their 
activity as endogenous ligands to PPARγ, protecting against LPS-induced cytotoxicity in 
cardiomyocytes (Spector et al., 2004; Liu et al., 2005; Samokhalov  et al., 2014). Furthermore, 
treatment with 10µM 14(15)-EEZE, a reported EET antagonist, blocked the protective effects 
of 14(15)-EET, which was accompanied by a decrease in PPARγ binding (Samokhalov et al., 
2014). In human umbilical vein ECs (HUVEC) transfected with a GAL-mPPARγ-LBD construct, 
measurement of PPARγ activity, assessed by luciferase activity, showed all four EETs, in the 
presence of the sEH inhibitor AUDA, increased relative luciferase activity, though to a lower 
level than with the synthetic PPARγ ligand rosiglitazone (Liu  et al., 2005). Moreover, DHETs 
failed to increase luciferase activity and in co-incubation with rosiglitazone resulted in a 50% 
decrease in luciferase activity compared to rosiglitazone treatment alone, confirming lack of 
activity of DHETs and suggesting possible competitive antagonistic activity at PPARγ (Liu et al., 
2005).  
EETs have also been reported to bind PPARα and in COS-7 cells luciferase activity 
following transfection with a PPARα reporter construct showed that at 10µM each EET 
significantly increased PPARα activation compared to control (Fang et al., 2006). In support of 
this, similar findings were observed in HEK293 cells with 8(9)-EET and 11(12)-EET up to 1µM, 
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showing significant increases in PPARα activation (Wray et al., 2009). Interestingly, Fang et al., 
(2006) also showed that 14(15)-DHET produced a significant increase in PPARα-luciferase 
activity compared to 14(15)-EET, comparable to the PPARα activator Wy-14643, suggesting 
differential activity of distinct EET/DHET species at different targets. Of note, in HepG2 cells 
these effects were associated with an increase in mRNA levels of CPT1A (Fang et al., 2006) 
which, in the context of regulating lipid homeostasis, may increase FFA oxidation, with CPT1 
over-expression shown to protect against palmitate toxicity in beta cell models (Sol et al., 
2008). Further to activating PPARα and γ, EETs have been reported to activate PPARβ/δ, 
however, less attention has focused on this as a target for EETs. PPARβ/δ has been shown to 
be highly expressed in ES cell-derived INS+ cells (Li  et al., 2015) and has also been detected in 
mouse islets in both alpha and beta cells, as well as human islets, with its activation shown to 
increase fatty acid oxidation in INS-1 cells (Lglesias et al., 2012; Ravnskjaer et al., 2009). 
PPARβ/δ activation was also reported in INS-1 cells by using a luciferase PPRE reporter 
construct, and treatment with unsaturated fatty acids showed similar activation to the use of 
PPARβ/δ agonists. Furthermore, PPARβ/δ activation synergised with RXR in the increased 
expression of a fatty acid translocase (CD36) and CPT1, promoting fatty acid oxidation capacity 
and potentiating GSIS (Ravnskjaer et al., 2009).  
As with other FFAs, EETs are activated for further metabolic processing by 
esterification to CoA, necessary for their incorporation into the phospholipid pool, with acyl-
CoA-synthetase-4 shown (ACS4) to be important in controlling the ratio of esterified/free-EETs 
(Klett et al., 2013), additionally the synthesis of 2-EG, with endocannabinoid-like activity, may 
also support that EETs can be incorporated into glycerol-lipids (Chen et al., 2008). With TAG 
and sterol esters making up the main lipids found in lipid droplets, and knockout of DGAT (the 
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enzyme responsible for the terminal, rate limiting step in TAG synthesis) in mice resulting in 
reduced TAG formation, several fatty acids have been studied for their contribution to TAG 
accumulation (Chen et al., 2002). Treatment with palmitate in rat hepatoma cells resulted in 
a significant increase in cell death, which was rescued by co-incubation with oleate, 
furthermore knockdown of DGAT1 and 2 reduced palmitate incorporation into TAG, alone or 
in combination with oleate, and decreased intracellular lipid accumulation (Leamy et al., 
2016), as supported by similar studies in CHO cells (Listernberger et al., 2003). Similarly, in 
several beta cell models, TAG formation is reportedly enhanced in co-incubation with 
palmitate and with unsaturated species, with one study reporting that DGAT inhibition 
reduced the protective effect of AA against palmitate in HIT-T15 cells (Cho et al., 2012); though 
whether or not this represents an important cytoprotective mechanism, sequestering FAs into 
neutral lipids, has been questioned (Plotz et al., 2006; Cnop et al., 2001; Diakogiannaki et al., 
2007; Borg et al., 2009). It is, though, tempting to speculate that EETs may play a role in the 
formation of TAG in beta cells, since these species are substrates for esterification to CoA. 
However, in HepG2 cells over-expression of CYP 2J2 or exogenous treatment with 14(15)-EET 
has been shown to reduce TAG accumulation and instead, lipid homeostasis appears to be 
achieved via a PPARα- and AMPK- dependent increase in FFA β-oxidation (Zhang et al., 2015). 
Enhancement of β-oxidation of FFAs in response to EETs may also infer potential mechanistic 
action of these species against palmitate-induced lipotoxicity in beta cells. Over-expression of 
CPT1 has been shown to protect against palmitate toxicity in INS-1 cells (Sol et al., 2008), with 
the CPT1 inhibitor Etomoxir augmenting palmitate toxicity in other studies (Choi et al., 2011; 
Sargsyan and Bergsten, 2011; Baldwin et al., 2012). In contrast, at low concentrations 2-
Bromopalmitate, a poorly metabolisable palmitate analogue known to inhibit CPT1, protected 
RINm5F cells against palmitate toxicity, however this was suggested to occur by mechanisms 
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independent to β-oxidation (Baldwin et al., 2012), although higher concentrations (>250µM) 
of this species alone are also toxic to beta cells (Cnop et al., 2001). In addition to stimulating 
FFA β-oxidation (Zhang et al., 2015), EETs are also substrates for oxidation, with several 
shortened-chain EET (and DHET) derivatives reported to possess potent biological activity 
(Fang et al., 1996; Fang et al., 2001; Fang et al., 2004).  
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4.2 Aims 
 Growing evidence supports an important biological role for EETs as AA-derived 
eicosanoids produced by CYP450 epoxygenases. Whilst much attention has focused on their 
activity in a variety of model systems, comparatively little is known about their roles in beta 
cell models of cytotoxicity. Evidence supports biological modes of action in context to 
mediating changes in lipid homeostasis, which may be attractive for the amelioration of 
lipotoxicity in type 2 DM, including PPAR-dependent activity and alterations in cellular FFA 
metabolism. Indeed, CYP 2J2 over-expression has been observed to restore glucose tolerance 
and improve hepatic insulin resistance in db/db mice (Li et al., 2015) and EETs have been 
suggested to protect liver cells against high fat diet-induced ER stress (Battaieb et al., 2013), 
yet no studies have directly assessed a role of EETs in beta cell models of palmitate toxicity. 
Therefore, the aim of this chapter is to establish the cytoprotective actions of the 
epoxyeicosatrienoic acids: 8(9)-EET, 11(12)-EET and 14(15)-EET and their corresponding 
DHETs in BRIN-BD11 cells exposed to palmitate, as well as potential mechanisms of EET action 
in this context. Specifically, the aims are to: 
 characterise the cytoprotective actions of EETs and DHETs in response to palmitate-
induced loss in cell viability and apoptosis induction in BRIN-BD11 cells. 
 investigate whether EETs mediate these effects through activation of known 
extracellular and intracellular fatty acid receptors using appropriate receptor 
antagonists. 
 investigate whether EETs alter FFA utilisation in BRIN-BD11 cells by comparing gene 
expression of relevant FFA-metabolising enzymes by RT-PCR and using 
pharmacological inhibitors. 
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 further explore potential mechanisms of EET action utilising the poorly metabolisable 
palmitate and EET analogues; 2-Bromohexadecanoic acid and 14(15)-EET-SI, 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
146 
 
4.3 Methods 
Cell viability was determined using MTT and trypan blue vital dye exclusion assays and 
apoptosis induction quantified by flow cytometry using MUSE® MutliCaspase assay. Although 
previous data for apoptosis quantification (Chapter 3) used an Annexin V & Dead Cell assay, 
the MUSE™ MultiCaspase assay was used for further studies, owing to better discrimination 
between live and early apoptotic cell populations. Similarly, given the comparable results 
obtained between the MTT and neutral uptake assays in response to palmitate treatment 
(Chapter 3) and the difficulties encountered in carrying out the final steps of the assay, this 
method was not considered further here. For all EET studies, BRIN-BD11 cells were treated 
with a fixed concentration of a 250µM palmitate:BSA complex, as established (Chapter 3), with 
EETs and their derivatives (DHETs and 14(15)-EET-SI) firstly prepared in BSA to a molar ratio 
of 3.3:1 and used at the concentrations indicated in relevant figure legends in media 
supplemented with 1% FBS. Of the four EETs produced by CYP450 epoxidation of AA: 8(9)-, 
11(12)-, and 14(15)-EET were used in this study since, during preparation of 5(6)-EET in BSA it 
was noted that, unlike the other EET isomers, 5(6)-EET failed to complex effectively, resulting 
in precipitation. Initial trials treating cells with 5(6)-EET in combination with 250µM palmitate 
failed to produce reliable results and examination of the cells under a light microscope 
revealed crystal-like structures, suggesting poor solubility and/or high reactivity facilitating 
rapid modification to and aggregation of the FFA, as reported by others. Due to these 
difficulties, no further investigations into the actions of 5(6)-EET were carried out. A range of 
pharmacological antagonists/inhibitors were also used in this study in co-treatment of cells 
with palmitate and EETs, using the concentrations indicated in table 2.1 (Chapter 2), having 
determined appropriate concentrations found to be non-toxic under control conditions, or  
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with minimal potentiate of palmitate toxicity, by MTT assay screening  (data not shown). 
During these studies, co-treatment with palmitate/EETs was preceded by a 1 hour pre-
incubation in the presence of the antagonists/inhibitors at the indicated concentrations.  RT-
PCR analysis for quantification of changes in gene expression was performed and analysed as 
described (Chapter 2.9).  
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4.4 Results 
This chapter reports novel observations on the treatment of BRIN-BD11 cells with EETs 
and their actions against palmitate-induced cytotoxicity. Initially, dose-dependent protective 
effects of 8(9)-EET, 11(12)-EET and 14(15)-EETs and their corresponding DHETs were 
determined using the MTT assay against a fixed concentration of 250µM palmitate (figure 4.1).  
  
 
 
 
 
 
 
 
 
Consistent with preliminary observations (Chapter 3), 250µM palmitate decreased cell 
viability to ~50% of control, an effect attenuated in co-incubation with increasing 
concentrations of each EET. With 8(9)-EET at 2.5µM, cell viability was increased to 88.6% (+/-
Figure 4.1. Protective effects of EETs but not DHETS against palmitate-induced BRIN-BD11 cell death. Cells were treated 
with a fixed concentration of 250µM palmitate co-incubated with increasing concentrations (0.625µM–10µM) of each EET or 
DHET, as indicated for 24 hours before cell viability was assessed using the MTT assay. Values are represented as mean (+/- 
SEM), n=3. #P<0.05 relative to palmitate treatment alone as determined by one-way ANOVA and Tukey’s post-test. 
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2.8), indicating near complete-protection against palmitate toxicity (P<0.05), to a level 
comparable to that previously seen with AA. There is an apparent decline in cell viability at 
concentrations from 2.5-10µM 8(9)-EET, decreasing to 68.5% (+/-1.3); an effect not observed 
with the other EETs used. However, as previously observed this may be an artefact of using 
the MTT assay in these models since visual inspection under light microscopy of the culture 
plates following treatment revealed an intact, healthy cellular morphology, comparable to 
control cultures (this was later confirmed with additional viability/apoptosis assays, figure 
5.2). Similarly, 11(12)-EET attenuated the palmitate-induced loss in cell viability, with 5µM and 
10µM showing a significant increase in cell viability compared to palmitate treatment alone, 
increasing from 53.6% (+/-1.9) to 73.1% (+/-0.1) and 81.5% (+/-2.6) (P<0.05), respectively. 
Interestingly, the concentration of 11(12)-EET required to achieve significant protection 
against palmitate was double that required with 8(9)-EET and there was no apparent decline 
in viability at higher concentrations, although even at 10µM 11(12)-EET cell viability was lower 
than that observed with 2.5µM 8(9)-EET. A similar difference is also evident with 14(15)-EET, 
with only 10µM significantly increasing cell viability to 78.3% (+/- 1.0) compared to palmitate 
alone (P<0.05).  
In contrast, incubation with DHETs failed to ameliorate the cytotoxic effects of 
palmitate-induced beta cell death regardless of the isomer used. Collectively, this initial data 
therefore supports that EETs, but not DHETs, are cytoprotective against lipotoxicity in BRIN-
BD11 cells treated with palmitate and with some subtle differences in the extent of the 
protective effect between distinct EET isomers, it is tempting to speculate that the difference 
in epoxide position in relation to the carboxylic acid group may be important. These effects 
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were further confirmed for each EET/DHET using the trypan blue vital dye exclusion assay and 
flow cytometry for apoptosis induction using the MUSE™ MultiCaspase assay (figure 4.2-4.4).  
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Figure 4.2 Comparative analysis of 8(9)-EET and 8(9)-DHET on palmitate-induced cell death and apoptosis. Cells were 
treated for 24 hours with 250µM palmitate in combination with 10µM 8(9)-EET or 8(9)-DHET and the total and viable cell 
numbers were determined using trypan blue vital dye exclusion (A) and apoptosis profile (B) was assessed by flow cytometry 
using the Muse™ MultiCaspase. Panels (C) to (F) show representative apoptosis profiles of cells under each treatment 
condition. Values represented as mean (+/- SEM), n=3. *P<0.05 relative to corresponding control. #P<0.05 relative to 
palmitate alone as determined by two-way ANOVA and Bonferroni’s post-test (A) and by one-way ANOVA and Tukey’s post-
test (B). 
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Treatment with 250µM palmitate for 24 hours resulted a significant reduction in viable 
cell number compared to control from 0.99 x106 cells/mL (+/-0.09) to 0.16 x106 cells/mL (+/-
0.2) (P<0.05), as suggested from previous data. When treated with the addition of 10µM 8(9)-
EET, there was a significant increase in viable cell number compared to palmitate treatment 
alone from 0.16 x106 cells/mL (+/-0.2) to 1.00 x106 cells/mL (+/-0.15) (P<0.05), an increase of 
~6-fold, to a level not significant to control (P>0.05). Of note, this in contrast to the apparent 
reduction in cell viability with 10µM 8(9)-EET observed in the MTT assay and supports 
potential limitations of the MTT assay in these models. Similar to the initial screening, 8(9)-
DHET failed to protect against the reduction in viable cell number when incubated with 250µM 
palmitate (P>0.05).   
Confirmation of protective effects is evident from the apoptosis profile, with 250µM 
palmitate significantly increasing apoptosis compared to control from 19.2% (+/-2.1) to 71.5% 
(+/-3.1) (P<0.05). In co-incubation, 8(9)-EET significantly reduced the percentage of cells 
displaying caspase activation to 12.7% (+/-3.4) (P<0.05), in comparison to 8(9)-DHET (P>0.05); 
effects which are evident in the representative profiles. Additionally, there is also some 
suggestion that 8(9)-EET may compensate for an increase in basal apoptosis exerted by using 
media supplemented with 1% FBS, as was observed in the preliminary Annexin V & Dead Cell 
assays with AA. Compared to the apoptosis profiling gathered from the preliminary results 
(Chapter 3, figure 3.13), where apoptosis was assessed by flow cytometry with an Annexin V 
& Dead Cell assay, palmitate increased the apoptotic population to 22.8% (+/-1.9) compared 
to 71.5% (+/-3.1) when assessed by MUSE™ MultiCaspase. The almost 5-fold difference 
suggests that MultiCaspase assay has a greater sensitivity compared to Annexin V & Dead Cell 
assay in this model, likely reflecting that caspase activation represents an early step in the 
initiation/execution of apoptosis.  
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Figure 4.3 Comparative analysis of 11(12)-EET and 11(12)-DHET on palmitate-induced cell death and apoptosis. Cells were 
treated for 24 hours with 250µM palmitate in combination with 10µM 11(12)-EET or 11(12)-DHET and the total and viable 
cell numbers were determined using trypan blue vital dye exclusion (A) and apoptosis profile (B) was assessed by flow 
cytometry using the Muse™ MultiCaspase. Panels (C) to (F) show representative apoptosis profiles of cells under each 
treatment condition. Values represented as mean (+/- SEM), n=3. *P<0.05 relative to corresponding control. #P<0.05 relative 
to palmitate alone as determined by two-way ANOVA and Bonferroni’s post-test (A) and by one-way ANOVA and Tukey’s 
post-test (B). 
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Similarly, the protective effects of 11(12)-EET were also confirmed, with 11(12)-EET 
significantly increasing total and viable cell numbers compared to palmitate alone from 0.84 
x106 cells/mL (+/-0.09) to 1.08 x106 cells/mL (+/-0.03) and 0.200 x106 cells/mL (+/-0.02) to 0.82 
x106 cells/mL (+/-0.02) (P<0.05), respectively.  The increase in viable cell number corresponds 
to previous data showing that 10µM 11(12)-EET is protective against palmitate toxicity, with 
11(12)-DHET failing to significantly increase viable cell number (P>0.05). As with 8(9)-EET, 
10µM 11(12)-EET reduced the percentage of cells displaying caspase activation from 66.1 (+/-
2.3) to 23.4% (+/-2.2) (P<0.05), a decrease to levels not significantly different to control 
(P>0.05), unlike data obtained with the MTT and trypan blue vital dye exclusion assays. In 
contrast, apoptosis levels in co-incubation with 11(12)-DHET, were comparable and 
insignificant to that seen in response to palmitate alone (P>0.05), again clearly visible in the 
representative apoptosis profiles.   
Data obtained with 14(15)-EET also demonstrate that co-incubation with 14(15)-EET 
significantly increased viable cell number from 0.21 x106 cells/mL (+/-0.01) with palmitate 
alone to 0.72 x106 cells/mL (+/-0.08) (P<0.05), to a level not significant to control (P>0.05). As 
seen with other DHET isomers, 14(15)-DHET failed to protect BRIN-BD11 cells against 
palmitate toxicity (P>0.05). Analysis of the apoptosis profiles also confirms that 14(15)-EET 
protects against palmitate-induced caspase activation, significantly decreasing apoptosis from 
75.9% (+/-1.6) to 34.1% (+/-2.5) (P<0.05), respectively.  However, unlike 8(9)-EET and 11(12)-
EET, the effects of 14(15)-EET were not complete, with apoptosis remaining significantly 
higher than the 18.4% (+/-2.0) under control conditions. As with previous DHETs, 14(15)-DHET 
failed to protect BRIN-BD11 cells from palmitate toxicity, with no decrease in apoptosis 
observed (P>0.05).  
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Figure 4.4 Comparative analysis of 14(15)-EET and 14(15)-DHET on palmitate-induced cell death and apoptosis. Cells were 
treated for 24 hours with 250µM palmitate in combination with 10µM 14(15)-EET or 14(15)-DHET and the total and viable 
cell numbers were determined using trypan blue vital dye exclusion (A) and apoptosis profile (B) was assessed by flow 
cytometry using the Muse™ MultiCaspase. Panels (C) to (F) show representative apoptosis profiles of cells under each 
treatment condition. Values represented as mean (+/- SEM), n=3. *P<0.05 relative to corresponding control. #P<0.05 relative 
to palmitate alone as determined by two-way ANOVA and Bonferroni’s post-test (A) and by one-way ANOVA and Tukey’s 
post-test (B). 
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Collectively, 8(9)-EET, 11(12)-EET and 14(15)-EET protect against palmitate-induced 
loss in cell viability and increased apoptosis in BRIN-BD11 cells. Interestingly, from the data 
collected, 8(9)-EET consistently displays a higher level of protection, followed by 11(12)-EET 
and then 14(15)-EET. Although significant variation was not always obtained, this is a 
consistent observation and it is tempting to speculate that, depending on the position of the 
epoxide group in relation to the carboxylic acid, this may influence its protective actions. 
 Several GPCRs have been identified as targets for EETs and FFAs including GPR40 and 
GPR120 and whilst high-affinity binding of EETs to a well-defined GPCR is yet to be fully 
established, there is evidence supporting a role for these two GPCRs in beta cell (dys)function. 
Therefore, whether or not the protective actions of EETs against palmitate toxicity were, in 
part, mediated by their binding to GPR40 or GPR120 was investigated using the selective 
antagonists DC260126 (GPR40) and AH7614 (GPR120). Initial MTT screening across varying 
concentrations of DC260126 and AH7614 were investigated (data not shown), showing low 
toxicity in BRIN-BD11 cells under control conditions. Furthermore, DC260126 and AH7614 
were screened against 250µM palmitate, showing low additional toxicity; from this data 
concentrations of 1.25µM and 2.5µM DC260126 or AH7614 were selected. Cells were pre-
incubated with either antagonist for 1 hour before treatment with 250µM palmitate alone or 
co-incubated with EETs; DHETs were not investigated further here, as the current data 
suggests no protective actions against palmitate toxicity. Since initial inhibitor screens were 
carried out using the MTT assay, 8(9)-EET was used at a concentration of 2.5µM, based on 
earlier observations (figure 4.1); the other EETs were used at 10µM (figure 4.5 A-F). 
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Treatment with 250µM palmitate decreased cell viability, compared to untreated 
control for all treatments and, as previously observed (figure 4.1), co-incubation with 2.5µM 
8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-EET significantly increased cell viability compared 
to palmitate alone (P<0.05). Similarly, in the presence of 1.25µM or 2.5µM DC260126 and 
AH7614, all EETs showed a significant increase in cell viability compared to the corresponding 
treatments with palmitate in the presence of the antagonists, showing that DC260126 and 
AH7614 failed to antagonise the protective effects of each EET isomer. Although in some 
treatment conditions, cell viability was lower with EETs in the presence of the antagonists, this 
Figure 4.5. Effects of the GPR40 (DC260126) or GPR120 (AH7614) antagonists on the cytoprotective actions of EETs against 
palmitate toxicity. Cells were pre-incubated with the antagonists at the indicated concentrations for 1 hour followed by 
treatment with palmitate, alone or in combination, with 2.5µM 8(9)-EET (panels A-B), 10µM 11(12)-EET (panels C-D) or 10µM 
14(15)-EET (panels) for 24 hours before cell viability was assessed using the MTT assay. Values are represented as mean (+/- 
SEM), n=3. *P<0.05 relative to corresponding palmitate treatment (without EET) #P<0.05 relative to palmitate alone as 
determined by two-way ANOVA and Bonferroni’s post-test. 
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was mirrored by a comparable small decrease in viability in the palmitate-alone groups, 
supporting that GPR40 and GPR120 do no contribute to the action of EETs in this model in 
BRIN-BD11 cells. 
Further to this, since EETs have been reported to act, in part, as PPAR agonists, 
investigations into the effects of PPAR antagonists; PPARα (GW6471), PPARβ/δ (GSK3787) and 
PPARγ (T0070907) were carried out in the presence of each EET isomer in combination with 
250µM palmitate (figure 4.6-4.8). BRIN-BD11 cells were pre-treated with either GW6471, 
GSK3787 or T0070907 for 1 hour prior to treatment in the presence of 250µM palmitate alone 
or in co-incubation with either 10µM AA, 2.5µM 8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-
EET. Cell viability was screened with all EETs and AA using the MTT assay, with the trypan blue 
vital dye exclusion and MUSE™ MultiCaspase flow cytometry assays used as confirmatory tests 
with 8(9)-EET.  
159 
 
 
 
In the presence of the antagonist GW6471, AA and all EET isomers resulted in a 
significant increase in cell viability compared to corresponding palmitate only treatment when 
assessed by the MTT assay (P<0.05), showing that GW6471 failed to decrease their protective 
actions, indicating effects are PPARα-independent. As with previous data using the GPR 
antagonists, decrease in viability in the presence of EETs/palmitate was mirrored with a 
comparable decrease in response to palmitate alone, indicating no difference in the relative 
Figure 4.6. Effects of the PPARα (GW6471) antagonist on the cytoprotective actions of EETs against palmitate toxicity. Cells 
were pre-incubated with GW6471 at the indicated concentrations for 1 hour followed by co-treatment with palmitate, alone 
or in combination, with 10µM AA, 2.5µM 8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-EET in the presence of the antagonist 
for 24 hours before cell viability was assessed using the MTT assay (panels A-D). Cell viability was further assessed in the 
presence of 10µM 8(9)-EET and the antagonist using the trypan blue vital dye exclusion assay and flow cytometry using the 
MUSE™ MultiCaspase (panels E-F). Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to corresponding 
palmitate treatment (without EET) #P<0.05 relative to palmitate alone as determined by two-way ANOVA and Bonferroni’s 
post-test. 
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increase in viability in combination with EETs (similar observations apply to the data with 
PPARβ/δ and PPARγ antagonists, figures 4.7-4.8). To confirm a lack of inhibitory activity of 
PPARα antagonism on the effects of EET protection against palmitate toxicity, cell viability was 
also assessed by trypan blue vital dye exclusion.  No significant effect of GW6471 on the 
reduction in viable cell number from 1.26 x106 cells/mL (+/- 0.03) at control to 0.13 x106 
cells/mL (+/-0.03) with palmitate was observed (P<0.05). Both 8(9)-EET alone and in 
combination with 2µM GW6471 significantly increased viable cell number compared to the 
corresponding palmitate-only treatment (P<0.05), with no significant difference between 
these two group. Similarly, the increase in palmitate-induced caspase activation was 
unaffected by the presence of the antagonist and was significantly attenuated by 10µM 8(9)-
EET, reducing apoptosis to levels comparable to control, indicating complete protection. This 
effect was equally unaltered in the presence of GW6471, with no significant difference in 
apoptosis compared to 10µM 8(9)-EET alone, confirming that GW6471 fails to reduce the 
protective effects of EETs against palmitate toxicity and supporting PPARα-independent 
effects. The PPARβ/δ antagonists GSK3787 was then used under the same treatment 
conditions.  
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Comparable results to that seen in the presence of GW6471 were observed, with AA 
and EETs significantly attenuating the palmitate-induced loss in cell viability irrespective of the 
presence of increasing concentrations of GSK3787 when assessed by MTT assay (P<0.05 
compared to corresponding treatment with palmitate alone). When assessed by trypan blue 
vital dye exclusion and MUSE™ MultiCaspase assay, 8(9)-EET significantly increased viable cell 
number compared to palmitate alone from 0.18 x106 cells/mL (+/-0.02) to 1.18 x106 cells/mL 
Figure 4.7. Effects of the PPARβ/δ (GSK3787) antagonist on the cytoprotective actions of EETs against palmitate toxicity. 
Cells were pre-incubated with GSK3787 at the indicated concentrations for 1 hour followed by co-treatment with palmitate, 
alone or in combination, with 10µM AA, 2.5µM 8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-EET in the presence of the 
antagonist for 24 hours before cell viability was assessed using the MTT assay (panels A-D). Cell viability was further assessed 
in the presence of 10µM 8(9)-EET and the antagonist using the trypan blue vital dye exclusion assay and flow cytometry using 
the MUSE™ MultiCaspase (panels E-F). Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to corresponding 
palmitate treatment (without EET) #P<0.05 relative to palmitate alone as determined by two-way ANOVA and Bonferroni’s 
post-test. 
 
162 
 
(+/-0.03) and reduced apoptosis from 69.5% (+/-4.1) to 14.9% (+/-1.8) (P<0.05). With the 
addition of 2µM GSK3787, no significant difference with corresponding treatment groups was 
observed, with 8(9)-EET co-incubated with 2µM GSK3787 producing comparable protection 
against palmitate toxicity. Therefore, similar to GW36471, GSK3787 failed to inhibit the 
protective actions of all EET isomers suggesting that EET effects are independent to the 
activation of PPARβ/δ.  
 
Figure 4.8. Effects of PPARγ (T0070907) antagonist on the cytoprotective actions of EETs against palmitate toxicity. Cells 
were pre-incubated with T0070907 at the indicated concentrations for 1 hour followed by co-treatment with palmitate, alone 
or in combination, with 10µM AA, 2.5µM 8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-EET in the presence of the antagonist 
for 24 hours before cell viability was assessed using the MTT assay (panels A-D). Cell viability was further assessed in the 
presence of 10µM 8(9)-EET and the antagonist using the trypan blue vital dye exclusion assay and flow cytometry using the 
MUSE™ MultiCaspase (panels E-F). Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to corresponding 
palmitate treatment (without EET) #P<0.05 relative to palmitate alone as determined by two-way ANOVA and Bonferroni’s 
post-test. 
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As with GW6471 and GSK3787, the PPARγ antagonists T0070907 failed to alter the 
protective effects of all EET isomers or AA against palmitate, with all EETs showing a significant 
increase in cell viability compared to palmitate alone when co-incubated with either 1.25µM 
or 2.5µM T0070907 (P<0.05). Similar results were obtained when cell viability was assessed 
by trypan blue vital dye staining, with 10µM 8(9)-EET significantly increasing viable cells 
compared to palmitate alone (P<0.05) and the addition of 2µM T0070907 resulting in no 
significant difference between treatment groups, showing that T0070907 fails to antagonise 
the protective effects of 8(9)-EET. Compared to corresponding treatment with palmitate in 
the presence of T0070907, viable cell number increased from 0.12 x106 cells/mL (+/-0.01) to 
0.86 x106 cells/mL (+/-0.04) with 8(9)-EET (P<0.05). In agreement with this, 8(9)-EET 
significantly reduced the palmitate-induced increase in apoptosis from 76.4% (+/-2.3) to 
10.7% (+/-1.0), a response unaffected with the addition of 2µM T0070907 (P>0.05). 
Collectively, the addition of each PPAR antagonists resulted in no significant changes in the 
extent of cytoprotection afforded by each EET isomer against palmitate toxicity, with 
confirmatory vital dye exclusion and apoptosis assays overall supporting the initial MTT data 
and together suggest that EETs exert these effects in a PPAR-independent manner.  
Upon activation, PPARs form heterodimers with RXR, therefore further to the effect of 
PPAR antagonists alone, co-stimulatory action of EETs in this context was also explored under 
similar experimental conditions as with the previous PPAR antagonist data. Firstly, the 
protective effects of 8(9)-EET and AA against palmitate-induced loss of cell viability were 
investigated in the presence of the RXR antagonist, HX531, alone and then in combination 
with each of the PPAR antagonists in the presence of each EET isomer (figure 4.9).  
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Treatment of BRIN-BD11 cells with palmitate co-incubated with 10µM AA or 2.5µM 
8(9)-EET observed a significant increase in cell viability compared to palmitate treatment 
alone (P<0.05). The addition of HX531 resulted in a slight decrease in viability in the palmitate-
only treatment, as observed in previous data, under these conditions, the relative effect of AA 
or 8(9)-EET was comparable regardless of the presence of HX561 (figure 4.9, panels: A-B), 
indicating effects on increased cell viability were independent to RXR activation. Similar 
Figure 4.9. Effects of the RXR (HX531) antagonist alone and in combination with PPAR antagonists on the cytoprotective 
actions of EETs against palmitate toxicity. Cells were pre-incubated with HX531, GW6471, GSK3787, T0070907 alone or in 
combination at the indicated concentrations for 1 hour followed by co-treatment with palmitate alone or in combination 
with 10µM AA, 2.5µM 8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-EET in the presence of the antagonists for 24 hours before 
cell viability was assessed using the MTT assay. Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to 
corresponding palmitate treatment (without EET) #P<0.05 relative to palmitate alone as determined by two-way ANOVA and 
Bonferroni’s post-test. 
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effects were observed with the inclusion of the PPAR antagonists, though overall this data 
demonstrates a more consistent reduction in cell viability in the palmitate treatment alone. 
With all EETs, a significant reduction in viability was observed in the presence of the combined 
inhibitors, though this remained significantly higher than the corresponding palmitate-only 
controls. Again, the relative increase in cell viability between this group and the data from the 
presence of the EETs is comparable to that in the absence of the antagonists, with ~30% 
increase in viability with each EET. Collectively, this data suggests PPAR/RXR-independent 
actions of EETs in this model of lipotoxicity in BRIN-BD11 cells.  
 Following from this, other potential mechanisms of EET action were explored, 
extending the approach with pharmacological receptor antagonists to other intracellular 
targets, with potential activity in the metabolism of EETs and other FFAs. Firstly, since release 
of AA from cellular phospholipids is controlled by the activity of PLA2 and that EETs can also 
be incorporated into membrane phospholipids, as a mechanism controlling total free-EET 
levels (Klett et al., 2013), the PLA2 inhibitor OBBA was investigated to explore whether cellular 
levels of exogenously applied EETs may be regulated in a similar way (figure 4.10).  
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A similar modest enhancement of palmitate toxicity (alone) was observed following 
treatment with either 1.25µM or 2.5µM OBBA. As with data obtained with the previous 
antagonists, treatment with each EET in combination with either 1.25µM or 2.5µM OBBA 
resulted in a significant increase in cell viability compared to their corresponding treatments 
comparable to the increase observed in the absence of the inhibitor (P<0.05).  
Changes in lipid homeostasis in response to FFA treatment may, in part, be mediated 
by alterations in TAG synthesis, thereby sequestering toxic FFA species into neutral lipids, or 
by increasing β-oxidation, decreasing cytosolic levels of acyl-CoAs. Alternatively the SCD 
enzyme family are involved in the conversion of saturated FFAs to unsaturated species, which 
may facilitate their incorporation into TAG. Processing of FFAs by these routes were then 
investigated in cells treated with 250µM palmitate co-incubated with 8(9)-EET in the presence 
Figure 4.10. Effects of the PLA2 (OBBA) inhibitor on the cytoprotective actions of EETs against palmitate toxicity. Cells were 
pre-incubated with OBBA at the indicated concentrations for 1 hour followed by treatment with palmitate alone or in 
combination with 10µM of each EET in the presence of the inhibitor for 24 hours before cell viability was assessed using the 
MTT assay. Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to corresponding palmitate treatment (without 
EET) #P<0.05 relative to palmitate alone as determined by two-way ANOVA and Bonferroni’s post-test. 
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of 2µM of the SCD inhibitor A939572, or with 50µM of the CPT1 inhibitor, Etomoxir, and 5µM 
of the DGAT inhibitor, Xanthohumol, alone and in combination with cell viability assessed 
using the MTT and MUSE MultiCaspase assays (figure 4.11).  
 
Figure 4.11. Effects of SCD (A939572), CPT1 (Etomoxir) and/or DGAT-1 (Xanthohumol) inhibition on the cytoprotective 
actions of EETs. Cells were pre-incubated with A939572, Etomoxir or Xanthohumol alone or in combination at the indicated 
concentrations for 1 hour followed by treatment with palmitate alone or in combination with 2.5µM (A-B) or 10µM (C) 8(9)-
EET in the presence of the inhibitors for 24 hours before cell viability was assessed using the MTT assay (A-B) or by flow 
cytometry with the MUSE™ MultiCaspase assay (C). Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to 
corresponding palmitate controls and #P<0.05 compared to treatment without the inhibitor as determined by two-way 
ANOVA and Bonferroni’s post-test (A-B) or one-way ANOVA and Tukey’s post-test (C). 
 
The SCD inhibitor A939572 enhanced palmitate toxicity (effects which were also 
evident when used at lower concentrations, data not shown), significantly reducing cell 
viability (P<0.05). As with previous antagonist/inhibitor data, the effect of 8(9)-EET was not 
significantly altered in the presence of the inhibitor, with a comparable increase in cell viability 
in the two EET treatment groups as compared to palmitate alone groups (P<0.05). Similarly, 
neither inhibition of CPT1 or DGAT diminished the protective effect of 8(9)-EET against 
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palmitate toxicity, with all inhibitor treatment groups producing a comparable increase in cell 
viability compared to their corresponding palmitate controls. Similarly, combined inhibition of 
these pathways had no effect on the reduction in caspase activity in response to 8(9)-EET 
(P>0.05), though the apparent trend on a reduction in cell viability in the combined inhibitor 
group is not evident here. This may indicate collectively that EETs regulate a distal step 
downstream in the apoptotic pathway/caspase activation, though given the nature of the MTT 
assay this is likely to continue to be an artefact of this assay format, particularly in data 
obtained using inhibitors that will likely alter mitochondrial substrate availability/reducing 
capacity.  
Although a range of complementary pharmacological inhibitors/receptor antagonists 
have so far been used to explore potential mechanisms of EET action in the current lipotoxicity 
model, problems may occur from poor cellular uptake (though a 1 hour pre-incubation was 
included) and/or potential off-target effects. Additionally, the minor enhancement of 
palmitate toxicity in some of the data obtained may limit the conclusions that can be drawn, 
though this may reflect a higher sensitivity to toxicity in palmitate/EET challenged cells and 
whilst collectively the data support that EETs may act downstream of a pro-apoptotic signal in 
controlling cell death, this does not preclude the possibility that other EET actions are 
contributing to changes in lipid handling in these cells, effects which are not directly apparent 
in inhibitor studies. Therefore, RT-PCR was used to determine the relative expression of select 
genes associated FFA metabolism in BRIN-BD11 cells treated with palmitate alone, or in the 
presence of each EET (figure 4.12). 
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A significant increase in the relative expression of CPT1, Ech1 and DGAT1 compared to 
palmitate control of ~2-fold, ~1.7-fold and ~1.6-fold (P<0.05), respectively, was observed in 
co-incubation with 8(9)-EET. Similarly, an increase in expression of these genes was also 
observed in co-incubation with 11(12)-EET and, to a lesser extent, 14(15)-EET, with the 
Figure 4.12. Effects of palmitate and EETs on relative gene expression. Cells were treated with a fixed concentration of 
250µM palmitate co-incubated with 10µM 8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-EET for 24 hours before samples were 
processed for RNA extraction, cDNA synthesis with relative gene expression determined by real-time PCR using SYBR green 
for CPT1 (A), Elovl6 (B), Ech1 (C) and DGAT1 (D). Expression levels were determined relative to 18S rRNA using the Ct 
method and values represented as mean fold change in relative expression (+/- SEM), n=3. *P<0.05 relative to control. 
#P<0.05 relative to palmitate. Statistically analysed by one-way ANOVA and Tukey’s post-test. 
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exception of CPT1. Although Elovl6 showed a significant increase compared to palmitate 
treatment alone, its relative expression was minimally different to the control level when 
compared to the increase over control with CPT1, Ech1 and DGAT1. This is likely due to EETs 
protecting against palmitate-induced cell death and so the relative change in expression of 
ELovl6 compared to palmitate alone may reflect cell/mRNA loss over the culture period used. 
Collectively, 8(9)-EET treatment resulted in the highest increase in gene expression for the 
majority of targets, followed by 11(12)-EET and 14(15)-EET; a consistent albeit not always 
significant trend seen throughout this chapter following treatments of cells with EETs co-
incubated with palmitate. Of note here is the observations that genes associated with 
increased β-oxidation (CPT1 and Ech1) and TAG synthesis (DGAT) are upregulated consistently 
across EET treatments and may support alterations in lipid handling in these cells under these 
conditions, though not necessarily reflective in the effects on cell viability, as reported by 
others (Diakogiannaki et al., 2007; Keane et al., 2011). Upregualtion of DGAT, as observed with 
all EETs (increasing 1.5-2 fold over control and a marked increase compared to palmitate 
treatment) may suggest an increase in TAG synthesis under these conditions and although 
DGAT inhibition suggested EET effects were independent to this, any increase in cellular lipid 
droplet accumulation was assessed by flow cytometry using Nile Red staining (figure 4.13).  
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Figure 4.13. Effects of EETs on lipid droplet accumulation in palmitate-treated BRIN-BD11 cells. Cells were treated with 
250µM palmitate +/- 10µM 8(9)-EET, 10µM 11(12)-EET, 10µM 14(15)-EET or 250µM oleate as a positive control for 24 hours 
before lipid droplet accumulation was assessed by Nile Red staining and flow cytometry. Data in panel A is expressed as 
relative fold change of mean fluorescence compared to control. n=3, with representative prolife plots shown in panels B-F 
(in all panels the control population is indicated in blue, with a right shift in response to treatment indicating an increase in 
lipid droplet accumulation). *P<0.05 relative to control. #P<0.05 relative to palmitate as determined by one-way ANOVA and 
Tukey’s post-test.  
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As would be expected, treatment with the monounsaturated fatty acid oleate 
significantly increased the accumulation of intracellular lipid droplets (P<0.05 compared to 
control) and in contrast, the saturated fatty acid palmitate did not. Representative profiles 
show a right shift in mean fluorescence with all EETs indicating an increase in intracellular lipid 
droplets in co-incubation with palmitate; however, the relative fold change was only 
significant in the presence of 8(9)-EET, with a modest increase in 11(12)-EET and to a lesser 
extent 14(15)-EET. Collectively, this supports the DGAT inhibitor data suggesting that 
intracellular lipid droplet accumulation is not required for EET action. To further explore the 
protective effects of EETs in context to whether changes in TAG formation and/or β-oxidation 
in response to palmitate are necessary, the palmitate analogue, 2-Bromopalmitate acid was 
investigated in co-incubation with each EET (figure 4.14). This palmitate derivative, as well as 
inhibiting palmitoylation and fatty acid oxidation, is a species capable of being esterified to 
CoA but is a poor substrate for further metabolic processing, including β-oxidation and is has 
not been observed to be incorporated into TAG (Cnop et al., 2001).  
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Comparison of the dose-dependent loss in cell viability as assessed by the MTT assay 
showed that all concentrations of palmitate resulted in a significant decrease in cell viability 
compared to control (P<0.05). In contrast, 2-Bromopalmitate displayed reduced toxicity and 
was well-tolerated up to 125µM, with a significant decrease in cell viability observed at a 
concentration of 250µM, decreasing to 82.2% (+/-1.5) in comparison to 26.9% (+/-2.4) with 
the same concentration of palmitate; ~3-fold difference in toxicity. Increasing concentrations 
of 2-Bromopalmitate to 500µM and 1000µM dose-dependently reduced cell viability to 64.1% 
(+/-2.3) and 51.7% (+/-3.0) (P<0.05 vs. control), respectively. Subsequent treatment of BRIN-
BD11 cells with 500µM 2-Bromopalmitate resulted in a significant decrease in viable cell 
number compared to control from 1.07 x106 cells/mL (+/-0.07) to 0.41 x106 cells/mL (+/-0.02) 
Figure 4.14. Effects of 2-Bromopalmitate on loss in cell viability in BRIN-BD11 and its attenuation by EETs. Cells were treated 
with increasing concentrations of palmitate and 2-Bromopalmitate (2-BP) for 24 hours before cell viability was assessed using 
MTT assay (A). 500µM 2-Bromopalmitate was used alone or in co-incubation with 10µM 8(9)-EET, 10µM 11(12)-EET or 10µM 
14(15)-EET for 24 hours before total and viable cell numbers were assessed by trypan blue vital dye exclusion (B) or apoptosis 
levels quantified by flow cytometry using the MUSE™ MultiCaspase assay (C). Values are represented as mean (+/- SEM), n=3. 
*P<0.05 relative to corresponding control. #P<0.05 relative to corresponding 2-Bromopalmitate treatment as determine by 
two-way ANOVA and Bonferroni’s post-test (A-B) or one-way ANOVA and Tukey’s post-test (C).  
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(P<0.05). Although the MTT assay shows a ~3-fold difference in cell viability between 
palmitate and 2-Bromopalmitate, data from the trypan blue vital dye exclusion assay shows 
similar findings to previous data collected with 250µM palmitate with this method, again 
suggesting difference in assay sensitivity. Co-incubation with either 10µM 8(9)-EET, 10µM 
11(12)-EET or 10µM 14(15)-EET attenuated the loss in viable cell number with 500µM 2-
Bromopalmitate, resulting in a significant increase from 0.41 x106 cells/mL (+/-0.02) to 0.97 
x106 cells/mL (+/-0.02), 1.00 x106 cells/mL (+/-0.05) and 0.98 x106 cells/mL (+/-0.05) (P<0.05), 
respectively. The protective effects of all EET isomers against 500µM 2-Bromopalmitate was 
further confirmed when apoptosis was assessed, showing a significant increase in apoptosis 
in response to 2-Bromopalmitate alone compared to control from 20.5% (+/-2.0) to 56.2% (+/-
3.6) (P<0.05), an almost 3-fold increase, similar to the data with palmitate. The addition of 
10µM of each EET isomer, resulted in a significant decrease in apoptosis compared to 2-
Bromopalmitate alone from 56.2% (+/-3.6) to 12.6% (+/-0.4) for 8(9)-EET, 15.9% (+/-1.1) for 
11(12)-EET and 16.3% (+/-0.7) for 14(15)-EET (P<0.05), to levels not significantly different to 
the control (P>0.05), showing that EETs can protect against cell death and apoptosis in 
response to the poorly metabolisable palmitate analogue, supporting data from some of the 
inhibitor studies.  
 Poorly metabolisable unsaturated FFA analogues, such as methyl-palmitoleate, have 
also been extensively studied to explore potential mechanisms of cytoprotection. One such 
analogue of EETs, a methylsulphonamide derivative which cannot be esterified to CoA and so 
is not a substrate for TAG formation or β-oxidation, was employed in the current study. As a 
14(15)-EET-SI derivative was used, its effects against palmitate toxicity were compared against 
14(15)-EET at equal concentrations (figure 4.15). 
175 
 
 
 
 
In support of all previous data, 14(15)-EET exerted protective effects against palmitate 
toxicity, significantly increasing viable cell number from 0.19 x106 cells/mL (+/-0.05) to 0.73 
x106 cells/mL (+/-0.04) (P<0.05). In comparison, co-incubation with 14(15)-EET-SI resulted in 
a significant decrease of ~50% in viable cell number compared to 14(15)-EET, with no 
significant increase compared to palmitate alone (P>0.05). To confirm this result, apoptosis 
profiling was carried out by assessment of caspase activation which showed that 14(15)-EET 
significantly attenuated the increase in apoptosis induced by palmitate from 69.2% (+/-7.3) to 
25% (+/-3.8) (P<0.05). Although 14(15)-EET-SI failed to significantly protect against palmitate-
induced apoptosis, the analysis shows no significant difference in apoptosis compared to 
14(15)-EET (P>0.05). Analysis of the data from using 14(15)-EET-SI collectively suggests that 
this EET derivative does not protect against palmitate toxicity, although both viable cell 
number and apoptosis were favourably altered, albeit not significantly. This may directly 
reflect that the mode of action of EETs require esterification to CoA, or the trend towards a 
protective effect may indicate that a higher concentration of 14(15)-EET-SI would significantly 
Figure 4.15. Effects of 14(15)-EET-SI and 14(15)-EET against palmitate-induced loss in cell viability and apoptosis induction. 
Cells were treated with 250µM palmitate alone or in co-incubation with 10µM 14(15)-EET or 10µM 14(15)-EET-SI for 24 hours 
before total and viable cell numbers were determined by trypan blue vital dye exclusion assay (A) and apoptosis assessed by 
flow cytometry using the MUSE™ MultiCaspase assay (B). Values are represented as mean (+/- SEM), n=3. *P<0.05 relative 
to corresponding control and #P<0.05 relative to corresponding palmitate alone as determined two-way ANOVA and 
Bonferroni’s post-test (A) or one-way ANOVA and Tukey’s test (B).  
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protect against palmitate toxicity, though this was not feasible in the current study. 
Nonetheless, comparison of the extent of the cytoprotective effects with equivalent 
concentrations of EET and EET-SI, comparable to the concentrations used throughout this 
chapter for all EETs, demonstrates a less potent effect of the SI derivative against palmitate 
toxicity. Collectively, the data presented in this chapter demonstrates that EETs protect 
against palmitate toxicity in BRIN-BD11 cells and that whilst increased expression of genes 
associated with altered cellular lipid handling and a modest increase in lipid droplet 
accumulation was observed, data from pharmacological inhibition of some of these pathways 
and use of the poorly metabolisable palmitate analogues, suggest that EET action is distinct 
from direct changes in palmitate metabolism.  
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4.5 Discussion 
The aims of this chapter were to investigate the potential actions of 
epoxyeicosatrienoic acids (EETs) and their corresponding diols, dihydroxyeicosatrienoic acids 
(DHETs), in an in vitro model of lipotoxicity associated with the pathogenesis of type 2 DM, in 
BRIN-BD11 cells. AA can be metabolised by COX, LOX and cytochrome P450 enzymes which, 
in addition to various prostaglandins and leukotrienes, produce three classes of NADPH-
dependent oxidative reaction products; i) epoxidation leading to the production of 5(6)-EET, 
8(9)-EET, 11(12)-EET and 14(15)-EET, ii) allylic oxidation producing 5,8,9,11,12 and 15 HETEs 
and iii) hydroxylation forming 19 and 20-HETE (Capdevila et al., 1992). Although the roles of 
the COX and LOX pathways of AA metabolism have been well-studied in beta cell models, with 
the contribution of their reaction products when applied exogenously reported (Bleich et al., 
1997; Carboneau et al., 2017; Robertson, 2017), comparatively little is known about the 
contribution of CYP450-derived EETs in these models (Xu et al., 2016).  Therefore the current 
data provides the entirely novel observations that EETs, but not DHETs, protect against 
palmitate-induced loss in cell viability and apoptosis induction in BRIN-BD11 cells. Whilst the 
anti-inflammatory activity of EETs is well-established in a number of models and others have 
shown that modulation of endogenous EET levels through over-expression of CYP 2J2, 
knockout of sEH or its inhibition can attenuate diet-induced hepatic dysfunction and improve 
insulin resistance in db/db mice (Battaieb et al., 2013; Li et al., 2015), little is known about the 
contribution of EETs to beta cell dysfunction. Earlier observations that EETs may positively 
influence insulin secretion (Falck et al., 1983) have been challenged more recently (Klett et al., 
2013), although others have shown that sEH inhibition or knockout can improve glucose 
tolerance and increase beta cell mass in STZ-induced DM in mice (Luo et al., 2010; Chen et al., 
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2013). Therefore the current data provides the first direct evidence of a role for EETs in a 
cellular model of lipotoxicity in response to a physiologically relevant inducer of beta cell 
death. 
The current study investigated the roles of three distinct EET isomers, 8(9)-EET, 11(12)-
EET and 14(15)-EET, reported to be produced by CYP450 isoforms 2J and 2C from the 
epoxidation of AA. Human CYP2C9, which displays high sequence homology to rat CYP2C11, 
with the rat isoforms shown to be present in rat islets (Chen et al., 2013), produces these three 
EETs at a relative ratio of 2.3:1.0:0.5 and so the 14(15)-EET is the predominant species (Zeldin, 
2001). Whilst these enzymes are capable of producing all four EET isomers, the 5(6)-EET 
species is highly reactive due to the proximity of the epoxide group to the carboxylic acid 
group, facilitating rapid hydration to the DHET and/or other products, hence why a 
comparison between any effects of 5(6)-EET and 5(6)-DHET was not included in the current 
study. Initial investigations into the protective effects of 5(6)-EET were explored however, 
inherent difficulties in preparation with BSA and subsequent cell treatment, resulted in an 
increase in cell death, likely due to poor solubility and formation of aggregate species, visible 
under a light microscope at all 5(6)-EET concentrations trialled.  
Cytoprotective actions of EETs against cell death and apoptosis induction in response 
to 250µM palmitate was assessed by the MTT assay, trypan blue vital dye exclusion assays and 
the MUSE™ MultiCaspase assay for apoptosis assessment by flow cytometry. Establishing 
protective effects with several complementary viability assay was necessary, since limitations 
with the nature of some assays was highlighted in the current data. With the MTT assay largely 
reflective of mitochondrial activity, it is likely that treatment with fatty acids may alter the 
respiratory capacity of mitochondria, resulting in an artefact of this assay being that cell 
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viability appeared limited to ~80-90% regardless of EET concentration (also observed with AA 
treatment in Chapter 3). This was particularly evident with 8(9)-EET, where concentrations 
above 2.5µM showed an apparent decrease in cell viability, which was not observed when 
viable cell numbers were determined, or from apoptosis profiling. Indeed a consistent 
observation in the current data is that the relative decrease in palmitate toxicity in response 
to EET treatment was greatest with 8(9)-EET, with this and 11(12)-EET showing complete 
protection, in comparison to 14(15)-EET, when assessed with the MultiCaspase assay. Reasons 
for this are not known but it may be that the position of the epoxide groups relates to a 
differential binding affinity to extra- or intra- cellular targets, or that the mode of action differs 
between distinct EET species, though there is no evidence to support the latter in the current 
data. Equally, these differences may also relate to the ability of EET species to readily undergo 
further metabolic processing, with EETs known to be substrates for COX and LOX pathways 
producing hydroxy-EETs (Rand et al., 2017). Similarly, EETs are thought to also under β-
oxidation producing several shortened-chain epoxide and hydroxy species with reported 
biological activity (Fang et al., 2004). Therefore it is interesting that of the EET species 
considered in the current data, 8(9)-EET displayed a higher degree of cytoprotection than the 
more predominant 11(12)-EET and, to a greater degree, 14(15)-EET isomers. Given this, fewer 
studies have directly assessed the biological role of 8(9)-EET/DHET in cellular models, with 
most reporting on the action of 11(12)- and 14(15)-EETs and similarly, studies on the 
endogenous production of EETs through over-expression of relevant CYP450- epoxygenases 
have largely attributed observed effects to production of these two EETs, therefore the 
current data also emphasises an important biological role, with an overall greater potency, of 
8(9)-EET compared to other isomers.  
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In contrast to EETs, all DHETs failed to attenuate palmitate toxicity in the current data. 
The conversion of EETs to DHETs represents the major route of EET metabolism and the diol 
products are widely reported to display considerably reduced activity compared to EETs, 
supported in studies exploring the beneficial effects of sEH inhibition (Xu et al., 2016). sEH 
inhibitors, limiting EET conversion to DHETs, have been shown to partially enhance the 
mitogenic activity of 8(9)-EET in endothelial cells (Pozzi et al., 2005) and sEH inhibitors 
enhanced beta cell mass in STZ-induced DM (Luo et al., 2010), though this study did not 
address the relative ratios of different EET/DHET species, nor mechanisms of EET action. 
Activity of 11(12)- and 14(15)-DHETs in Ca2+-activated K+ channels has been reported in 
isolated rat coronary arterial myocytes (Lu et al., 2001) and the hypoxic response of human 
hepatoma cells and umbilical artery endothelial cells (Suzuki et al., 2008), and whilst others 
have shown that 14(15)-DHET has weak binding affinity to a putative EET membrane receptor 
(Yang et al., 2010), this was attributed to antagonistic activity with a radiolabelled 14(15)-EET 
analogue. Nonetheless, the current data supports a low activity of DHETs in context to the 
attenuation of lipotoxicity in BRIN-BD11 cells and that sEH inhibitors may be attractive in 
improving functional beta cell mass, as shown in limited in vivo data (Luo et al., 2010; Chen et 
al., 2013).  
Mechanisms of EET action remain to be fully elucidated, though data have suggested 
activity at an, as yet unidentified, extracellular receptor (Yang et al., 2008; Lui et al., 2017). 
GPR40 is reported to be highly expressed in islets (Itoh et al., 2003), predominately in beta 
cells and its expression has also been shown in several beta cell lines, with MIN6 cells showing 
the highest expression at the mRNA level, followed by β-TC-3, HIT-T15 and RINm5F. Although 
expression in BRIN-BD11 cells is uncertain, with low levels of GPR40 expression in RINm5f (the 
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parental cell line to BRIN-BD11) it is possible that BRIN-BD11 cells retain a low level of this 
(Itoh and Hinuma, 2005). GPR40 has been suggested to mediate, in part, the cytoprotective 
effects of oleate against palmitate toxicity, with reduction in effects observed with GPR40 
knockdown by siRNA. Previous studies have also shown that 8(9)-EET and 14(15)-EET 
stimulate GPR40 activity at concentrations of 6.1µM and 1.4µM, respectively (Itoh et al., 
2003), broadly comparable to the EET concentrations used in the current study. Introduction 
of the epoxide group into AA and alteration in position of the epoxide group in different EET 
isomers has been shown to preferentially alter binding ability of EETs to GPR40, as seen in  a 
study comparing 14(15)-EET GPR40 activation with AA in HEK293 cells, which required a 6.7-
fold increase in the concentration of AA to produce comparable activity (Park et al., 2018). Co-
incubation with 5(6)-, 8(9)-, 11(12)- and 14(15)-EET stimulated an increase in Ca2+, 
downstream of GPR40 activation, with concentration-dependent agonistic activity and 11(12)-
EET and 14(15)-EET observing increased potency compared to 5(6)-EET and 8(9)-EET (Park et 
al., 2018), though this would not support the observations in the current data that 8(9)-EET 
appeared more potent in terms of attenuating palmitate toxicity. Of note though, Park et al., 
(2018) also showed that 11(12)-DHET and 14(15)-DHET had comparably lower affinity in 
activating GPR40 than EETs (Park et al., 2018). However in the current data, treatment with 
the GPR40 antagonist in combination with 250µM palmitate co-incubated either 2.5µM 8(9)-
EET, 10µM 11(12)-EET or 10µM 14(15)-EET, failed to attenuate EET action suggesting that 
although EETs may be reported to bind GPR40, effects in this model are GPR40-independent. 
Equally, whether or not EETs display potent activity at GPR40 waits to be confirmed in further 
studies, especially since other recent data screening EET activity at 105 GPCRs failed to identify 
a single high-affinity receptor site (Lui et al., 2017). Similarly, although GPR120 has been 
shown to be involved in insulin secretion and its activation may be protective against 
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palmitate toxicity through regulation of Pdx-1 activity (Wang  et al., 2019), effects of EET action 
in BRIN-BD11 cells were unaffected by the presence of a GPR120 antagonist.  
Whether EETs signal through an extracellular receptor site remains to be determined 
and cannot be entirely excluded based on the current data. However, the recent observations 
that EETs may act through several low affinity prostaglandin (PG) receptors (including PTGER2, 
PTGER4, PTGFR, PTGDR and PTGER3IV), conclude that EETs may signal through multiple GPCRs 
(Lui et al., 2017). Of note, this may be important in a beta cell context since the roles of 
prostaglandins in regulating beta cell function have been well-studied (reviewed recently by 
Carboneau et al., 2017) and whilst the role of PGE2 in insulin secretion (which signals through 
PTGER2, PTGER4 and PTGER3IV) remains unclear, activation of these receptors (and PTGDR by 
PGD) leads to increased cAMP, supporting a possible role in EET-Gαs signalling, as reported by 
others; an effect that can be blocked with the EET antagonist 14(15)-EEZE (Wong et al., 2000; 
Yang et al., 2008). The concentrations of EETs used in this study (10µM), whilst comparable to 
some other studies (Davies et al., 2002; Gross et al., 2013), precluded use of the 14(15)-EEZE 
antagonist, since the requirement for a molar excess of the antagonist would have resulted in 
a higher residual ethanol concentration yielding artefactual effects in vehicle controls. 
However, although EETs are reported to bind to extracellular sites and indeed may display 
important autocrine and paracrine signalling activity (Spector and Norris 2006), extracellular 
activity of EETs in the current model is inconsistent with the observation that the non-
metabolisable analogue 14(15)-EET-SI failed to confer a similar level of protection against 
palmitate as the free-EET, which may support intracellular activity and the requirement for 
EET esterification to CoA.  
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Other more well-established mechanisms of EET action are their roles as endogenous 
PPAR agonists, particularly PPARγ and, to a lesser extent, PPARα (Liu et al., 2005; Fang et al., 
2006). However, in the current data investigations into the actions of each EET isomers co-
incubated with 250µM palmitate in the presence of PPARα, β/δ, γ antagonists did not 
attenuate EET action. Although a modest reduction in cell viability when assessed by the MTT 
assay was observed in response to palmitate treatment alone and with EETs, the relative 
increase in cell viability between this group and in co-incubation was comparable regardless 
of the presence of the PPAR antagonists. Confirmatory analysis with trypan blue vital dye 
exclusion and MultiCaspase assay with 8(9)-EET supported these observations and although it 
was not feasible to carry out additional confirmatory tests in this way with all EET isomers, 
comparable data in the MTT assay support this observation. With RXR known to be a PPAR 
heterodimer binding partner, HX531 (RXR antagonist), was also used alone and in combination 
with all PPAR antagonists under the same experimental conditions. As with PPAR antagonists 
alone, HX531 did not attenuate EET action, including in combination with the PPAR 
antagonists, further supporting these observations. All PPAR isoforms have been reported to 
be expressed in BRIN-BD11 cells (Welters et al., 2004c), so a lack of PPAR-dependency cannot 
be attributed to lack of expression in the current model. Additionally, the activation of PPARγ 
by TZDs in this cell line has only been observed using supraphysiological concentrations of 
rosiglitazone, at concentrations which failed to attenuate palmitate-induced cell death 
(Welters et al., 2004c).  Similarly, conflicting observations in MIN6 mouse beta cells have 
reported differential effects of TZDs in models of lipotoxicity (Nakamichi  et al., 2003; Saitoh  
et al., 2008; Hong et al., 2018); such differences may be reflective of differential expression 
levels of PPARs and/or co-activator proteins between different beta cell line models (Welters  
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et al., 2004c). Additional studies should determine through use of PPRE luciferase constructs 
whether or not EETs lead to an increase in PPAR activation in BRIN-BD11 cells. 
Others have reported a differential expression of genes associated with FFA 
metabolism in BRIN-BD11 cells in response to AA treatment (Keane et al., 2011). Although 
there is conflicting data in beta cell models on whether changes in lipid handling can alter the 
extent of lipotoxicity (Cnop et al., 2001; Busch et al., 2005; Borg et al., 2009; Sol et al., 2008; 
Sargsyan and Bergsten, 2011) and if this contributes to the cytoprotective effects of mono- 
and poly-unsaturated FFAs (Moffitt et al., 2005; Diakogiannaki et al., 2007; Plotz et al., 2016), 
whether or not similar changes were associated with EET effects were explored in the current 
model. RT-PCR analysis showed that CPT1, Ech1 and DGAT were over-expressed in cells 
treated with palmitate in the presence of each EET, with effects more pronounced with 8(9)-
EET. Collectively, this may indicate increased entry of fatty acids into β-oxidation pathways 
and/or TAG formation, with current data also suporting a modest increase in intracellular lipid 
droplets in response to EET treatment. However, pharamcological inhibition of DGAT or CPT1, 
alone and in combination, did not block the protective effects of EETs against palmitate 
toxicity. A previous study in HIT-T15 beta cells did show that the DGAT inhibitor, Xanthohumol, 
markedly reduced the protective effects of AA against palmitate toxicty at concentrations up 
to 10µM of the inhibitor (Cho et al., 2012). However, this data was only reported from an MTT 
assay, which may be limited in application to studies focused on FFA treatment/metabolic 
dysfucntion, with additional confirmatory analysis required, evident in the current data. 
Although attenuation of AA effects were observed at 10µM Xanthohumol, concentrations of 
20µM were shown to be toxic to the cells, with 1µM producing a measured cell viability 
approaching 75% (Cho et al., 2012), close to the limit of 80-90% achieved with EETs in the 
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current data. Overall this data suggests that whilst an increase in DGAT expression and 
formation of TAG/lipid droplets was observed in BRIN-BD11 cells treated with all EETs in the 
presence of palmitate, that this is dispensible for their cytoprotetive effects. In support of this, 
previous studies have shown that although palmitoleate increased TAG formation in BRIN-
BD11 cells, this was not observed with the poorly metabolisable methyl-ester; a treatment 
which still protected against palmitate-induced loss in cell viability (Diakogiannaki et al., 2007). 
Similarly, previous studies have shown that 200µM Etomoxir failed to block the protective 
effects of palmitoleate after 48 hours (Welters et al., 2004a), with similar effects observed 
with EET treatment, suggesting that increased mitochondrial β-oxidation is not a mode of 
action of EETs against palmitate toxicity. Inhibition of SCD was also explored, this has been 
previously shown to desaturate palmitate into palmitoleate and protect CHO cells against 
apoptosis (Listenberger et al., 2003). However, treatment of BRIN-BD11 cells with 2µM of the 
SCD inhibitor A939572, similar to the CPT1 and DGAT inhibitor did not alter the relative effect 
of EETs in increasing cell viability in response to palmitate. Collectively, this data with a range 
of pharmacological inhibitors suggest that EET action is independent to TAG synthesis or 
enhancement of palmitate β-oxidation.  
In HepG2 cells Zhang et al., (2015) reported that EETs increased fatty oxidation in a 
PPARα and AMPK-dependent manner and although this is in contrast to the current data with 
Etomoxir, alone and in combination with Xanthohumol, whether EET action against 
lipotoxicity occurs via an enhancement of β-oxidation was explored using the palmitate 
derivative, 2-Bromopalmitate. This species has been shown to display toxicity in primary 
culture models exceeding that of palmitate and although it can be esterified to CoA it is not a 
substrate for further metabolic processing in context to TAG synthesis or β-oxidation (Cnop et 
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al., 2001). In cell line models, low concentrations of 2-Bromopalmitate appear well-tolerated 
and may protect against lipotoxicity, likely through sequestration of CoA and inhibition of 
post-translational protein modification by palmitoylation, as well as reported inhibitory action 
at CPT1 (Chase and Tubbs, 1972; Bladwin et al., 2012). Higher concentrations of 2-
Bromopalmitate are toxic to beta cells (Cnop et al., 2001), as demonstrated in the current data 
whereby concentrations exceeding 250µM significantly reduced cell viability in BRIN-BD11 
cells. Similar to the palmitate data, all EET isomers markedly reduced the loss in cell viability 
and increased apoptosis induction in response to 2-Bromopalmitate, suggesting that EET 
action is not via an enhancement of fatty acid oxidation, as suggested by others (Zhang et al., 
2015) and supporting the current data with Etomoxir.  
The poorly metabolisable 14(15)-EET analogue, 14(15)-EET-SI, which contains a 
substituted methyl sulphonamide group insensitive to esterification to CoA, β-oxidation or 
membrane esterification, showed no significant protection against palmitate. In contrast to 
other studies using methyl-ester derivatives and poorly metabolisable mono- and poly-
unsaturated FFAs (Diakogiannaki et al., 2007; Dhayal and Morgan 2011), this data suggests 
that esterification to CoA and/or further metabolic processing is necessary for EET action. 
Although EETs are substrates for membrane esterification to phospholipids, represening an 
important mechanisms controlling cellular levels of free EETs (Klett et al., 2013), EET action in 
the current model was insentive to PLA2 inhibition, suggesting against incorporation/release 
of EETs into phosopholipid pools. EETs are also known to be converted to biologically active 
shortened-chained epoxides and other derivatives, as well as being metabolites for COX and 
LOX enzymes, which may indicate an important contribution of EET metabolites in this model. 
However, whilst 14(15)-EET-SI did not significantly attenuate the palmitate-induced increase 
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in apoptosis, in contrast to 14(15)-EET, the mean apoptosis was reduced to a level not 
significant to either palmiate alone or in the presence of 14(15)-EET. This may indicate that 
higher concentrations of the SI derivative would be required, possibly reflecting a reduction 
in delivery of the analogue to the cells and/or changes in binding affinity to BSA in which the 
EETs were first prepared to maintain the 3.3:1 FFA:BSA ratio during culture. Nonetheless, the 
data demonstrates a limited effect of the EET derivative in the amelioration of palmitate 
toxicity.  
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4.6 Conclusion 
The data collected in this chapter report novel observations of the protective actions 
of 8(9)-EET, 11(12)-EET and 14(15)-EETs against palmitate toxicity in BRIN-BD11 cells as an in 
vitro model of lipotoxicity associated with the pathogenesis of type 2 DM. In agreement with 
others that report reduced activity of the EET vicinal diol products from sEH metabolism; 8(9)-
DHET, 11(12)-DHET and 14(15)-DHET did not exert any protective effects against palmitate 
toxicity. The current data also indicate that EET action appears independent of agonistic 
activity at the extracellular receptors, GPR40 and 120 or intracellular PPAR receptors. Whilst 
this does not preclude that EETs are acting via receptor-mediated agonistic effects, further 
studies are needed to define a specific high-affinity EET putative receptor, or to further 
confirm that activity may be mediated through multiple low-affinity sites. The current data 
from RT-PCR, lipid droplet formation and inhibitor studies targeting SCD1, CPT1 and DGAT 
suggest that although EET actions may modulate intracellular lipid handling, cytoprotective 
effects appear independent to this, supported with data showing protective effects against 2-
Bromopalmitate. Collectively, this suggests that EETs may act at a distal step in the apoptotic 
pathway, possibly via regulation of the release of cytochrome c from the mitochondria 
through alterations in the synthesis of cardiolipin, a mitochondrial phospholipid with activity 
associated with the regulation of apoptosis. It has been suggested that increased levels of 
monounsaturated fatty acids may promote cardiolipin synthesis in beta cells contributing to 
mechanisms of cytoprotection (Welters et al., 2004a). Of note Kiebish et al., (2012) observed 
an increase in cellular EET levels in mice with transgenic over-expression of cardiolipin 
synthase and Ting et al., (2015) showed that treatment of H9C2 cardiac myoblasts with 
polyunsaturated FFAs, including AA, increased cellular cardiolipin content. Although no 
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studies have directly addressed the role of EETs in cardiolipin modelling, this may represent 
an important control point in the regulation of apoptosis by EETs. The current data therefore 
observes, for the first time, that the AA-derived eicosanoids EETs are cytoprotective against 
palmitate toxicity in a beta cell model and supports a rationale for further studies to elucidate 
their mode of action and indeed whether their cytoprotective effects and reported anti-
inflammatory activity can be recapitulated in beta cell models of pro-inflammatory cytokine 
toxicity.  
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Chapter Five  
 
 
 
 
 
 
 
 
 
 
 
 
191 
 
5. Cytoprotective effects of epoxyeicosatrienoic 
acids and their derivatives in in vitro models of type 
1 DM 
 
5.1 Introduction 
 In type 1 DM, pro-inflammatory cytokines are well-documented to contribute to a 
reduction in functional beta cell mass as part of the autoimmune attack during insulitis. The 
presence of CD8+ T-cells and other APCs form the basis of a regimented attack, specifically 
targeting beta cells, resulting in beta cell apoptosis and reduced insulin production (Cardozo 
et al., 2003; Pirot et al., 2008; Willcox et al., 2009). Mechanisms associated with this include 
FasL/FasR binding and the release of the pro-apoptotic factors perforin/granzyme B, pro-
inflammatory cytokines and an increase in NO/ROS (Yoon and Jun, 2005). Treatment of beta 
cell lines with the cytokines IL-1β, IFN-γ and TNF-α in varying concentrations and combinations 
increase cell death and apoptosis via synergistic effects resulting in the induction of several 
known pro-apoptotic pathways. These effects are exerted through activation of NF-κB, IRF-1 
and STAT1, leading to alterations in target gene expression, including iNOS expression and 
subsequent production of NO however, both NO-dependent and NO-independent effects in 
different beta cell and islet models have been reported (Southern et al., 1990; Eizirik et al., 
1996; Cnop et al., 2005). Although limited studies have documented the cytokine response in 
BRIN-BD11 cells, particularly with regards the contribution of cytokine-derived NO production, 
collectively, the data reported in comparison to other cell line models suggest that BRIN-BD11 
cells are less sensitive to NO (Michalska et al., 2010; Hsu et al., 2012). In context to the effects 
of unsaturated FFA species in cell line models of pro-inflammatory cytokine toxicity, previous 
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studies in BRIN-BD11 cells have shown that co-incubation with 500µM palmitoleate 
ameliorates cytokine-induced cell death by ~50%, a response that was not associated with a 
reduction in cytokine-induced NO production, suggesting an NO-independency of cytokine 
toxicity in this model and that unsaturated species may act at a distal step in the apoptotic 
pathway (Welters et al., 2004).  
Whilst EETs have not been studied in the context of pro-inflammatory cytokine toxicity 
in beta cell models, their anti-inflammatory activity is well-documented in other models, with 
8(9)-EET, 11(12)-EET and 14(15)-EET attenuating TNF-α-induced apoptosis in primary rat 
cardiomyocytes (Zhao et al., 2012). In other cardiovascular models IL-1β and TNF-α negatively 
impact the production of EETs and reduce expression of cytochrome p450 2C epoxygenases 
in endothelial cells and 11(12)-EET has been shown to decrease LPS-stimulated PGE2 
production via dose-dependent inhibition of COX-2 (Kessler et al., 1999; Sudhahar et al., 
2010). Mechanistically, the anti-inflammatory action of EETs is, in part, attributed to a 
reduction in NF-κB activation, with studies in endothelial cells observing that treatment with 
11(12)-EET in the presence of TNF-α reduced nuclear accumulation of the p65 subunit of 
activated NF-κB, showing that 11(12)-EET and to a lesser extent 5(6)-EET and 8(9)-EET, but not 
14(15)-EET, prevented the rapid degradation of IκB-α by inhibition of IKK (Node et al., 1999). 
In support of this action, human dermal fibroblasts transfected with NF-κB-responsive IL6 
luciferase reporter vector showed TNF-α induced luciferase activity was reduced in co-
incubation with EETs (Rompe et al., 2010).  
Anti-inflammatory activity of EETs, including their capacity to limit NF-κB activation, 
have been partly attributed to their role as PPAR antagonists, with PPARγ shown to increase 
expression of IκBα, which retains NF-κB in an inactivate state in the cytosol (Scirpo et al., 
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2016). EETs have been shown to dose-dependently antagonise the binding of a radiolabelled 
rosiglitazone to a recombinant PPARγ-LBD and in endothelial cells the inhibitory action of EETs 
against TNF-α-induced IκBα degradation was reduced in the presence of the PPARγ antagonist 
GW9662 (Liu et al., 2005), with similar effects also reported in cardiomyocytes, attenuating 
LPS-induced caspase-3 activation (Zhang et al., 2012; Samokhvlov et al., 2014). Treatment of  
H9C2 cardiomyocytes with 11(12)-EET has also been associated with increased Akt 
phosphorylation and enhanced PI3K expression, effects markedly enhanced with a dual EET 
mimetic and sEH inhibitor, UA-8, and which were blocked by GW9662, again supporting a 
PPARγ-dependent mechanism, (Batchu et al., 2011). Further in vivo studies observed that the 
EET antagonist, 14(15)-EEZE, and PI3K inhibitor, PI-103, attenuated the protective actions of 
EET-mediated improvements in left ventricular functional recovery following ischaemia-
reperfusion, supporting a PI3K-dependent activity of EETs (Batchu et al., 2012). Increased 
activity of the pro-survival PI3K pathway in response to EETs has also been observed to protect 
against apoptosis induction via upregulation of anti-apoptotic Bcl2 and BclxL and down 
regulation of pro-apoptotic Bax (Dhanasekaran et al., 2008), with overexpression of CYP 2J2 
producing comparable EET-dependent results (Zhao et al., 2012). Others have also reported 
that EETs can protect against apoptosis via attenuating a loss in mitochondrial membrane 
potential (Katragadda et al., 2009), effects which may be associated with activation of a 
mitochondrial ATP-sensitive potassium channel (Seubert et al., 2004).  
 
 
 
194 
 
5.2 Aims 
Accumulating evidence supports an important anti-inflammatory action of EETs, with 
activity associated with the modulation of pro-inflammatory signalling pathways, including 
NF-κB activation, though to date no studies have directly explored such activity in a beta cell 
model. Therefore, the aim of this chapter is to investigate the actions of EET and DHET isomers 
in response to pro-inflammatory cytokine toxicity as an in vitro model of type 1 DM in BRIN-
BD11 cells and to explore potential mechanisms of action. Specifically, the aims are to: 
 characterise the actions of EETs and DHETs in response to pro-inflammatory cytokines 
in BRIN-BD11 cells in terms of effects on cell viability and apoptosis induction. 
 investigate whether any effects of EETs and DHETs in response to cytokines are 
associated with changes in cytokine-induced NF-κB activity and nitrite production as 
an indirect assessment of cytokine-induced iNOS expression/activity. 
 further investigate potential mechanisms of EET action in this model using the poorly 
metabolisable analogue of 14(15)-EET; 14(15)-EET-SI and an antagonist of PPARγ. 
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5.3 Method 
Cells were treated with IL-1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) in 
combination; the most pathophysiologically relevant combination and having been previously 
established as appropriate in inducing loss in BRIN-BD11 cell viability (Chapter 3). Cell viability 
was assessed using the trypan blue vital dye exclusion assay since, during preliminary 
investigations (Chapter 3), the use of the MTT assay in the context of cytokine treatment in 
this cell line resulted in low-sensitivity when compared to the neutral red and trypan blue vital 
day exclusion assays. Equally, treatment of BRIN-BD11 cells with media supplemented with 
1% FBS resulted in difficulties in obtaining reproducible results by neutral red assays under 
these conditions. Therefore this method was not considered further here since, in congruence 
with the methods used to study EET/DHET action in response to palmitate treatment (Chapter 
4), all FFA species, including the EET analogue 14(15)-EET-SI, were prepared in BSA (3.3:1 
molar ratio) and diluted to a final assay concentration of 10µM in media supplemented with 
1% FBS for cell treatment. Apoptosis induction was determined by flow cytometry using the 
MUSE™ MultiCaspase assay, as a preferred method in this cell line model compared to the 
Annexin V & Dead Cell assay. Effects of EETs/DHETs on cytokine-induced NF-κB activation were 
determined using the pNL3.2.NF-κB-RE[NlucP/NF-κB-RE/Hygro] reporter vector (Promega) 
transfected into BRIN-BD11 cells using Lipofectamine2000® and activity determined using the 
Nano-Glo® Luciferase Assay System (Chapter 2.7.2), with data expressed as fold-change in 
luminescence units. Nitrite levels were determined using Griess reagent, relative to a sodium 
nitrite standard curve. To determine whether activation of PPARγ was, in part, responsible for 
mediating EET action against cytokine-induced apoptosis, the PPARγ antagonist T0070907 
(2µM) was used in co-incubation studies. 
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5.4 Results 
 Having established the cytoprotective actions of EETs against palmitate-induced 
lipotoxicity in BRIN-BD11 cells, in contrast to their DHET metabolites (Chapter 4), these effects 
were then explored in models of cytokine toxicity. Firstly, the cytoprotective actions of 8(9)-
EET, 11(12)-EET and 14(15)-EET in the presence of IL-1β (100U/mL), IFN-γ (20U/mL) and TNF-
α (500U/mL) in combination were assessed by trypan blue vital dye exclusion (figure 5.1).   
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Figure 5.1. Effects of EETs on cytokine-induced BRIN-BD11 cell death. Cells were treated with IL-1β (100U/mL), IFN-γ 
(20U/mL) and TNF-α (500U/mL) in co-incubation with 10µM 8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-EET for 24 hours, 
before total and viable cell numbers were assessed by trypan blue vital dye exclusion. Values are represented as mean (+/- 
SEM), n=3. *P<0.05 relative to corresponding control and #P<0.05 relative to corresponding cytokine treatment alone as 
determined by two-way ANOVA and Bonferroni’s post-test. 
 
 Treatment with cytokines for 24 hours witnessed a significant decrease in BRIN-BD11 
viable cell number compared to control from 0.79 x106 cells/mL (+/-0.02) to 0.33 x106 cells/mL 
(+/-0.01) (P<0.05), confirming earlier work during preliminary investigations (Chapter 3). Co-
incubation with each EET isomers and cytokines resulted in a significant increase in viable cell 
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number from 0.33 x106 cells/mL (+/- 0.01) to 0.64 x106 cells/mL (+/-0.04) for 10µM 8(9)-EET, 
0.61 x106 cells/mL (+/-0.03) for 10µM 11(12)-EET and 0.59 x106 cells/mL (+/-0.02) for 10µM 
14(15)-EET (P<0.05). Treatment with 8(9)-EET and 11(12)-EET in combination with cytokines 
resulted in no significant decrease in viable cells compared to control (P>0.05), suggesting 
complete protection from cytokine toxicity in the presence of these two EETs however, in the 
presence of 14(15)-EET viable cell number remained significantly lower than control (P<0.05). 
To further establish the protective effects of EETs in this models, BRIN-BD11 cells were 
assessed for apoptosis induction when treated with cytokines co-incubated with 10µM 8(9)-
EET, 11(12)-EET, or 14(15)-EET, assessed by MUSE™ MultiCaspase (figure 5.2).  
Cytokines in combination resulted in a significant increase in apoptosis compared to 
control from 14.1% (+/-2.2) to 35.4% (+/-5.7) (P<0.05). Furthermore, co-incubation with 10µM 
of each EET resulted in a significant decrease in total apoptosis from 35.4% (+/-5.7) to 18.5% 
(+/-1.9) for 8(9)-EET, 19.1% (+/-2.0) for 11(12)-EET and 19.3% (+/-1.9) for 14(15)-EET (P<0.05). 
Broadly in agreement with effects of EETs on cell viability, there was no significant increase in 
apoptosis above control in all co-incubation groups, suggesting complete protection from 
cytokine-induced beta cell toxicity (P>0.05).  
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Figure 5.2. Effects of EETs on cytokine-induced apoptosis in BRIN-BD11 cells. Cells were treated with IL-1β (100U/mL), IFN-
γ (20U/mL) and TNF-α (500U/mL) in combination co-incubation with either 10µM 8(9)-EET, 10µM 11(12)-EET or 10µM 14(15)-
EET for 24 hours before total apoptosis profile (A) was assessed by flow cytometry with the MUSE™ MultiCaspase assay. 
Panels B-F show representative apoptosis profiles of cells under each treatment condition. Values in panel (A) are mean (+/- 
SEM), n=3. *P<0.05 relative to control and #P<0.05 relative to cytokines alone as determined by one-way ANOVA and Tukey’s 
post-test. 
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With all EET isomers showing protective actions against cytokines toxicity, trypan blue 
vital dye exclusion and MUSE™ MultiCaspase assays were then used to assess any effects of 
their corresponding DHETs; 10µM 8(9)-DHET, 11(12)-DHET, or 14(15)-DHET (figures 5.3 and 
5.4). 
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Figure 5.3. Effects of DHETs on cytokine-induced BRIN-BD11 cell death. Cells were treated with IL-1β (100U/mL), IFN-γ 
(20U/mL) and TNF-α (500U/mL) in co-incubation with 10µM 8(9)-DHET, 10µM 11(12)-DHET or 10µM 14(15)-DHET for 24 
hours before total and viable cell numbers were assessed by trypan blue vital dye exclusion. Values are represented as mean 
(+/- SEM), n=3. *P<0.05 relative to corresponding control and #P<0.05 relative to corresponding cytokines alone as 
determined by two-way ANOVA and Bonferroni’s post-test. 
 
Remarkably, 8(9)-DHET significantly increased viable cell numbers compared to 
corresponding cytokine treatment alone from 0.33 x106 cells/mL (+/-0.01) to 0.67 x106 
cells/mL (+/-0.01), an over 2-fold increase. As with the lipotoxicity model (Chapter 4), 11(12)-
DHET and 14(15)-DHET failed to ameliorate cytokine-induced loss in cell viability. 
Furthermore, co-incubation with 10µM of each DHET resulted in a significant decrease in total 
apoptosis only with 8(9)-DHET from 41.33% (+/-4.5) to 21.71% (+/-2.4) (P<0.05), with 11(12)-
DHET and 14(15)-DHET showing no significant decrease in total apoptosis (P>0.05). 
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Figure 5.4 Effects of DHETs on cytokine-induced apoptosis in BRIN-BD11 cells. Cells were treated with IL-1β (100U/mL), IFN-
γ (20U/mL) and TNF-α (500U/mL) in combination co-incubation with either 10µM 8(9)-DHET, 10µM 11(12)-DHET or 10µM 
14(15)-DHET for 24 hours before total apoptosis profile (A) was assessed by flow cytometry with the MUSE™ MultiCaspase 
assay. Panels B-F show representative apoptosis profiles of cells under each treatment condition. Values in panel (A) are 
mean (+/- SEM), n=3. *P<0.05 relative to control and #P<0.05 relative to cytokines alone as determined by one-way ANOVA 
and Tukey’s post-test. 
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With 8(9)-DHET unexpectedly showing similar protective effects to EETs, apoptosis 
induction was re-assessed to confirm this observation and provide a direct comparison 
between EETs and 8(9)-DHET (figure 5.5). 
C
o n
tr
o l
C
y t
o k
in
e s
1 0
µ
M
 8
(9
)-
E E
T
1 0
µ
M
 1
1 (
1 2
)-
E E
T
1 0
µ
M
 1
4 (
1 5
)-
E E
T
1 0
µ
M
 8
(9
)-
D
H
E T
0
1 0
2 0
3 0
4 0
5 0
%
 A
p
o
p
to
s
is
IL - 1  +  IF N -+  T N F -
* *
*
#
#
#
#
 
Figure 5.5. Effects of EETs and 8(9)-DHET on cytokine-induced apoptosis. Cells were treated with IL-1β (100U/mL), IFN-γ 
(20U/mL) and TNF-α (500U/mL) in combination co-incubated with either 10µM 8(9)-EET, 10µM 11(12)-EET, 10µM 14(15)-EET 
or 10µM 8(9)-DHET for 24 hours before apoptosis induction was assessed by flow cytometry with the MUSE™ MultiCaspase 
assay. Values are represented as mean (+/- SEM), n=3. *P<0.05 relative to control and #P<0.05 relative to cytokines alone as 
determined by one-way ANOVA and Tukey’s post-test. 
 
Treatment with cytokines in combination with 10µM 8(9)-EET, 10µM 11(12)-EET, 
10µM 14(15)-EET and 10µM 8(9)-DHET resulted in a significant decrease in apoptosis from 
45.6% (+/-1.6) to 25.5% (+/-0.8), 29.6% (+/-2.6), 29.8% (+/-3.9) and 23.4% (+/-2.8) (P<0.05), 
respectively, confirming the previous data on their protective effects (figure 5.2). 
Interestingly, 8(9)-DHET produced the largest decrease in apoptosis compared to all EETs, 
however there was no significance between EET and DHET treatments (P>0.05), confirming 
the surprising protective effects of 8(9)-DHET against cytokine toxicity.  
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With EETs reported to reduce NF-κB activity in other models, NF-κB activation was 
assessed using a NF-kB luciferase reporter assay in BRIN-BD11 cells treated with cytokines in 
combination, co-incubated with 10µM 8(9)-EET, 10µM 11(12)-EET and 10µM 14(15)-EET for 
24 hours (figure 5.6). 
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Figure 5.6. Effects of EETs on cytokine-induced NFκB activity in BRIN-BD11 cells. Cells were treated with IL-1β (100U/mL), 
IFN-γ (20U/mL) and TNF-α (500U/mL) in combination co-incubation with either 10µM 8(9)-EET, 10µM 11(12)-EET or 10µM 
14(15)-EET for 24 hours before NF-κB activity was assessed using a NF-κB Luciferase Reporter assay. Values are represented 
as mean fold change in luminescence units relative to control (+/- SEM), n=5. *P<0.05 compared to cytokines as determined 
by one-way ANOVA and Tukey’s post-test. 
 
 Treatment with cytokines alone resulted in a significant increase in NF-κB activity 3.9-
fold compared to control (P<0.05) which was significantly reduced by ~34% in co-incubation 
with each EET isomer (P<0.05), though this remained elevated over 2-fold above control. With 
all EETs showing a significant decrease in NF-κB activity, investigations into whether this was 
also associated with a decrease in nitrite production, likely by a reduction in iNOS expression, 
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nirite levels were assessed by Griess assay over 24 and 48 hours (figure 5.7); this data was 
additionally collected in cells treated with different cytokine combinations. 
  
 
As with preliminary investigations, treatment of BRIN-BD11 cells with varying 
combinations of cytokines resulted in a significant increase in nitrite production compared to 
untreated cells over both 24 and 48 hours (P<0.05), with the combination of all three cytokines 
Figure 5.7. Nitrite production in BRIN BD11 cells exposed to cytokines co-incubated with EETs. Cells were treated with IL-
1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) in different combination with or without 10µM of each EET for 24 (panels 
A, C, E) or 48 (panels B, D, F) hours before nitrite production was assessed by Griess reagent. Values are represented as mean 
(+/- SEM), n=3. *P<0.05 relative to corresponding control and #P<0.05 relative to corresponding cytokine treatment alone as 
determined by two-way ANOVA and Bonferroni’s post-test.   
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producing the largest increase. The addition of 10µM of all EETs resulted in a significant 
decrease in nitrite production compared to their corresponding cytokine treatments after 
both 24 and 48 hours (P<0.05), with the exception of the combination of IL-1β plus IFN-γ after 
48 hours (P>0.05). This is a surprising, yet consistent observation that all EETs failed to reduce 
nitrite production in treatment with IL-1β plus IFN-γ in combination for 48 hours, despite 
attenuating the higher level of nitrite production on the addition of TNF-α with all three 
cytokines.  This may indicate a maximum level of iNOS activity in the presence of EETs, 
regardless of the presence of TNF-α, given the similar nitrite levels in these groups.  
Nonetheless, the data suggests that, likely as a result of a decrease in NF-κB activity, iNOS 
expression/activity is also reduced under these conditions, which is most evident after 24 
hours. A diminishing effect in prolonged culture up to 48 hours may reflect a reduction in 
available EETs, or that higher concentrations may be required, though it was not feasible to 
explore this in the current study.  
 With each EET isomer reducing NF-κB activity and nitrite production, and 8(9)-DHET 
showing protective actions against cytokine-induced toxicity, BRIN-BD11 cells were then 
assessed for NF-κB activity in co-incubation with cytokines and all DHET isomers (figure 5.8). 
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Figure 5.8. Effects of DHETs on cytokine-induced NF-κB activity in BRIN-BD11 cells. Cells were treated with IL-1β (100U/mL), 
IFN-γ (20U/mL) and TNF-α (500U/mL) in combination co-incubation with either 10µM 8(9)-DHET, 10µM 11(12)-DHET or 10µM 
14(15)-DHET for 24 hours before NF-κB activity was assessed using a NF-κB Luciferase Reporter assay. Values are represented 
as mean fold change in luminescence units relative to control (+/- SEM), n=3. *P<0.05 compared to cytokines as determined 
by one-way ANOVA and Tukey’s post-test. 
 
 The addition of 10µM 8(9)-DHET reduced the ~3-fold increase in NF-κB activity induced 
by cytokines by ~32% (P<0.05), similar to the 34% reduction in activity observed in co-
incubation with 8(9)-EET (figure 5.5), confirming the positive effect of 8(9)-DHET against 
cytokine toxicity. However, the addition of 11(12)-DHET or 14(15)-DHET failed to significantly 
reduce NF-κB activity (P>0.05). As with EETs, DHET actions were further explored through 
assessment of their effects on cytokine-induced nitrite production over 24 hours (figure 5.9).  
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Treatment of BRIN-BD11 cells with IL-1β, IFN-γ and TNF-α in combination resulted in a 
significant increase in nitrite levels compared to control (P<0.05) however, unlike their EET 
counterparts, all DHETs failed to reduce nitrite production (P>0.05 vs. cytokine treatment 
alone). Although 8(9)-DHET reduced NF-κB activity by 32% compared to cytokines alone, this 
was not associated with changes in iNOS activity, and may suggest a differential mode of 
action of distinct EET/DHET species.  
The effects of EETs on NF-κB activity have been (partly) attributed to their action as 
PPARγ agonists in other models, therefore the selective antagonist of PPARγ, T0070907 was 
used in co-incubation with cytokines and all EETs or 8(9)-DHET to determine whether this 
would reduce their effects against cytokine-induced apoptosis (figure 5.10).   
 
 
Figure 5.9 Nitrite production in BRIN-BD11 cells exposed to cytokines co-incubated with DHETs. Cells were treated with IL-
1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) in combination co-incubation with 10µM of each DHET for 24 hours 
before nitrite production was assessed by Griess reagent. Values are represented as mean (+/- SEM), n=3. *P<0.05 relative 
to control as determined by one-way ANOVA and Tukey’s post-test.   
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Figure 5.10. Effects of the PPARγ (T0070907) antagonist on the protective actions of EETs and 8(9)-DHET against cytokine-
induced apoptosis. Cells were treated with IL-1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) in combination co-
incubated with 10µM of each EET or 8(9)-DHET in the presence or absence of 2µM T0070907 for 24 hours before total 
apoptosis was assessed by flow cytometry using the MUSE™ MultiCaspase assay. Values are represented as mean (+/- SEM), 
n=3. *P<0.05 relative to control and #P<0.05 relative to corresponding cytokine treatment as determined by two-way ANOVA 
and Bonferroni’s post-test 
 
As with previous data, a significant increase in apoptosis was observed in response to 
cytokine treatment alone as compared to control (P<0.05). Similarly, co-incubation with 
cytokines and either 8(9)-DHET or each EET isomer resulted in a significant decrease in 
apoptosis compared to cytokine treatment alone (P<0.05). However, the addition of 2µM 
T0070907 failed to alter the ability of EETs or 8(9)-DHET to protect against cytokine-induce 
apoptosis, similar to data obtained with investigations into the role of PPARγ in this context in 
the lipotoxicity model (Chapter 4).  
 
 
208 
 
Previous data with the use of the poorly metabolisable EET analogue, 14(15)-EET-SI, 
showed no significant protection against palmitate toxicity, suggesting, in part, that 
cytoprotective effects of EETs in BRIN-BD11 cells may arise from EETs being able to undergo 
additional metabolic processing. With clear differences in mechanisms of cytotoxicity in terms 
of the nature of the apoptotic stimuli between cellular models of type 1 and 2 DM, 
investigations into the actions of 14(15)-EET-SI against cytokine toxicity were also explored by 
apoptosis assessment and trypan blue vital dye exclusion (figure 5.11). 
 
 
 
Treatment of BRIN-BD11 cells with IL-1β, IFN-γ and TNF-α in combination resulted in a 
significant decrease in viable cell numbers and a significant increase in apoptosis compared to 
control (P<0.05), as expected. Similarly, co-incubation with 10µM 14(15)-EET significantly 
increased viable cell number compared to cytokine treatment alone and significantly 
decreased apoptosis levels (P<0.05). Furthermore, co-incubation with 14(15)-EET-SI produced 
a comparable effect to the free-EET, attenuating both the decrease in viable cell number and 
increased apoptosis levels (P<0.05 vs. cytokines alone), with no significant difference between 
Figure 5.11 Effects of 14(15)-EET or 10µM 14(15)-EET-SI against cytokine-induced loss in viability and apoptosis induction. 
Cells were treated with IL-1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) in combination co-incubated with 10µM 
14(15)-EET or 10µM 14(15)-EET-SI for 24 hours. Total and Viable cell numbers was assessed by trypan blue exclusion dye (A) 
and apoptosis profiling assessed by MUSE™ MultiCaspase (B). Values are represented as mean (+/- SEM), n=3. *P<0.05 
relative to cytokines as determined by two-way ANOVA and Bonferroni’s post-test (A) or one-way ANOVA and Tukey’s post-
test (B). 
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the two EET treatments (P>0.05). Treatment with 14(15)-EET-SI in models of palmitate toxicity 
showed no protective effect, however the result in this model of cytokine toxicity, suggests 
that EETs may act differently depending on the type of in vitro investigations and nature of 
the apoptotic stimuli.   
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5.5 Discussion 
 The aims of this chapter were to characterise the response of BRIN-BD11 cells to pro-
inflammatory cytokines in co-incubation with EETs and their corresponding diols, DHETs, to 
reflect potential anti-inflammatory actions in an in vitro model of type 1 DM. Additionally, this 
chapter also aimed to investigate whether effects of EETs and DHETs were associated with 
changes in NF-κB activity and subsequent NO production/nitrite accumulation, as well as 
establishing any PPARγ-dependency.  
 With EETs shown to protect BRIN-BD11 cells against palmitate-induced lipotoxicity 
(Chapter 4), similar investigations into the protective effects of EETs and DHETs were assessed. 
Since preliminary studies (Chapter 3) highlighted lack of sensitivity of the MTT assay in context 
to cytokine toxicity and the neutral red assay in models of fatty acid (and EET) treatment, these 
were not considered here. With all EET isomers observed to significantly attenuate a cytokine-
induced loss in cell viability and apoptosis induction in BRIN-BD11 cells, the current data 
provides the first direct assessment of the cytoprotective effects of EETs in a beta cell context, 
in agreement with anti-inflammatory activity reported in other models (Liu et al., 2005; 
Rompe et al., 2010; Zhao et al., 2012) and in contrast in the lack of effect of AA against cytokine 
toxicity in BRIN-BD11 cells (Chapter 3).  
Whilst others have shown that potential manipulation of endogenous EET levels 
through inhibition or knockdown of sEH can improve glucose tolerance and functional beta 
cell mass in STZ-induced DM in mice (Luo et al., 2010; Chen et al., 2013), the current data 
directly links EET action to the inhibition of pro-inflammatory cytokine toxicity; 
pathophysiologically relevant inducers of beta cell death and dysfunction. Both of these 
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previous studies used a multiple-low-dose regime to induce DM with STZ, a process which is 
thought to initiate an inflammatory response in islets leading to beta cell loss via cell-mediated 
autoimmune processes, broadly comparable to the pathophysiology of type 1 DM and 
attributed, in part, to the presence of pro-inflammatory cytokines (Graham et al., 2011). 
However, whilst Luo et al., (2010) observed a marked reduction in apoptotic cells of sEH 
knockout mice with STZ-induced DM, no direct assessment of any islet infiltrate (or lack of) 
was measured, nor were ex vivo islet beta cells studied for their response to EETs in context 
to cytokine toxicity. Additionally, although a complementary approach to sEH inhibition 
and/or sEH knockout was used, pancreatic levels of EETs were not measured, which would 
have allowed direct inference of improved beta cell mass consequential to increased 
endogenous EET levels; though an enhancement of plasma EET:DHET ratios has been reported 
by others in sEH knockout models (Seubert et al., 2006). Similar data was reported by Chen et 
al., (2013), demonstrating a reduction in apoptotic cells in islets of STZ models with sEH 
inhibition, though this study failed to detect differences in pancreatic EET:DHET ratios, 
questioning whether the effects were reflective of EET action, further supporting that the 
current data represents a novel observation for the cytoprotective effects of EETs against 
cytokine toxicity in a beta cell model.  
 The previous data in the lipotoxicity model (Chapter 4) supported observations by 
others that DHETs displayed reduced activity to their respective EETs (Imig and Hammock, 
2009), with no effect against palmitate-induced cytotoxicity. However, in the current model 
of pro-inflammatory cytokine toxicity, 8(9)-DHET exerted comparable effects against cytokine-
induced beta cell death and apoptosis compared to the effect of 8(9)-EET. In contrast, whilst 
11(12)-DHET and 14(15)-DHET showed a modest increase in viable cell number, they failed to 
212 
 
significantly attenuate cytokine toxicity. Although it is widely reported that DHET products of 
sEH action on EETs are considerably less active, Fang et al., (2006) showed that 14(15)-DHET 
was as potent as a the full agonist, Wy-14643, in the activation of PPARα. Others have also 
reported that 14(15)-DHET displays weak binding to a putative EET receptor (Yang et al., 2008) 
and that this and 11(12)-DHET may also display activity in the regulation of Ca2+-activated K+ 
channels (Lu et al., 2001), though no reports have assessed 8(9)-DHET in this context. This may 
therefore indicate differential actions of EETs/DHETs in a cell-specific manner, possibly 
attributed to variation in expression of membrane receptors capable of binding, albeit with 
low affinity, to EETs/DHETs, or intracellular targets including PPAR isoforms. Whether these 
receptors display differential affinity across all EET and DHET isomers is yet to be clearly 
established but could account for the surprising observation in this study that 8(9)-DHET 
conferred similar protection against cytokine-induced cell death as 8(9)-EET, unlike other 
DHET isomers. Such an observation warrants further investigation, since this suggests 
differential activity of distinct EET/DHET species, which may also be reflective of the specific 
apoptotic stimuli, given the lack of DHET activity against palmitate toxicity.   
 Further to the protective effects of EETs and 8(9)-DHET against pro-inflammatory 
cytokine-induced cell death and apoptosis, the current data supports observations in other 
models that EETs can inhibit a cytokine-induced increase in NF-κB activity (Node et al., 1999; 
Liu et al., 2005; Rompe et al., 2010; Zhao et al., 2012). All EETs reduced NF-κB activation by 
~34% in response to cytokine treatment, with a comparable ~32% reduction in activity with 
8(9)-DHET, supporting the surprising action of this species, but not 11(12)-DHET or 14(15)-
DHET, in the attenuation of cytokine toxicity. Protective effects of EETs were also mirrored in 
the reduction of cytokine-stimulated increases in nitrite levels, reflective of iNOS activity. 
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These effects were more evident after 24 hours, with the nitrite levels in treatment with IL-1β 
plus IFN-γ in combination after 48 hours not being significantly altered by EET treatment, 
whereas despite the addition of TNF-α increasing nitrite further, levels were significantly 
reduced, albeit to a level similar to that with the IL-1β plus IFN-γ treatment. Collectively, this 
may suggest that the reduction in NF-κB activity contributes to a decrease in iNOS expression, 
reducing nitrite levels, with the overall relative decrease in effect compared to cytokine 
treatment alone at 48 hours compared to 24 hours suggesting the EET concentration may 
become limiting in prolonged culture. The observations that nitrite levels in the presence of 
EETs appeared to reach a maximum level after 48 hours, regardless of co-stimulatory cytokine 
activity on NF-κB and STAT may support [EETs] as a limiting factor for the regulation of iNOS 
expression, though NF-κB activity was not measured at 48 hours it may be expected that the 
relative decrease in activity by EETs would be smaller than the ~34% reduction after 24 hours. 
However, whether the EET effects on nitrite levels can be directly attributed to the inhibition 
of NF-κB activity is questionable given that with 8(9)-DHET treatment nitrite levels were 
unchanged, despite a comparable reduction in NF-κB activity. Together, this would suggest 
that changes in NF-κB activation are a likely contributing factor in the attenuation of cytokine 
toxicity by EET and 8(9)-DHET but that these effects are independent of iNOS expression and 
NO production. Similarly, Welters et al., (2004a) showed that palmitoleate could protect BRIN-
BD11 cells against cytokine toxicity but that this was independent of a reduction in nitrite 
levels, which supports data from others suggesting that cytokine toxicity does not require NO 
generation in these cells (Hsu et al., 2012). Given the variation in effect of EETs or 8(9)-DHET 
on nitrite levels, this may indicate additional differential modes of action of these species, 
possibly in terms of potential receptor binding activity, though little is known about the 
mechanisms of 8(9)-DHET action.  
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 Since EET activity is, in part, attributed to agonistic activity at PPARγ (Liu et al., 2005), 
investigations into the contribution to protective actions against cytokines in the current 
model were explored using the PPARγ antagonist (T0070907). However, similar to the actions 
of EETs in the previous lipotoxicity model, the application of T0070907 failed to antagonise 
the protective actions of EETs and 8(9)-DHET, suggesting PPARγ-independent activity. This 
may indicate that effects in this model are either attributed to the regulation of a distal step 
in the apoptotic pathway via undefined EET activity, which could be in relation to effects on 
cardiolipin modelling and the regulation of the release of apoptotic factors from the 
mitochondria. However, this is inconsistent with the observation that 14(15)-EET-SI similarly 
protected against cytokine-induced apoptosis, in contrast to the data from palmitate 
treatment (Chapter 4), suggesting that EET-CoA esterification is not a requirement for 
cytoprotection in the current model. This, and the observations that effects of EETs appear 
PPARγ-independent may suggest that mechanisms of action are via extracellular receptor 
activation, thought to be associated with Gαs signalling, increasing cellular cAMP levels (Yang 
et al., 2008). In support of this hypothesis, cAMP levels have also been linked to an inhibitory 
effect on NF-κB activity, mediated via PKA activation (Minguet et al., 2005) and the GPCR 
kinase 5 has been shown to inhibit NF-κB activation in endothelial cells, attributed to nuclear 
retention of IκBα and impaired transcriptional activity of NF-κB (Sorriento et al., 2008). 
Potential activity of EETs at multiple low affinity GPCR sites known to mediate prostaglandin 
signalling, via cAMP levels (Lui et al., 2017) may similarly support this as a mode of EET action 
in the current model of cytokine toxicity, though if such a spectrum of receptor sites is 
mediating the effect, then it will be difficult to fully dissect the pathways involved. 
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 5.6 Conclusion 
 The data collected in this chapter report the novel observations that 8(9)-EET, 11(12)-
EET, 14(15)-EET and, surprisingly, 8(9)-DHET protect BRIN-BD11 cells from pro-inflammatory 
cytokine-induced beta cell death as a model of type 1 DM. Furthermore, this is associated with 
a down regulation of NF-κB activity by >30% and appears to be mediated by a PPARγ-
independent mechanism. The effect of 8(9)-DHET in this context is particularly interesting, 
since activity of DHETs are less well documented and comparatively few studies have directly 
assessed a role of 8(9)-EET and 8(9)-DHET, in contrast to other isomers (Pozzi et al., 2005). The 
current data therefore suggests that although the 8(9)- species may represent a minor product 
of the endogenous EET (and DHET) pool produced by CYP450 epoxygenases, these possess 
comparable biological activity to the more well-studied 11(12)- and 14(15)- species. Further 
work is needed to define the modes of action of distinct EET/DHET species, since some have 
shown that, independent to PPARγ, these may also signal through PPARα, which may display 
greater activity than 14(15)-DHET than EETs, though this species was inactive in the current 
model. Additionally, others have noted that anti-inflammatory actions of EETs in terms of iNOS 
activity in smooth muscle cells appears to be independent to the activation of all thee PPAR 
isoforms (Thompson and Bishop-Bailey, unpublished observations, cited in Thompson et al., 
2015) and so a better understanding of their mechanisms of action is needed. Whether activity 
at a single high-affinity or multiple low-affinity receptor site(s) is responsible is yet to be fully 
established, a wider range of EET analogues may be used to study this further. Of note, the 
current data with the more stable, poorly metabolisable EET analogue, 14(15)-EET-SI, suggest 
that EET-esterification to CoA, EET β-oxidation or esterification into the phospholipid pool is 
not a requirement for cytoprotection, in contrast to the result observed in the previous 
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lipotoxicity model (Chapter 4), this may therefore indicate a differential mode of action 
dependent on the nature of the apoptotic stimuli. In the current model of cytokine toxicity, 
EETs may be regulating PI3K/Akt activity and/or downstream apoptosis regulators, Bcl-2, Bcl-
xL and Bax, as suggested by others (Dhanasekaran et al., 2008; Katragadda et al., 2009; Batchu 
et al., 2012), though further investigations would be needed to confirm this. The current data 
therefore observes, for the first time, that EETs and 8(9)-DHET protect against cytokine-
induced cell death in a beta cell line, effects partly associated with an inhibition of NF-κB 
activity, providing a rationale for further study in their mechanisms of action in this context. 
Additionally, it is also yet to be determined whether manipulation of endogenous EET levels 
can confer similar activity; given the uncertainty regarding a direct EET action in in vivo DM 
models with sEH inhibition (Luo et al., 2010; Chen et al., 2013), studies focussing on the over-
expression of CYP450 epoxygenases in beta cell models of cytotoxicity are warranted.   
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Chapter Six  
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6 Overexpression of CYP 2C11 in in vitro models of 
type 1 and 2 DM 
 
6.1 Introduction 
 With exogenous application of 8(9)-EET, 11(12)-EET and 14(15)-EET showing protective 
actions against palmitate and cytokine-induced beta cell death and apoptosis, and 8(9)-DHET 
showing comparable effects in the cytokine model in BRIN-BD11 cells, investigations into 
modulation of endogenous levels of EETs were explored by over-expression of CYP 2C11. 
Several CYP isoforms have been reported to produce EETs through selective epoxidation of 
AA, with CYP 2J and CYP 2C isoforms reported to be expressed in islets (Imig and Hammock, 
2009), particularly CYP 2C11 where higher expression than 2J3 in comparison to kidney was 
report in one study (Chen et al., 2013). CYPs are known for their contribution to oxidative 
metabolism of many drugs and carcinogenic chemicals, as well as endogenous roles in steroid 
and prostaglandin synthesis, and are usually expressed in the ER. CYPs are predominantly 
expressed in the liver, though several isoforms show wider tissue-distribution and catalyse 
monoxygenase biotransformation reactions, requiring molecular oxygen and reducing one 
oxygen atom to water whilst incorporating the other atom into an organic product (Huang  et 
al., 2016). The reaction mechanism of CYPs require a four part component system: the CYP 
enzyme; consisting of a haem prosthetic group, NADPH CYP450 reductase, cytochrome b5 and 
phosphatidylcholine (White, 1991; Huang et al., 2016). Substrate molecules bind to the active 
heme with the iron in a 3+ (ferric) oxidation state, this binding changes the redox potential 
facilitating single electron transfer from the reductase domain, requiring FAD and FMN as 
electron donors, reducing the iron to a 2+ (ferrous) oxidation state. Molecular oxygen then 
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binds, abstracting an electron from the higher spin heme iron, followed by the transfer of a 
second electron from the reductase domain, activating the oxygen for scission.   
A role for EETs in beta cell and islet function was first reported by Falck et al., (1983), 
whereby 1µM 5(6)-EET, but not 8(9)-EET, 11(12)-EET or 14(15)-EET,  induced insulin secretion 
from beta cells, though all EETs were able to induce glucagon release by alpha cells. Though 
later studies (Klett et al., 2013) observed an inhibitory action of EETs on insulin, which was not 
explored in the current study, this thesis has reported on the novel cytoprotective effects of 
EETs in BRIN-BD11 cells. Others have reported on the in vivo manipulation of endogenous EET 
levels in positively regulating dysglycaemia and dyslipidaemia in context to insulin action, with 
over-expression of CYP 2J3 in mice models increasing 14(15)-EET levels and potentiating 
insulin receptor signalling in kidney, heart, muscle and liver, resulting in improved insulin 
sensitivity (Zeldin  et al., 1997; Xu  et al., 2010). Whilst there is limited direct evidence for 
functional roles of EETs and DHETs in vitro and in vivo models reflecting the pathophysiology 
of beta cell dysfunction in type 1 and 2 DM, the first in vivo investigations by Luo et al., (2010) 
showed sEH knockout in STZ-mice increased insulin secretion and prevented hyperglycaemia, 
associated with increased beta cell mass, with application of the sEH inhibitor t-AUCB 
producing similar findings. Similar results were also reported in a later study (Chen et al., 2013) 
and together suggest that strategies aimed at altering the EET to DHET ratio may produce 
beneficial effects on beta cell function as observed with exogenous EET application in the 
current data. Moreover, whilst in other model systems over-expression of relevant CYP-
epoxygenases increase EET levels and produce comparable functional activity to exogenous 
EET application, such a role, including with rat CYP 2C11, has not been investigated in a beta 
cell context. 
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6.2 Aims 
 Having established protective effects of exogenous EET treatment in BRIN-BD11 cells 
against palmitate and pro-inflammatory cytokines, the aim of this chapter is to establish 
whether these effects can also be achieved through manipulation of endogenous EET levels 
by over-expression of rat CYP 2C11. Specifically, the aims are to: 
 generate a BRIN-BD11 cell line with stable over-expression of CYP 2C11 and 
appropriate vector-controls. 
 characterise the response of the stable 2C11 expressing cells to lipotoxicity and pro-
inflammatory cytokine exposure, including in the presence of the endogenous 2C11 
substrate, AA. 
 explore the effects of sEH inhibition in increasing endogenous EET levels in 2C11 
expressing cells. 
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6.3 Methods 
 Initially, transient transfection of a pCMV6-2C11 vector was trialled however, the 
requirement to maintain cultures for up to 48 hours post-transfection prior to re-plating for 
24 hours prior to treatment with test agents may result in significant loss of transgene 
expression, particularly approaching 96-hours post-transfection, further hampered by the 
short doubling time of ~20 hours of BRIN-BD11 cells. Therefore, stable cell lines were 
generated as described in Chapter 2 (section 2.7.3), stable lines transfected with the pCMV6 
empty vector were also produced, with cells maintained in Geneticin (G481) (1µg/mL)-
supplemented complete media. Successful stable expression of CYP 2C11 was confirmed by 
Western blotting using a mouse mono-clonal mouse anti-rat 2C11 antibody (1:1000) following 
separation of proteins on 12% resolving gels, all other processing steps were as described 
(Chapter 2.8). The response of the cells to the cytotoxic action of palmitate (dose response 
(15.625µM-1000µM) or a fixed 250µM) or cytokines (100U/mL IL-1β, 20U/mL IFN-γ and 
500U/mL TNFα) were determined using the MTT assay and by flow cytometry with the MUSE™ 
MultiCaspase assay. In the palmitate model, effects of 2C11 over-expression on cell viability 
were also explored in the presence of increasing concentrations of AA (0.156-20µM) or 10µM 
of the sEH inhibitors t-AUCB or TPPU.  
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6.4 Results 
 Following transfection of BRIN-BD11 cells with relevant vectors and isolation of 
colonies by G418 selection, four cell lines from CYP 2C11 (arbitrarily designated 2C11-1 – 
2C11-4) and two cell lines from vector-only transfections were generated. Before proceeding 
with cytotoxicity studies, these were evaluated for the expression of CYP 2C11 by Western 
blotting (figure 6.1). 
 
 
 
 
Figure 6.1 Expression of rat CYP 2C11 in stable-transfected BRIN-BD11 cells. Cells were transfected with either pCMV6-rat-
CYP2 C11, or corresponding empty vector (EV) and single cell lines selected and expanded by G418 selection. Cell lysates were 
separated on 12% resolving gels followed by transfer to PVDF membranes and probed with primary antibodies for rat 2C11 
(1:1000) or β-actin (1:1000), followed by detection using an HRP-conjugated secondary antibody (1:1000) and ECL blot 
imaging. A representative blot image is shown where n=3.  
 
Analysis of the expression level of CYP 2C11 in EV1 and 2 BRIN-BD11 cell lines showed 
no CYP 2C11 expression, suggesting lack of expression of this epoxygenase in these cells. Of 
the four stable CYP 2C11- transfected cell lines established 2C11-1 and -2 showed no 
successful transfection/over-expression of CYP 2C11 enzyme at the protein level, which may 
indicate lack of successful integration and/or low expression of the construct. In contrast, the 
2C11-3 and -4 cell lines both demonstrated successful generation of two stable cells, 
consistently showing a differential level of 2C11 expression, with clone line -3 having a higher 
expression than clone line -4. To establish whether stable over-expression in either of these 
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two lines could attenuate palmitate cytotoxicity, cells were incubated in the presence of a 
palmitate dose response for 24 hours and viability assessed with the MTT assay and MUSE™ 
MulitCaspase assay using a fixed 250µM palmitate (figure 6.2).   
 
 
 
 
 
 
 
 
 
 
Increasing concentrations of palmitate resulted in a dose-dependent reduction in cell 
viability in EV transfected cells and palmitate toxicity was not attenuated in either of the 2C11 
over-expressing cell lines (P>0.05 vs. corresponding palmitate concentrations in EV cells). 
Similar results were obtained by apoptosis profiling showing that over-expression of CYP 2C11 
failed to ameliorate the cytotoxic effects of palmitate, with no reduction in apoptosis 
witnessed for both stable lines (P>0.05). This may indicate that although 2C11 is over-
expressed, the enzyme is non-functional, or that availability of the endogenous substrate AA 
is rate-limiting. This may be reflective of low expression of PLA2, necessary for the release of 
Figure 6.2. Effects of CYP 2C11 over-expression against palmitate toxicity. A stable EV cell line and both lines with stable 
expression of 2C11 were treated with increasing concentrations of palmitate (15.625µM-1000µM) for 24 hours before cell 
viability was assessed with the MTT assay (panels A-B), or with a fixed 250µM palmitate for 24 hours and apoptosis assessed 
by flow cytometry using the MUSE™ MultiCaspase assay (C). Values are represented as mean (+/- SEM), n=3. *P<0.05 relative 
to corresponding control as determined by two-way ANOVA and Bonferroni’s post-test 
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AA from membrane phospholipids as a precursor for many metabolic pathways, including EET 
production. To explore this further, these cells were treated with exogenous AA to investigate 
whether over-expression of 2C11 would alter the dose-dependent attenuation of palmitate 
toxicity as a consequence of increased substrate availability for EET synthesis, screened using 
the MTT assay (figure 6.3). 
 
 
 
 
 
 
 
Increasing concentrations of AA resulted in a significant dose-dependent increase in 
cell viability both in BRIN-BD11 cells transfected with EV and in 2C11 stable cell lines compared 
to palmitate treatment alone (P<0.05). At all concentrations of AA there was no significant 
difference between the increase in cell viability between 2C11 lines and corresponding EV 
controls (P>0.05), suggesting that increasing substrate availability by exogenous AA treatment 
does not increase the production of EETs supporting an increase in cell viability in BRIN-BD11 
cells overexpressing CYP 2C11; though in the current study it was not possible to directly 
measure whether or not EETs were being produced in these cells.    
Since EETs are converted to DHETs by the action of sEH, with these products previously 
shown not to attenuate palmitate toxicity in BRIN-BD11 cells, and this being the predominant 
Figure 6.3 Effects of CYP 2C11 over-expression on the dose-dependent effects of AA against palmitate toxicity. EV and 2C11 
over-expressing BRIN-BD11 cell lines were treated with increasing concentrations AA from 0.1562µM-20µM in co-incubation 
with 250µM palmitate for 24 hours before cell viability was assessed by the MTT assay. Values are represented as mean (+/- 
SEM), n=3. #P<0.05 relative to palmitate treatment alone as determined by two-way ANOVA and Bonferroni’s post-test. 
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route for EET metabolism, whether significant sEH activity in these cells was responsible for 
rapid clearance of any EETs being produced by these cells was explored. Initially, five sEH 
inhibitors were screened under control conditions for 24 hours (data not shown) to determine 
suitable concentrations that were non-toxic to BRIN-BD11 cells; AUDA, CUDA, t-AUCB, TPPU 
and CAY10640. From these screens, t-AUCB and TPPU were selected for further study, with 
lower solubility of some of the other inhibitors, particularly AUDA and CUDA, limiting their 
application in the current model. Both BRIN-BD11 2C11 stable lines and the EV control were 
pre-treated with either 10µM t-AUCB or TPPU followed by co-incubation against a palmitate 
dose response for 24 hours and viability assessed with the MTT assay and MUSE™ 
MultiCaspase assay  (figure 6.4).  
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In all cases, treatment with increasing concentrations of palmitate dose-dependently 
reduced cell viability in both EV controls and 2C11 expressing cell lines. The addition of either 
10µM t-AUCB or 10µM TPPU failed to increase cell viability compared to corresponding 
treatments in both stable lines (P>0.05), suggesting that inhibition of sEH in all models does 
Figure 6.4. Effects of sEH inhibition on palmitate toxicity in CYP 2C11 stable cells. Cells were pre-treated with 10µM of either 
t-AUBC or TPPU for 1 hour followed by co-treatment with increasing concentrations of palmitate (15.62µM-1000µM) (panels 
A-D) or a fixed 250µM palmitate with 10µM TPPU (panel E) in co-incubation for 24 hours before cell viability was assessed by 
the MTT assay (A-D) or flow cytometry with the MUSE™ MultiCaspase assay. Values are represented as mean (+/- SEM), n=3. 
*P<0.05 relative to corresponding control (sEH inhibitor alone) as determined by two-way ANOVA and Bonferroni’s post-test. 
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not increase cell viability against all concentrations of palmitate, with neither cell lines over-
expressing CYP 2C11 exerting protective actions. These effects were also confirmed by 
assessment of apoptosis, which again showed that overexpression of CYP 2C11 in BRIN-BD11 
cells did not attenuate palmitate toxicity in the presence of the sEH inhibitor TPPU. Since 
exogenous EET treatment at levels exceeding 5µM was observed to exert significant 
cytoprotective against palmitate toxicity (Chapter 4), the data presented here would suggest 
that the over-expressed 2C11 was non-functional, or that spatio-temporal differences 
between endogenous EET production and exogenous application may impact on the extent of 
their activity, though further work is needed to confirm this. Since this was beyond the scope 
of this thesis and since the data demonstrating EET cytoprotective effects against cytokines 
(Chapter 5) suggested potential mechanistic differences in their mode of action between 
these models, the cytotoxic response of the 2C11 over-expressing cell lines to cytokines was 
assessed by the MUSE™ MulitCaspase assay (figure 6.5).  
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Figure 6.5. Effects of CYP 2C11 over-expression against cytokine-induced apoptosis. EV and 2C11 over-expressing cell lines 
were treated with or without IL-1β (100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) in for 24 hours before apoptosis 
induction was assessed by flow cytometry using the MUSE™ MultiCaspase assay. Values are represented as mean (+/- SEM), 
n=3. *P<0.05 relative to corresponding control treatment (without cytokines) as determined by two-way ANOVA and 
Bonferroni’s post-test. 
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As with the palmitate model, pro-inflammatory cytokines increased apoptosis in BRIN-
BD11 cells, effects not attenuated in either CYP 2C11 over-expressing cell lines (P<0.05). Since 
previous data (Chapter 5) showed that 8(9)-DHET protects against cytokine toxicity and that 
sEH inhibitors did not alter the response of the 2C11 over-expressing cells to palmitate, 
investigations into sEH inhibition in the cytokine model were not considered. Collectively this 
data suggests that over-expression of CYP 2C11 in BRIN-BD11 cells cannot emulate the 
cytoprotective effects observed with exogenous EET treatment, although overall the data may 
suggest that 2C11 was non-functional.   
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6.5 Discussion  
The aims of this chapter were to investigate the response of BRIN-BD11 cells following 
selection of stable cell lines over-expressing CYP 2C11 to palmitate and pro-inflammatory 
cytokines to see whether increasing production of endogenous EETs could mimic the effects 
of exogenous EET treatments in these models (Chapter 4 and 5). Of the CYP 450 epoxygenases 
in rat, CYP 2C11 accounts for 50% of total P450 enzymes expressed in rat male livers, with 
roles including the epoxidation of AA producing EETs (Morgan et al., 1985; Zeldin et al., 1996; 
Imig and Hammock, 2009). Additionally, whilst other CYP450 isoforms, particularly 2J, are also 
known to produce EETs, limited previous data has reported higher expression of 2C11 in rat 
islets compared to 2J isoforms (Chen et al., 2013), hence the initial focus on 2C11 in the current 
model.  
In this study, two BRIN-BD11 cell lines over-expressing CYP 2C11 were produced for 
further characterisation following stable transfection and G418-selective culture. Of the two 
cell lines produced, a differential expression level of 2C11 was observed, with a ‘high’ and 
‘low’ expression model produced. However, the current data has shown that increased 
expression in both models was unable to attenuate the cytotoxicity of either palmitate or pro-
inflammatory cytokines in contrast to EV transfections, as determined by MTT assay and flow 
cytometry for apoptosis profiling, confirming lack of cytoprotection. Similarly, modulation of 
endogenous substrate available with application of AA, or inhibition of sEH, limiting EET 
conversion to DHETs, also failed to emulate the effect of exogenous treatment.  
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To explore whether sEH could enhance the production of EETs in the current model, a 
range of inhibitors were initially screened, with t-AUCB and TPPU selected for further study. 
Although previous studies have shown that administration of the sEH inhibitor AUDA in the 
drinking water in in vivo animal models at 25mg/L can decrease mean arterial blood pressure, 
associated with an increase in urinary epoxide-to-diol ratios (Imig et al., 2005), in the current 
model, AUDA presented with poor solubility, contributing to cytotoxicity and so was not 
continued in these investigations. Similarly, although CUDA has been reported to block the 
conversion of 1μM 14(15)-EET to 14(15)-DHET by 94% in COS-7 cells (Fang et al., 2005), similar 
poor solubility and lack of effect of this inhibitor against palmitate toxicity alone in preliminary 
screening (data not shown) limited its application in this study. Unlike AUDA and CUDA, t-
AUCB displays a more favourable solubility profile and did not exert similar toxicity at 
equivalent concentrations. t-AUCB  has been shown to promote dose-dependent angiogenesis 
when treated in co-incubation with EETs in endothelial progenitor cells in a myocardial 
infarction model (Xu et al., 2013), effects which were attributed to the EET-PPARγ pathway, 
suggesting that there is a potential utility of sEHi in the therapy of ischemic heart disease. As 
with t-AUCB, TPPU and CAY10640 (phenyl-urea classes of sEH inhibitors) were well tolerated 
by BRIN-BD11 cells, with no concentrations displaying significant loss of cell viability. TPPU has 
previously been shown to be a potent inhibitor of both human and mouse sEH (Rose et al., 
2010) however, a study by Ostermann et al., (2015) concluded that whilst TPPU showed high 
metabolic stability in vivo it showed no significant effect on epoxide/diol ratio in plasma, 
though favourable effects were observed in tissue samples suggesting inhibition ex vivo. 
Similarly, CAY10640 has been shown to be a potent inhibitor of both human and mouse sEH 
and has demonstrated a 1,000-fold increase in potency compared to morphine in reducing 
hyperalgesia in an in vivo carrageenan-induced inflammatory pain model (Rose et al., 2010), 
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though there are comparatively few studies reporting its use. Collectively, the use of t-AUCB 
and TPPU in BRIN-BD11 cells over-expressing CYP 2C11 failed to attenuate the cytotoxic 
effects exerted by palmitate, suggesting that in the current model, over-expression of CYP 
2C11 was ineffective, possibly attributable to lack of function.  
Lack of function of the expressed 2C11 is unlikely to be due to improper vector 
sequence or random point mutations, since purified vectors were sequenced prior to 
transfection into BRIN-BD11 cells, with results showing 100% homology to the ncbi database 
entry for 2C11. Similarly the methods used for amplification and purification of the vector are 
robust, producing a high-yield of transfection-ready plasmids. Non-functional expression of 
2C11 may instead be attributed to the association of CYP450 enzymes with oxidoreductase 
domains in cells, necessary for their catalytic activity. In support of this Yang et al., (2007) used 
an adenoviral vector containing rat NADPH-cytochrome P450 oxidoreductase fused with CYP 
2C11: rAAV-CYP2C11-CYPOR, which was used to infect endothelial cells and observed to 
synthesise a biologically active regioisomeric mixture of 5(6)-EET, 8(9)-EET, 11(12)-EET and 
14(15)-EETs. In contrast, others have shown that over-expression of CYP 2J isoforms alone in 
a pcDNA vector produced EETs and inhibited NF-κB activation in HEK293T cells in a PPARα-
dependent manner (Wray et al., 2009) and a similar pcDNA3.1-CYP 2J2 construct reduced 
oxidative stress markers and increased antioxidant enzyme expression in lung endothelial cells 
(Chen et al., 2014). Further work is therefore necessary in the current model to directly 
compare the effect of over-expression of CYP 2C11 alone to that of a similar CYPOR fusion 
construct. Although it was not possible to explore this in the current study, others have shown 
that the addition of a molar excess of a mammalian NADPH oxidoreducatse to purified CYP 
2C11 markedly enhanced catalytic efficiency and production of AA-derived eicosanoids (Helvig 
232 
 
and Capdevila, 2000), therefore one initial approach could be to transiently transfect the BRIN-
BD11-2C11 stable cell lines with a vector encoding the oxidoreductase enzyme, though 
expression of the fusion construct is likely to be more favourable given the necessary P450-
OR interactions required. NADPH substrate availability for oxidoreductase activity is unlikely 
to have been a limiting factor in the current data, since beta cells are reported to have a high 
turnover of cellular NADPH/NADP+, as well as expressing several NADPH oxidase isoforms, 
which contribute to oxidative stress (Koulajian et al., 2013). Further characterisation of BRIN-
BD11 cells under these conditions, and in the 2C11 stable lines generated in the current study 
with an EET/DHET ELISA format would be necessary to establish whether the effect (or lack 
of) in cytotoxicity studies is directly associated with changes in cellular EET levels. 
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6.6 Conclusion  
 The data presented in this chapter successfully met the aim of producing two BRIN-
BD11 cell lines with stable over-expression of CYP 2C11. However, in contrast to the 
application of exogenous EETs, these cells displayed no resistance to palmitate or pro-
inflammatory cytokines, effects which were insensitive to the application of AA or sEH 
inhibition. This is possibly suggestive of low functionality of the expressed enzyme and so 
provides a rationale for further studies into the use of a CYP450-OR fusion construct and/or 
other CYP450-epoxyganses for manipulating endogenous EET levels.  
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Chapter Seven  
 
General Discussion & Future Work 
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7 General Discussion 
 
 Diabetes mellitus is primarily classified as type 1 and type 2 DM, with type 1 resulting 
from an autoimmune attack, specifically targeting pancreatic beta cells in the islets of 
Langerhans, leading to a reduction beta cell mass of ~80%, associated with a progressive 
decline in insulin production. The condition manifests as a consequence of, as yet poorly 
defined, environmental trigger(s) in genetically predisposed individuals and necessitates life-
long exogenous insulin replacement; though establishing normoglycaemia comparable to a 
non-diabetic state can be difficult. Type 2 DM, as a continuum of a DM ‘spectrum’, represents 
an extreme of metabolic dysfunction, typically associated with sedentary lifestyles and 
obesity, leading to elevated circulating glucose and fatty acids. Dyslipidaemia and chronic 
hyperglycaemia directly contribute to the development of insulin resistance in peripheral 
tissues, worsening a dysregulation in metabolic control and increasing secretory demands on 
beta cells. The capacity of the beta cells to maintain insulin output may become overwhelmed, 
in part, as a consequence of increased demands on the ER for protein translation and export, 
but also as a direct consequence of the presence of high a glucose load and increased 
circulating FFAs, which in a process of glucolipotoxicity, directly contribute to a decline in 
functional beta cell mass and increased beta cell apoptosis. Whilst current therapeutic 
strategies aimed at restoring appropriate insulin responses either through exogenous 
treatment (type 1 and in some cases type 2) or by promoting endogenous secretion, together 
with countering peripheral insulin resistance and metabolic dysregulation (type 2), improves 
glycaemic control and metabolic homoeostasis, long-term co-morbidities as a result of the 
secondary complications of sub-optimal control and associated mortalities continue to place 
a large burden on global healthcare. Therefore, one of the major aims of diabetes research 
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continues to be to increase our understanding of the intracellular mechanisms contributing to 
beta cell death and dysfunction, to identify novel areas for potential therapeutic intervention 
to preserve functional cell mass. To this end, pancreatic beta cell lines as in vitro models of 
type 1 and 2 DM have been extensively utilised, alongside ex vivo islet models and in vivo 
animal studies. Whilst there may be important differences between model systems, not least 
how well the data can be translated to human beta cell biology, the lack of well-established 
human beta cell lines and limited primary human islet tissue available means rodent beta cell 
lines have prevailed in much of the initial basic science research in DM.  
In in vitro cellular models reflecting pro-inflammatory cytokine toxicity, application of 
cytokines IL-1β, IFN-γ and TNF-α alone or in combinations replicates pro-apoptotic 
autoimmune activity against beta cells with pathophysiological relevance. Similarly, in cellular 
models reflective of type 2 DM, application of saturated fatty acids, such as palmitate, have 
been used to induce beta cell death and study processes of glucolipotoxicity, as well as the 
now well-established cytoprotective actions of mono- and poly- unsaturated fatty acids such 
as palmitoleate, oleate and arachidonic acid. Therefore the initial aim of this thesis was to 
establish models of pro-inflammatory cytokine- and lipo- toxicity in the rat pancreatic beta 
cell line BRIN-BD11 (Chapter 3), in preparation for future investigations. In agreement with 
others (Cnop et al., 2005), the data (Chapter 3 and 5) observed that the cytokines IL-1β 
(100U/mL), IFN-γ (20U/mL) and TNF-α (500U/mL) alone and in combination significantly 
reduced cell viability and increased total apoptosis as determined by a variety of 
complementary methods for the assessment of cell death and apoptosis, supporting the 
synergistic activity of cytokines in this context. As seen in RINm5F cells, cytokine-induced beta 
cell death was observed with IL-1β and IFN-γ treatment, but not with TNF-α (Holohan  et al., 
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2007), which corresponds to previous studies showing similar effects in isolated primary rat 
beta cells and human beta cells (Rabinovitch and Suarez-Pinzon, 1998; Eizirik and Mandrup-
Poulsen, 2001). Nonetheless, synergistic activity of TNF-α has been observed, including in the 
current data, and the combination of these three main pro-inflammatory cytokines in the 
islets milieu in vivo represents the most pathophysiologically relevant treatment. Cytokine 
signalling is associated with the activation of the transcription factors NF-κB and STAT1, 
leading to changes in expression of target genes, promoting an increase in cellular nitrosative 
and oxidative stress (in part via increased expression of iNOS), a reduction in beta cell function, 
increased ER stress and mitochondrial dysfunction, and further recruitment of mononuclear 
immune cells associated with the augmentation of insulitis in vivo (Cnop et al., 2005). The 
contribution of cytokine-induced iNOS expression and NO production are well-established 
mediators of beta cell death in a number of model systems (Cnop et al., 2005), with a sub-set 
of genes differentially expressed in response to cytokines shown to be NO-dependent over 8-
24 hours treatment (Kutlu et al., 2003). Whilst iNOS expression is largely dependent on NF-κB 
activation (Flodstrom et al., 1996; Kutlu et al., 2003), with co-stimulatory activity of STAT1 and 
IRF-1 in combined treatment, the contribution of NO production and its impact on beta cell 
death may largely be species dependent, as although exogenous treatment with chemical NO 
donors has replicated cytokine-induced beta cell death in several models (Eizirik et al., 1996; 
Oyadomari et al., 2001; Cardozo et al., 2005), the impact of iNOS silencing on mitigating beta 
cell death in vivo and sensitivity of human islets to NO toxicity have questioned the overall 
significance of this species. Though effects of cytokines on cellular oxidative and nitrosative 
are likely to extend beyond a single dependency on the NO radical directly, instead associated 
with a complex interplay between distinct pools of ROS and RNS produced under these 
conditions. Even so, iNOS expression and assessment of nitrite accumulation are commonly 
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used in the assessment of cytokine action in beta cells, evident in the current model with the 
effect of cytokine treatment combinations on loss in cell viability largely reflected in data from 
the Griess assay. 
Further to establishing a model of cytokine toxicity in BRIN-BD11 cells, palmitate 
treatment (Chapter 3 and 4) observed a significant dose-dependent decrease in cell viability 
and an increase in total apoptosis, supporting observations in a number of other in vitro beta 
cell lines, as well as toxicity in islet cultures and in vivo studies using high-fat diet-induced DM 
and spontaneous obesity-induced DM models such as the ob/ob mouse and Zucker-fatty rat. 
Excessive intracellular palmitate levels result in an accumulation of acyl-CoA from cellular lipid 
overload and increased rates of production of ceramide and extra-mitochondrial metabolism, 
including peroxisomal β-oxidation, which leads to an increase in H2O2 suggesting a strong link 
between ROS accumulation and lipotoxicity (Tiedge et al., 1997; Elsner et al., 2011). Further 
mechanisms of palmitate toxicity as a result of dysregulated lipid homeostasis include the 
activation of ER stress, with a marked increase in expression and/or activation of the three 
main branches of the UPR observed under these conditions in a variety of models (Cnop et al., 
2008; Diakogiannaki et al., 2008; Cuhna et al., 2008), though the dependence of palmitate-
induced cell death on these pathways has been questioned (Lai et al., 2008).  
 Much interest has also focused on strategies aimed at the attenuation of beta cell 
cytotoxicity, including in the context of mono- and poly- unsaturated fatty acids and whilst 
these studies have focused more in lipotoxicity models, cytoprotective effects in models of 
cytokine toxicity have also been reported (Welters et al., 2004a). Current data for preliminary 
investigations also support that the polyunsaturated FFA, AA, can protect against both 
palmitate and, to a limited extent, cytokine-induced beta cell death. Mechanisms for how this 
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is achieved are still poorly understood and although effects of exogenous treatment with AA 
(and indeed other unsaturated species) have been suggested to be independent to their 
metabolism, established from using methyl ester derivatives and other analogues (Dhayal and 
Morgan, 2011), endogenous pathways of AA metabolism and the products produced from 
some of these have also been explored. However, much attention has focused on COX and 
LOX metabolites in this context, with comparatively few studies concerned with the action of 
CYP450-derived eicosanoids in these models. Consequently, the primary aim of this thesis was 
to investigate the cytoprotective actions of CYP450 epoxygenase-derived products of AA 
metabolism, epoxyeicosatrienoic acids (EETs) and their corresponding diols, 
dihydroxyeicosatrienoic acids (DHETs), produced by the action of soluble epoxide hydrolase 
(sEH) against pro-inflammatory cytokines and palmitate-induced lipotoxicity in BRIN-BD11 
cells. Since protective effects of EETs and, to a lesser extent, DHETs are reported in a number 
of other disease models and the reported activity of precursor polyunsaturated FFAs in beta 
cells (Keane et al., 2011), there is a clear rationale for the investigation into EET action in these 
models (Xu et al., 2016). Therefore this thesis reports, for the first time, that 8(9)-EET, 11(12)-
EET and 14(15)-EET are cytoprotective against cytokine- and palmitate- induced beta cell 
death and apoptosis in BRIN-BD11 cells and furthermore reports the novel observation that 
8(9)-DHET similarly protects against cytokine-induced beta cell death, with comparable 
activity to that of all EETs. Although earlier studies have yielded conflicting observations on 
the effect of EETs on insulin secretion (Falck et al., 1983; Klett et al., 2013) and that diminished 
activity of sEH protected against STZ-induced DM in mice (Luo et al., 2010), effects which could 
not be attributed to changes in endogenous EET/DHET ratios (Chen et al., 2013), the current 
data reports the first observations of a direct cytoprotective action against 
pathophysiologically-relevant inducers of beta cell death.  
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The differential effect of EETs and 8(9)-DHET on the attenuation of cytokine-induced 
nitrite accumulation, despite a comparable reduction in NF-κB activity, as determined using 
an NF-κB luciferase reporter vector, and observations that 8(9)-DHET failed to protect against 
lipotoxicity, suggest that the mode of action may differ between distinct EET/DHET species, 
which may depend on the nature of the apoptotic stimuli. This is further supported by 
observations that the poorly metabolisable EET analogue, 14(15)-EET-SI failed to attenuate 
palmitate toxicity, in contrast to comparable effects to 14(15)-EET observed in response to 
cytokine treatment. As a result, receptor-mediated activity of EETs (and 8(9)-DHET) in the 
latter model is supported, effects associated with a reduction in NF-κB activity, whereas with 
palmitate treatment, EET action may be associated with the generation of further EET 
metabolites, or from esterification into other cellular lipids, such as cardiolipin, though further 
work is needed to confirm this. Collectively, in context to the effects of EETs in response to 
cytokines, reflecting a model of type 1 DM, the data suggests that EETs act, in part, by reducing 
NF-κB activity, through a PPARγ-independent mechanism. Since whilst EETs are reported to 
act as endogenous PPARγ ligands (Liu et al., 2005), a PPARγ antagonist failed to block to the 
protective effect of EETs against cytokine-induced apoptosis. This further supports that EET 
action may be mediated through an extracellular receptor site in this model, as also suggested 
in the data with 14(15)-EET-SI, though additional intracellular receptor activity cannot be 
excluded based on the current data. With recent studies suggesting that EETs display activity 
at multiple low-affinity extracellular receptor sites (Lui et al., 2017; Park et al., 2018), 
dissecting the contribution of distinct receptor-mediated signalling pathways may well be 
difficult to achieve, further hampered by a potential differential affinity between EET and 
DHET isomers.  
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 In contrast, in the current model of lipotoxoicity, all DHETs failed to attenuate 
palmitate toxicity and a general trend in the extent of cytoprotective effects of EETs was also 
noted, with 8(9)-EET exerting the highest level of protection, followed by 11(12)-EET and then 
14(15)-EET and the apoptosis level in this latter treatment remained significant elevated 
compared to control. This may suggest that position of the epoxide group is important in the 
extent of cytoprotection, which may directly contribute to the reactivity of EETs towards 
esterification to CoA and/or further metabolic processing, or that these structural features 
reflect binding affinity at receptor site(s). A requirement for EET esterification to CoA, β-
oxidation or incorporation into the phospholipid membrane/other cellular lipids, is supported 
by the observation that 14(15)-EET-SI, which is resistant to esterification to CoA failed to 
protect BRIN-BD11 cells from palmitate-induced toxicity and others have shown that 90% of 
EETs are sequestered by this route (Bernstrom  et al., 1992). Additional extra- or intra-cellular 
receptor activity of EETs in this model cannot be entirely excluded from the current data, 
although neither pharamacological antagonism of GPR40 and GPR120 nor PPAR isoforms 
(including co-antagonism with the heterodimer partner RXR) blocked EET effects. Whether 
action was dependent on EET-mediated changes in lipid handling were also explored in a 
number of complementary methods and although a modest increase in lipid droplets was 
observed, inhibition of DGAT, the terminal committed enzyme in the pathway of TAG 
synthesis, did not alter EET action in terms of attenuating palmitate toxicity. Similar effects 
were observed with CPT1 inhibition, including when combined with DGAT inhibition, 
suggesting that EETs do not stimulate an increase in palmitate oxidation in the mitochondria. 
Although CPT1 over-expression has been shown to protect INS-1 cells from palmitate toxicity 
(Sol et al., 2008) and the current data showed an increased in CPT1 at the mRNA level 
following EET treatment, with the relative fold increase in the expression of this and DGAT 
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broadly reflecting the extent of apoptosis suppression by each EET, that EETs protected 
against loss in viability and apoptosis in response to the poorly metabolisable 2-
Bromopalmitate, further supports that EET action is independent to increased β-oxidation. 
Although EETs are also reported to undergo β-oxidation themselves, producing shortened-
chain epoxides, with biological activity (Fang et al., 2001; Fang et al., 2004), this is also unlikely 
to solely reflect EET action in this model, since this would also be limited in the presence of 
the CPT1 inhibitor, etomoxir, or 2-Bromopalmitate. Collectively, these data suggest EETs may 
act at a distal step in apoptosis, possibly by release of cytochrome c through alterations in 
synthesis of cardiolipin, as an increase in EET levels has been associated with over-expression 
of cardiolipin synthase, similar to that seen with treatment of AA in H9C2 cells (Kiebish et al., 
2012; Ting et al., 2015). 
 
7.1 Future Work 
 Having now established that EETs are cytoprotective in BRIN-BD11 cells in response to 
both cytokines and palmitate, future work should include replicating these studies across a 
range of beta cell lines, including the other commonly used beta cell lines INS-1 and MIN6, as 
well as determining whether this can be reproduced in primary beta cells and islet cultures. 
The validity of this to human beta cell biology should also be explored in human islets, though 
the more recent human pancreatic beta cell line EndoC-βH1 or 1.1B4 could initially explore 
this. However, as with earlier attempts to produce an established clonal human cell line the 
validity of these more recent models has been questioned (Oleson et al., 2015), though recent 
evidence has shown that EndoC-βH1 cells do resemble human islet physiology in context of 
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GSIS and the incretin effect (Tsonkova et al., 2018). Having established, for the first time, that 
EETs are cytoprotective in a beta cell model, the limited studies in this field (save two reports 
on the effect of sEH activity on STZ-induced DM) and the inherent differences between beta 
cell models provides a further clear rationale for additional work on EET action. In context to 
the type 2 DM lipotoxicity model, the current data suggest that EET effects may be 
independent of changes in lipid handling, though there is some evidence that increased lipid 
droplet accumulation may be occurring; subtle differences between beta cell line models in 
terms of lipid homeostasis should allow further analysis of the relative contribution of these 
process to EET action. Not least since a differential effect of glucose on the enhancement, or 
lack thereof, on palmitate toxicity has been reported in INS-1 and MIN6 beta cell lines, 
respectively, possibly attributed to a higher acetyl-CoA carboxylase activity in INS-1 cells, 
increasing sensitivity to glucose-derived malonyl-CoA (Sargsyan and Bergsten, 2011). 
Moreover, human islets and MIN6 cells express higher levels of SCD1 in comparison to INS-1 
cells, suggesting a higher tolerance of these model to saturated fatty acids. Collectively, the 
use of these additional cell lines and model systems will further our understanding of the 
functional roles of EETs in beta cells and exploration of their mode of action. Though this was 
not feasible in the current study, further work should also explore the contribution of EETs to 
insulin secretion and importantly whether secretory capacity is retained in cells where the 
pro-apoptotic actions of palmitate and/or cytokines are attenuated by EETs, given the limited 
and conflicting data in this area (Falck et al., 1983; Klett et al., 2013).   
 Further to the investigations carried out in the current study to define potential 
mechanisms of EET action, a wider range of antagonists/inhibitors could be implemented in 
both of the models established in the current BRIN-BD11 cell line and other model beta cell 
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systems. In particular, the current data does not support a PPAR-dependent activity of EETs in 
either of the BRIN-BD11 cytotoxicity models, in contrast to reported activity in other models 
(Liu et al., 2005; Wray et al., 2009) and whilst agonistic activity of EETs at PPARs, particularly 
PPARγ, are not the sole mechanisms of EET action, a further understanding of any potential 
activity at these targets is important, given their roles in regulating lipid homoeostasis and 
that PPARγ is the target of the glitazone class of oral antidiabetic agents. In particular, whether 
EETs activate PPARγ directly could be explored using a PPRE-luciferase reporter construct, as 
reported in other models using EETs and DHETs (Fang et al., 2006; Wray et al., 2009). It will be 
interesting to see if a differential activity and/or dependence of EETs on PPARγ can be 
observed in different beta cell models, since though BRIN-BD11 cells express PPARγ (and other 
PPAR isoforms), its activation required supra-physiological concentrations of rosiglitazone, at 
concentrations which failed to attenuate palmitate-induced cell death in a model of 
lipotoxicity (Welters et al., 2004b). Of note, pioglitazone has been shown to attenuate 
palmitate-induced lipotoxicity in MIN6 cells (Hong et al., 2018) and in response to cytokines 
in NIT-15 cells (Wang et al., 2013), though others failed to detect PPARγ expression in MIN6 
cells and showed that its over-expression in the presence of pioglitazone diminished GSIS 
(Nakamich et al., 2003). Although these studies disagree on whether PPARγ is expressed in 
beta cell lines, a dual and conflicting action of both PPARγ-dependent cytoprotection against 
palmitate toxicity and PPARγ-dependent inhibition of insulin secretion with pioglitazone are 
reported in these studies. This may rationalise why EETs were shown to confer cytoprotective 
effects in BRIN-BD11 cells in the current data, whilst one previous study reported that EETs 
partially reduced insulin secretion in INS-1 cells (Klett et al., 2013). However, this study did not 
determine whether PPARγ was required for this and the current data supports PPARγ-
independent mechanisms of cytoprotection by EETs in BRIN-BD11 cells, therefore further 
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studies exploring both of these factors in a more PPARγ responsive model would be useful. 
Furthering the data on EET action and exploring PPARγ dependency is also of relevance to pro-
inflammatory cytokine toxicity since studies have reported the effects of EETs on NF-κB 
activation as PPARγ-dependent (Spector et al., 2004; Liu et al., 2005). Although the current 
data would suggest that the cytoprotective effects of EETs in context to cytokine-induced 
apoptosis are PPARγ-independent, whether this was necessary for inhibitory action against 
NF-κB was not determined.  Overall though the dependency of any of these responses on 
PPARγ should be explored by its down-regulation with siRNA, an approach complementary to 
and, perhaps, more selective than the pharmacological antagonist approach used in the 
current model.  
 Additional studies should also further consider the relative roles of pathways 
responsible for EET metabolism, particularly given the differential action of the EET-SI 
derivative used in the two models in this thesis. Whether receptor-mediated activity is directly 
responsible for their mode of action can be explored using the purported EET antagonist 
14(15)-EEZE and additional methyl-ester EET derivatives, which similarly are not substrates for 
esterification to CoA, can be used to support the current data with 14(15)-EET-SI. With 
membrane esterification to phospholipids important in controlling free cellular EET levels, a 
contribution of both the acyl-CoA-synthetase enzymes necessary for EET activation for 
esterification and the phospholipase enzymes responsible for their release from the 
phospholipid pool, should allow a further insight into the regulation of endogenous EET levels 
in these models and the fate of EETs when exogenously applied, given that as much as 90% of 
total cellular EETs may be sequestered in this way (Bernstrom et al., 1992). Furthermore, the 
scarcity of data on the functional roles of β-oxidation products of both EET and DHET 
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metabolites warrants further study. However, the major route for EET metabolism, once 
liberated from phospholipids, is the conversion to DHETs from the action of sEH and the 
current data largely support that this is a mechanisms which would inhibit cytoprotective 
actions, save for that of the largely unexplored 8(9)-DHET in context to cytokine toxicity. 
Whilst the current study could not determine an attenuation of palmitate toxicity in the 
presence of a range of sEH inhibitors, including when CYP 2C11 was over-expressed, the use 
of siRNA to down-regulate sEH expression could again be a more selective approach, 
particularly given the poor solubility of some of the current sEH inhibitors available. An 
approach to manipulating EET levels through a combination of CYP450 epoxygenase over-
expression or exogenous application in combination with sEH inhibition is supported by 
observations in endothelial cells showing that PPARγ transcriptional activity was enhanced 
following EET treatment but only in the presence of the sEH inhibitor, AUDA (Liu et al., 2005). 
Further to this, the use of the EET mimetic and sEH inhibitor, UA-8, could be utilised in context 
to these models, since treatment with UA-8 in H9C2 cardiomyocytes protected against 
mitochondrial injury following anoxia, and in vivo, protected against ischaemia reperfusion; 
effects which were blocked by the PPARγ antagonist, GW9662 (Batchu et al., 2011).  
 Evidently EET action is not solely mediated through the activation of PPARγ and whilst 
evidence supports an extracellular binding site, which may signal through Gαs-associated 
GPCR activation (Yang et al., 2008; Lui et al., 2017), the identification of the receptor(s) 
involved is yet to be determined. If the more recent data suggesting binding activity at 
multiple low-affinity sites is substantiated, then defining the contribution of these will be 
difficult. Recent reports of EET activity at GPR40 (Park et al., 2018) are not supported by the 
current data and so future work could further explore a wider range of potential targets. 
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However, this may be a laborious process and it is difficult to envisage a meaningful outcome, 
since the requirement to target multiple sites will increase the likelihood of additional 
cytotoxicity, though the potential activity of EETs at prostaglandin receptors (Lui et al., 2017), 
with characterised activity in beta cell models (Carboneau et al., 2017) should provide an initial 
starting point. Furthermore, development of additional EET analogues may help further define 
the relative contribution of receptor sites, given that 14(15)-EEZE can antagonise EET action 
and competitively block binding of a radiolabelled 14(15)-EET to the plasma membrane in 
U937 cells (Yang et al., 2008). However, this species is cell permeable and has been shown to 
block EET-induced activation of PPARγ (Samokhalov et al., 2014) and so its application in the 
current model would be theorised to anatagonise a range of potential EET binding sites, 
limiting its applicability to differentiating between extra- and intra-cellular effects, though the 
requirement for a molar excess of 14(15)-EEZE precluded its application in the current data. 
Therefore further work is necessary to identify relevant binding sites and their contribution to 
EET action. 
 Having now established that EETs are cytoprotective in a beta cell model when 
exogenously applied, this provides a further rationale to expand the current data on the over-
expression of relevant CYP450 epoxygenases responsible for their production. Although this 
thesis successfully generated stable BRIN-BD11 cell lines with over-expression of CYP 2C11, a 
CYP epoxygenase previously reported to be expressed at high levels in rat islets (Chen et al., 
2013), the data indicates that the construct may be non-functional. So additional studies are 
necessary to characterise this further, including a direct assessment of EET/DHET levels in 
these cells and, more importantly, the use of CYP2C11-CYPOR fusion construct, as reported 
by others (Helvig and Capdevila, 2000). It is important to note however, other studies using 
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the isoform CYP 2J have shown protective actions with transiently transfecting a CYP 2J 
pcDNA3 vector alone, arising to the rationale in overexpressing CYP 2C11 without the CYPOR 
attachment in this study. This therefore provides a preliminary foundation on which to further 
explore a range of CYP450 enzymes known to produce EETs and importantly, these studies 
should be replicated in a range of other beta cell models. In human pancreatic tissues samples 
the CYP 2C8 and 2C9 isoforms have been detected, with expression associated with islets 
(Standop et al., 2002), supporting expression of the 2C11 rat homology reported by Chen et 
al., (2013) in rat islets, though the current data could not detect a baseline expression of 2C11 
in the empty-vector stable transfection BRIN-BD11 lines. Therefore, further work should aim 
to establish, by RT-PCR and Western blotting, the expression level of a range of CYP450-
epoxygenases and sEH in a number of beta cell lines and islets models, followed by exploration 
of their roles in controlling endogenous EET levels and potential cytoprotective activity.  
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7.2 Concluding Remarks 
 Overall this thesis reports, for the first time, the novel observations that EETs are 
cytoprotective against palmitate and cytokine toxicity in the rat pancreatic beta cell line BRIN-
BD11 and also the surprising observation that 8(9)-DHET conferred similar protection against 
cytokines. Since no studies have previously reported EET (and DHET) activity in these models, 
these data now provide a foundation for further studies to explore mechanisms of EET action, 
including in terms of other beta cell functions, as well as the roles of CYP450 epoxygenases 
and other pathways responsible for controlling endogenous EET levels in this context. The 
parity in the extent of cytoprotection mediated by EETs observed in both of the models utilised 
in this thesis and data on EETs reported in other model systems, with synergy to some of the 
processes associated with beta cell dysfunction and DM development, suggests that strategies 
targeting EET production and/or metabolism may possess future clinical utility in the 
amelioration of beta cell death in both type 1 and 2 DM. Whilst application of such an 
approach to controlling beta cell demise in type 1 DM may well be limited to an early pre-
diabetic state, non-specific intra-islet inflammatory responses are also associated with the low 
yield of islets currently used in clinical islet transplantation. This, and a variety of confounding 
factors in the host system post-transplantation, including portal vein glucolipotoxicity at the 
transplant site, contributes to a rapid early loss in functional islet mass in the immediate post-
transplant period and so pre-transplant culture conditions associated with enhancing intra-
islet EET production may promote long-term survival during initial transplant adaptation. With 
limited previous data on the beneficial action of EETs in a beta cell context, the current data 
provides a rationale for further studies to build on our knowledge of the functional roles of 
these hitherto largely unexplored eicosanoids in beta cell biology.  
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Appendix A: Supplementary method data 
 
 
Figure A.1 Representative Sodium Nitrite Calibration Graph: Griess Assay. Sodium nitrite standards (0-100µM) were 
prepared in distilled water and incubated, in triplicate wells of a 96-well plate, with Griess reagent (1% sulphanilamide in 5% 
orth-phosphoric acid and 0.1% NEDA) for 10 minutes before absorbance was measured at 540nm, with 0µM sodium nitrite 
used as a blank. Representative standard is shown, calibration data was collected each time the assay was performed.   
 
 
Figure A.2 Optimisation of transfection of BRIN-BD11 cells with a GFP-encoding plasmid. Cells were transfected in 24-well 
plates with a pmaxGFP expressing plasmid using Lipofectamine® 2000 to a final concentration of 0.5µg DNA:1.5µL 
Lipofectamine/well. After 24 hours cells were imaged using a EVOS fluorescent microscope. Cells were counted under bright-
field illumination with the percentage scored as GFP positive calculated to an average of 56% where n=3.   
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Figure A.3 Representative agarose gel for RNA integrity. Total RNA was extracted in Trizol and processed using a Direct-zol™ 
RNA MiniPrep kit (Zymo Research) following maufacturers procedures. Eluted RNA was quantified using a ThermoScientific 
NanoDrop 1000 Spectrophotometer with A260/A280 of 1.8-2.1 indicating a high purity RNA. RNA samples (1µg) were 
prepared in 1 X loading buffer and separated on a 1% agarose gel containing ethidium bromide in TAE buffer at 100V for 20 
minutes and visualised. Representative image shows an approximate 2:1 ratio of the 28S and 18S rRNA bands, the absence 
of high molecular weight gDNA bands or band smearing. Difuse low molecular weight band indicates the prescence of 
miRNAs.  
 
 
Table A.2. RT-PCR primer efficiency and comparative amplification efficiency gradients. cDNA standard (10ng-0.01ng) were 
amplified using QuantiNova RT-PCR SYBR Green kit (Qiagen). Efficiency values (based on the standard curve gradient between 
–3.58 and –3.1) were obtained from the Agilent Aria-MX software (column A), comparative amplification efficiency gradients 
(column B) were determined from a graph of ΔCt 18SrRNA-GOI against input amount of sample, with gradient <0.1 considered 
acceptable.  
 
 
 
 
 
 
 
 
 
 
Target (A) Primer Efficiency (%) 
(based on standard curve 
gradient) 
(B) Comparative Amplification Efficiency 
18S 108.17 N/A 
CPT1 108.09 0.0128 
Elovl6 109.38 0.0052 
Ech1 104.79 0.0143 
DGAT1 109.79 0.0165 
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Figure A.4 Melt curve analysis following RT-PCR.  Melt curves (XXX temp) generated following RT-PCR amplification, using 
Agilent-AriaMX programme were generated automatically following amplification for every sample. Representative curves 
shown are from standard curve amplifications with a single peak above XC at all in-put template amounts indicate 
amplification specificity and absence of any interference from primer dimers (low temperature peak) or non-specific 
amplification.  
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Appendix B: Plasmid Vectors 
 
 
Figure B.1 Vector map of pNL3.2NF-κB-RE plasmid. Vector contains five copies of the NF-κB RE consensus sequence upstream 
of the NanoLuc® luciferase. The ampicillin resistance gene (Ampr) was used for selection of bacterial transformation during 
vector isolation (Promega).  
 
 
Figure B.2 Vector map of pCMV6-Entry Vector. An untagged vector was used for over-expression of CYP 2C11, inserted 
between Sgf1 and Mlu1 restriction sites, as supplied by the manufacturer. The kanamycin resistance gene (Kanr) was used 
for selection of bacterial transformation during vector isolation and the neomycin resistance gene was used for selection of 
stable BRIN-BD11 cell lines in G418 selective media (OriGene) 
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Appendix C: Abstracts arising from this thesis 
Grimes, D., Watson, D. (2017). Structure:activity relationships for the cytoprotective effects 
of epoxyeicosatrienoic acids (EETs) and their corresponding diols against palmitate-induced 
lipotoxicity in BRIN-BD11 cells. Diabetic Medicine, vol 
Introduction: Palmitate is a well-established contributor to pancreatic beta cell death in type 
2 DM, with effects ameliorated by polyunsaturated fatty acids, including arachidonic acid (AA, 
C20:4). Whilst AA-derived metabolites from COX and LOX enzymes have been extensively 
studied, little attention has focused on EETs derived from cytochrome-P450 (CYP450) 
enzymes. This study therefore aimed to investigate the cytoprotective effects of CYP450-
derived EET regioisomers and their less-active vicinal diols against palmitate-induced 
lipotoxicity. 
Methods: BRIN-BD11 cells were treated with 250µM palmitate in co-incubation with 8,9; 
11,12; 14,15 EETs, or their dihydroxyeicosatrienoic acid derivatives (DHETs) for 24 hours. Cell 
viability was assessed by vital dye exclusion using Trypan Blue (results expressed as total and 
viable cells/ml +/-SEM), or multicaspase-activity assay. 
Results: Data showed that all EETs protected cells against palmitate-induced cell death, such 
that palmitate decreased viable cell number from 1.02x106 (+/-0.8) to 0.21x106(+/-XX) and in 
co-incubation with 8,9EET, 11,12EET and 14,15EET, viable cell number was significantly 
increased to 1x106, 0.82x106 and 0.72x106, respectively (P<0.05). Structural differences for 
protective activity in relation to position of the epoxide group were also reflected in caspase 
activity, whereby palmitate alone increased activity to 71%(+/-2.9), decreasing to 13%(+/-), 
23%(+/-) and 34%(+/-) in the presence of these EETs, respectively (P<0.05). In comparison, 
corresponding DHETs failed to significantly attenuate palmitate cytotoxicity. 
Conclusion: CYP450-derived EETs protect against palmitate-toxicity, with position of epoxide 
group reflecting structural differences in cytoprotection. Ongoing work is exploring 
mechanistic actions of EETs in beta cells and the role of CYP450 isoforms in production of 
endogenous EETs.   
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Grimes, D., Watson, D. (2018). Anti-inflammatory effects of epoxyeicosatrienoic acids (EETs) 
and their corresponding diols against pro-inflammatory cytokine-toxicity in BRIN-BD11 cells. 
Diabetic Medicine, vol 
Introduction: CYP450-derived EETs display anti-inflammatory activity in cardiac models of 
inflammation, in part through activation of PPARγ and inhibition of NF-κB activation. 
Therefore we aimed to investigate the cytoprotective effects of EET regioisomers and their 
corresponding vicinal diols in a beta cell model of pro-inflammatory cytokine-toxicity.  
Methods: BRIN-BD11 cells were treated with 100U/mL IL-1β, 20U/mL IFNγ and 500U/mL TNFα 
in co-incubation with either 10µM 8(9)-EET, 11(12)-EET, 14(15)-EET, or their 
dihydroxyeicosatrienoic acid derivatives (DHETs) for 24 hours. Cell viability was assessed by 
vital dye exclusion (Trypan Blue; expressed as viable cells/mL) or multicaspase-activity assay 
and NF-κB activity was measured using a NanoLuc® luciferase reporter assay. 
Results: All EETs protected against cytokine-induced cell death, such that cytokines decreased 
viable cell number from 0.79x106 to 0.33x106 and in co-incubation with 8(9)-EET, 11(12)-EET 
and 14(15)-EET, this increased to 0.64x106, 0.61x106 and 0.59x106, respectively (p<0.05). 
Similarly, cytokine treatment increased caspase activity to 35%(+/-5.7), decreasing to 18%(+/-
1.9), 19%(+/-2) and 19%(+/-1.9) in the presence of these EETs (p<0.05), accompanied by a 32% 
decrease in NF-κB activation. Of the corresponding diols only 8(9)-DHET attenuated cytokine-
toxicity, reducing caspase activity from 41%(+/-4.5) to 21%(+/-2.4) (p<0.05).  
Conclusion: EETs protected against cytokine-toxicity in BRIN-BD11 cells, in part via reduced 
activation of NF-κB. We also consider the novel observation that 8(9)-DHET, unlike other EET-
derived DHETs, similarly protected against cytokine-induced apoptosis. This data highlights a 
potential role of EETs in attenuating cytokine-toxicity in type 1 diabetes and our ongoing work 
is exploring the production of endogenous EETs by CYP450 isoforms and actions of EET 
analogues. 
 
 
 
 
